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Abstract
The overall antibiotic resistance of a bacterial population results from the combination of
a wide range of susceptibilities displayed by subsets of bacterial cells. Bacterial heteroresistance
to antibiotics has been documented for several opportunistic Gram-negative bacteria, but the
mechanism of heteroresistance is unclear. I use Burkholderia cenocepacia as a model
opportunistic bacterium to investigate the implications of heterogeneity in the response to the
antimicrobial peptide polymyxin B (PmB) and also other bactericidal antibiotics. Here, I report
that B. cenocepacia is heteroresistant to PmB. Population analysis profiling identified B.
cenocepacia subpopulations arising from a seemingly homogenous culture that are resistant to
higher levels of PmB than the rest of the cells in the culture, and protect the more sensitive cells
from killing, as well as sensitive bacteria from other species, such as Pseudomonas aeruginosa
and Escherichia coli. Communication of resistance depended on upregulation of putrescine
synthesis and YceI, a widely conserved low-molecular weight secreted protein. Deletion of genes
for the synthesis of putrescine and YceI abrogate protection, while pharmacologic inhibition of
putrescine synthesis reduced resistance to PmB. Polyamines and YceI were also required for
heteroresistance of B. cenocepacia to various bactericidal antibiotics. I propose that putrescine
and YceI resemble "danger" infochemicals whose increased production by a bacterial
subpopulation, becoming more resistant to bactericidal antibiotics, communicates higher level of
resistance to more sensitive members of the population of the same or different species.
Putrescine protects from antibiotics through its ability to compete with PmB for surface
binding and protection against antibiotic-induced oxidative stress. YceI proteins are conserved
bacterial lipocalins or “bacteriocalins”. Bacteriocalins from different Gram-positive and Gramnegative bacteria are involved in the response to hydrophobic or amphiphilic antibiotics (PmB,
rifampicin, norfloxacin and ceftazidime) but not hydrophilic ones (such as gentamicin). This
effect is achieved by their preferential binding affinity to hydrophobic moieties. Together, my
findings uncover a novel, non-genetic and cooperative mechanism of transient increase in
resistance chemically communicated from more resistant members of heterogeneous populations
to less resistant bacteria of the same or other species. This multifactorial mechanism of
communication of antibiotic resistance offers novel targets for antimicrobial intervention.
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Introduction
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El-Halfawy OM, and Valvano MA (2012). Non-genetic communication of antibiotic resistance:
Rethinking the mechanisms of intrinsic resistance and strategies for antimicrobial drug design.
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with permission of Informa Healthcare.
El-Halfawy OM, and Valvano MA (2011). Heteroresistance of opportunistic bacteria to
antimicrobial peptides: a new challenge to antimicrobial therapy of cystic fibrosis infections.
Therapy 8, (6), 591-595. With permission of Future Medicine Ltd.
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1.1. Introduction
Infectious diseases are among the most aggressive killers worldwide claiming the lives of
millions of people annually. Microbial infections in general constitute a major burden on the
society and the healthcare systems. While immunization provides a preventative approach
against infection with certain bacteria; this strategy does not provide protection against the
increasing variety of microbial infections. Since the middle of the twentieth century, antibiotics
helped eradicate infections saving lives. However, the rapid emergence of antibiotic resistance in
addition to the severe decline in development of new antibiotics following the golden era of
antibiotic discovery have often put patients and healthcare practitioners in the losing side of
combating microbial infections. Furthermore, the individuality of response to antibiotics within a
population of bacteria also known as antimicrobial heteroresistance may further complicate the
clinical picture impeding the eradication of microbial infections. On the other hand, the ability of
bacteria to transfer antibiotic resistance determinants by means of horizontal gene transfer
mechanisms has led to the rapid spread of multi-drug resistance across various bacterial species.
The ability of bacteria to communicate antibiotic resistance among each other via small
molecules has recently drawn attention to the probability of the transient increase in antibiotic
resistance and protection of bacteria, normally sensitive to an antibiotic, mediated by more
resistant bacteria by non-genetic mechanisms leading to therapeutic failure. In this section, I will
introduce different classes of antibiotics together with the mechanisms of response and resistance
of bacteria to antibiotic exposure. In addition, I will discuss the phenomenon of antimicrobial
heteroresistance, which has been poorly characterized in the literature despite its clinical
importance, as well as the chemical communication of antibiotic resistance among different
bacteria.

1.2. Antibiotics and the dilemma of antibiotic resistance
Common usage of the term antibiotics often extends to include synthetic antimicrobial
chemotherapeutic agents, such as sulfonamides and quinolones (1). Antibiotics differ markedly
in physical, chemical, and pharmacological properties, in antimicrobial spectra, and in
mechanisms of action (1).
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1.2.1. Classes of antibiotics
Classically, antibiotics are classified into two broad classes; bacteriostatic and bactericidal
agents. Bacteriostatic agents act by preventing the growth of bacteria, whereas bactericidal ones
act by killing bacteria. A generally accepted definition of bactericidal activity is ~99.9%
reduction in viable bacterial density in an 18–24-h period in a standard Minimum bactericidal
concentration (MBC) assay according to the CLSI guidelines, whereas bacteriostatic activity has
been defined as a ratio of MBC to MIC of >4 (2). Indeed, these 2 categories may overlap in that
no category of antibiotics exclusively kills bacteria and another that only inhibits growth of
bacteria; bacteriostatic and bactericidal categorizations in clinical practice are not absolute (2).
Selected classes of antibiotics pertaining to the work of the present thesis will be discussed
briefly in this section.
1.2.1.1. Antimicrobial peptides
Antimicrobial peptides (APs) are evolutionarily conserved molecules involved in the defense
mechanisms of a wide range of organisms. Produced in bacteria, insects, plants and vertebrates,
APs protect against a broad array of infectious agents (3). Moreover, APs are being tested in
clinical trials as anti-infective agents while others are already in use, such as polymyxin B (PmB)
(4). APs vary enormously in sequence and structure, but certain features are common. The
natural APs are generally 12–50 amino acids in length, have a net positive charge, and contain
around 50% hydrophobic amino acids. They fold into amphiphilic structures in which the
positively charged and hydrophilic domain(s) are well separated from the hydrophobic domain(s)
(4). Such molecules are well suited to interact with membranes, especially bacterial membranes
with their negatively charged and hydrophilic head groups and hydrophobic cores (4). Based on
their amino acid composition, size and conformational structures, APs can be divided into
several categories, such as peptides with (i) α- helix structures, e.g. human cathelicidin; (ii) βsheet structures stabilized by disulfide bridges, e.g. human defensins; (iii) extended structures,
e.g. indolicidin, a bovine AP; and (iv) loop structures, e.g. cyclic defensins found in rhesus
macaques (3), and cyclic lipopeptides like polymyxin B (PmB) (4).
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The exact mechanism by which APs exert their antimicrobial properties is continuously being
investigated, but it is generally accepted that cationic APs interact by electrostatic forces with the
negatively charged phospholipid headgroups on the bacterial membrane and cause disruption (3).
The most widely accepted mechanisms of interaction are the “barrel stave” model, in which the
peptides bind to the cell membrane, then the peptides themselves insert into the hydrophobic
core of the membrane forming a pore, causing leakage of cytoplasmic material and death of the
cell, and the “carpet model” in which peptides bind to the phospholipids at the outer surfaces of
the cell membrane, followed by the alignment of the peptide monomers, then the peptides
reorient themselves towards the hydrophobic core of the membrane causing the disintegration of
the lipid bilayer (3). Permeabilization of bacterial membranes is a crucial step in the
antimicrobial activity of APs, but evidence shows that they also inhibit a variety of essential
microbial processes, such as protein, cell wall, and nucleic acid synthesis (5).
Alteration of the surface charges by reducing the net negative charges is one of the major
mechanisms that bacteria utilize to resist killing by antimicrobial peptides (5). Examples of this
strategy of resistance are phosphoethanolamine or aminoarabinose modifications of lipid A, lysyl
phosphatidylglycerol modification of membranes, and shielding of surface charges by capsular
polysaccharides (5). Other mechanisms of resistance include degradation by extracellular
proteases, reduced import and increased export by efflux pumps (5, 6).
1.2.1.2. β- lactams
Penicillin G (benzylpenicillin) was the first β-lactam antibiotic introduced into clinical practice.
β-lactam antibiotics now include: penicillinase-resistant, amino-, carboxy- , indanyl-, and ureidopenicillins; first- to fifth-generation cephalosporins; monobactams; and carbapenems. The
distinctive structural feature of a β-lactam is the highly reactive four-membered ring (7). All βlactam antibiotics are bactericidal agents that inhibit cell wall synthesis through inhibition of
bacterial transpeptidases known as penicillin-binding proteins (PBPs), which are essential
enzymes that catalyze the final crosslinking step since the β-lactams are structurally similar to
the penultimate D-Alanyl-D-Alanine of the pentapeptide that is attached to N-acetyl muramic
acid. Subsequent steps in cell wall synthesis are hindered while autolysis by cell wall degrading
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(autolytic) enzymes continues. Bacterial cells become permeable to water, rapidly take up fluid,
and eventually lyse (7, 8).
Bacteria tend to avoid the bactericidal effect of β-lactams through: production of betalactamases, altered PBPs that exhibit low affinity for β-lactam antibiotics such as PBP 2'
(PBP2a) of Staphylococcus aureus and lack or diminished expression of outer membrane
proteins (OMPs) in Gram-negative bacteria which restricts the entry of certain β-lactams into the
periplasmic space of Gram-negative bacteria and hence access to PBPs on the inner membrane
(7). Furthermore, efflux mechanisms have been described in which bacteria pump out β-lactam
antibiotics (9).
1.2.1.3. Aminoglycosides
The aminoglycosides are bactericidal antibiotics active against many Gram-negative aerobes and
against some strains of staphylococci. They are taken up into sensitive bacterial cells by an active
transport process that is inhibited in anaerobic, acidic, or hyperosmolar environments (10). An
essential target of aminoglycoside antibiotics is the ribosome where they bind to the 16S
ribosomal RNA and this binding interferes with protein synthesis. Low concentrations of
aminoglycosides can cause misreading of the genetic code and higher concentrations will block
translation (11). The bactericidal effect of aminoglycosides may be due to aberrant proteins
resulting from misreading which form membrane channels or inhibition of other steps in
metabolism (12). Aminoglycosides are also capable of directly disrupting the integrity of the
outer membrane in Gram negative bacteria by displacing the divalent cations which bridge
adjacent LPS molecules and are required to maintain integrity. This alteration in outer membrane
results in the 'self-promoted' uptake into the cell (11, 12).
The major mechanisms of resistance to aminoglycosides in pathogenic bacteria are: (i)
deactivation of the drug, e.g. by N-acetylation, O-nucleotidylation, or O-phosphorylation, (ii)
reduction of the intracellular concentration of the drug by alteration of outer membrane
permeability, decreased inner membrane transport, or active efflux from the cell, and (iii)
alteration of the target by mutation in ribosomal proteins or in 16S rRNA (13, 14). Methylation
of 16S ribosomal RNA has emerged as a mechanism of resistance against aminoglycosides
among Gram-negative pathogens belonging to the family Enterobacteriaceae and glucose5

nonfermentative microbes, including Pseudomonas aeruginosa and Acinetobacter species. This
event is mediated by a newly recognized group of 16S rRNA methylases, which share modest
similarity to those produced by aminoglycoside-producing actinomycetes (15).
1.2.1.4. Tetracyclines
The tetracyclines are mainly bacteriostatic, with a broad spectrum of antimicrobial activity
including many aerobic and anaerobic Gram-positive and Gram-negative pathogenic bacteria,
Chlamydiaceae, Mycoplasma spp., Rickettsia spp., spirochaetes, and some protozoa (10).
Tetracyclines are taken up into sensitive bacterial cells by an active transport process (11). Once
within the cell they bind reversibly to the 30S subunit of the ribosome, preventing the binding of
aminoacyl transfer RNA and inhibiting protein synthesis and hence cell growth (16). Although
tetracyclines also inhibit protein synthesis in mammalian cells they are not actively taken up,
permitting selective activity against the infecting organism (11).
Resistance to the tetracyclines is usually plasmid-mediated and transferable (10). It is often
inducible, and appears to be associated with the ability to prevent accumulation of the antibiotic
within the bacterial cell, both by decreasing active transport of the drug into the cell and by
increasing tetracycline efflux most commonly through the tetracycline resistant efflux proteins
which belong to the major facilitator superfamily (MFS)(16, 17).
1.2.1.5. Chloramphenicol
Chloramphenicol is a naturally occurring compound discovered in a systematic screening of
Streptomyces strains following the discovery of streptomycin in the 1940s (18).
Chloramphenicol acts by inhibiting the peptidyl transferase reaction at which the peptide bond is
formed on 70S ribosomes (18). It possesses a broad spectrum of activity by acting against Grampositive and Gram-negative bacteria, in addition to chlamydiae and rickettsiae; being mainly
bacteriostatic in action especially against Gram-negative bacteria (18). Acetyltrasferases,
bacterial enzymes that acetylate the hydroxyl groups of chloramphenicol hence inactivating it,
are the most common mechanism of resistance against this antibiotic (19). In addition, efflux
proteins specific for chloramphenicol has been described providing high-level resistance (19).
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1.2.1.6. Rifampicin
Rifampicin (known in the US as rifampin) is a semi-synthetic derivative of rifamycin B produced
by Streptomyces mediterranei. It interferes with mRNA formation by binding to the β-subunit of
DNA-dependent RNA polymerase (RpoB) (20). It exhibits potent bactericidal activity against a
range of bacteria, notably staphylococci and legionellae; it is a useful antimycobacterial drug
used for tuberculosis and leprosy (20). Resistance readily arises by point mutations in the
rifampicin-binding region of rpoB (19).
1.2.1.7. Quinolones
Fluoroquinolones are bactericidal (10, 21). They inhibit bacterial DNA synthesis by inhibiting
the A subunit of DNA gyrase and topoisomerase (10). DNA gyrase, encoded by gyrA and gyrB,
is the enzyme responsible for inducing negative supercoils in DNA, whereas topoisomerase IV,
encoded by parC and parE, is involved in DNA relaxation and separation (22). In general,
fluoroquinolones have good in vitro activity against many Gram-positive and Gram-negative
pathogens. These agents also are active against some drug resistant pathogens, including
penicillin- or macrolide-resistant Streptococcus pneumoniae (21).
Mutations in specific regions termed quinolone resistance-determining regions (QRDR) of the
parC or gyrA genes of topoisomerase IV and DNA gyrase lead to development of resistance to
quinolone antimicrobials (21). Active efflux, an alternate mechanism leading to fluoroquinolone
resistance, prevents accumulation of the antimicrobial in the bacterial cell. Efflux typically
results in low-level resistance and may or may not occur in conjunction with mutations in
topoisomerase IV or DNA gyrase (21).There is complete cross-resistance between ciprofloxacin
and the other fluoroquinolones (10, 23).
1.2.1.8. Novobiocin
Novobiocin is a bacteriostatic coumarin antibiotic that binds to the B subunit of DNA gyrase
(GyrB) blocking the ATPase activity and hence inhibiting DNA supercoiling (24). It is active
against Gram-positive organisms, with little activity against enteric Gram-negative bacilli (20).
Resistance against novobiocin may be mediated by multi-drug efflux systems (19), or due to
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mutation in gyrB (24). In 2009, FDA withdrew the approval for use of novobiocin capsules on
the market (25).
1.2.1.9. Trimethoprim
Trimethoprim, a bacteriostatic agent (2), is a diaminopyrimidine that inhibits dihydrofolate
reductase (DHFR), the enzyme that converts the metabolically inactive dihydrofolate into the
active form tetrahydrofolate (20). Such inhibition leads to various effects, including failure to
synthesize purine nucleotides and thymidine (20). The selective toxicity of trimethoprim stems
from its greater affinity for the dihydrofolate reductase of bacteria than for the corresponding
mammalian enzyme (20). Mutations of the chromosomal DHFR or plasmid-encoded, druginsusceptible DHFRs are the most common means of resistance against trimethoprim that also
led to rapid dissemination of resistance in particular the insusceptible enzyme encoded by mobile
genetic elements (26).
1.2.2. Intrinsic versus acquired resistance to antibiotics
Bacterial resistance to antibiotics can be achieved through intrinsic or acquired mechanisms (19).
Intrinsic resistance to antibiotics is a natural trait independent of antibiotic selective pressure;
whereas acquired resistance is induced upon exposure of previously susceptible bacteria to
antibiotics.
1.2.2.1. Intrinsic resistance to antibiotics
Many bacteria display intrinsic resistance to different classes of antibiotics; a trait that is
genetically encoded within their genome, and not accredited to horizontal gene transfer (27).
Intrinsic resistance is conventionally attributed to impermeability of the bacterial cell envelope
(mainly due to the outer membrane of Gram-negative bacteria) in conjunction with multidrug
efflux pumps that effectively reduce the intracellular concentration of antibiotics (28). However,
recent studies have revealed that intrinsic antibiotic resistance further involves a complex
network of genetic loci; deletion of such genes renders bacteria hyper-susceptible to antibiotics
(27).
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Outer membrane (OM) impermeability acts as a barrier in Gram-negative bacteria that
overcomes the large permeability threshold of the peptidoglycan layer (which renders Grampositive bacteria susceptible to various antibiotics). Moreover, porins, proteins channels within
the OM for the uptake of key nutrients, restricts the influx of numerous antibiotics [references in
(27)]. Alternatively, constitutive modification of the OM results in intrinsic resistance; for
example, the decoration of Burkholderia cenocepacia OM with the positively charged
aminoarabinose sugar prevents the essential initial binding of antimicrobial peptides to its
surface rendering it highly resistant to APs (29).
Efflux as a mechanism of antibiotic resistance was first reported for tetracyclines; since then, it
has been documented as a mechanism of resistance against a wide range of antibiotics in many
Gram-positive and Gram-negative bacteria [references in (19)]. Efflux pumps can either be
substrate specific such as the Mef efflux transporters in streptococci which transport 14- and 15membered macrolides only, or they can be more broad-spectrum dealing with different antibiotic
classes such as the Escherichia coli AcrAB efflux system (19). Most drug efflux proteins that
span the bacterial membrane belong to five distinct families: the ATP binding cassette (ABC),
the major facilitator (MF), the multidrug and toxic-compound efflux (MATE), the small
multidrug resistance (SMR), and the resistance-nodulation-division family (RND) [references in
(27)]. ATP hydrolysis drives efflux in the primary (ABC) transporters; whereas efflux by the
other families is driven by proton (and sodium) motive force and is hence called secondary
transport (19).
Synergistic relationship between OM permeability barrier and active efflux systems results in
high-level of intrinsic resistance in many Gram-negative bacteria (27); conceivably, certain
porins and efflux systems are co-regulated (19). However, additional chromosomally encoded
elements are involved in intrinsic resistance to antibiotics; such elements act in a concerted
manner towards such resistance phenotype [references in (27)]. Evidences challenging the
classical definition of intrinsic resistance demonstrate that such resistance is not merely due to
protective shields, but rather encompass the action of numerous proteins from all functional
categories forming a complex and dynamic network including proteins involved in amino acid
biosynthesis and metabolism, protein secretion and export, and transport of small molecules (30).
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1.2.2.2. Acquired resistance to antibiotics
Acquired mechanisms of antibiotic resistance involve mutations in chromosomally located genes
and the horizontal genetic transfer (HGT) of resistance determinants borne on plasmids,
bacteriophages, transposons, and other mobile genetic material (19). HGT is generally
accomplished through the processes of transduction (via bacteriophages), conjugation (via
plasmids and conjugative transposons), and transformation (via incorporation of free DNA from
dying organisms) (31).
Alteration of the antibiotic target sites is one mechanism of acquired resistance. This can be
mediated through mutation(s) of gene encoding these targets leading to non-susceptible variants;
examples are discussed in previous sections about different classes of antibiotics. Alternatively,
this can occur through chemical modifications such as the vanA gene cluster-mediated
modification of peptidoglycan in response to glycopeptide antibiotics (32). Genomic duplication
of antibiotic resistance genetic determinants is another means of acquired resistance leading to
overexpression of the resistance mechanism (19). Other mechanisms of acquired resistance
include enzymatic chemical modification of the antibiotic itself rendering it inactive. Antibioticmodifying enzymes may either degrade the antibiotics such as β-lactamases and extracellular
proteases, or perform chemical transformations such as aminoglycoside-modifying proteins
[references in (19)].
1.2.3. Antibiotic resistant bacteria
The crisis of antibiotic resistance presents a unique clinical challenge due to the widespread of
multi-drug resistant (MDR) organisms.These MDR organisms may be classified into at least two
groups; well-known (or primary) pathogens, and opportunistic pathogens (33).
1.2.3.1. Antibiotic resistant primary pathogens
Primary pathogens are highly virulent microorganisms capable of causing a disease in an
otherwise normal or healthy individual (34). These pathogens may also cause more drastic
disease in a host with compromised immunity (34). Many of these pathogens are former nonpathogenic commensal flora that acquired antibiotic resistance genes and increased virulence
such as community-associated methicillin resistant Staphylococcus aureus (CA-MRSA), and
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multi-drug resistant Escherichia coli (35). Mycobacterium tuberculosis is another serious
pathogen specially that it mostly displays extensive drug-resistance (XDR) (19). Other important
pathogens that may display MDR include Shigella spp. and Salmonella spp (36).
1.2.3.2. Antibiotic resistant opportunistic pathogens
Opportunistic pathogens are mostly environmental bacteria and may be normally in contact with
the host; however, they only cause an infectious disease following an injury such as an open
fracture; or immunosuppression whether due to a disease such as malaria or cystic fibrosis (CF),
or a drug as cytotoxic chemotherapy (34). The bacterial opportunistic pathogens are frequently
intrinsically resistant to multiple antibiotics (33). Examples of these pathogens include
Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Acinetobacter baumannii and
Burkholderia cepacia complex (33).
In this thesis, I investigate novel mechanisms of high-level intrinsic multidrug resistance using
Burkholderia cenocepacia as a model bacterium. B. cenocepacia is an environmental,
opportunistic pathogen that belongs to the B. cepacia complex; it causes serious respiratory
infections in CF patients and expresses high-level multidrug intrinsic resistance (37). These
infections are associated with faster decline in lung function, debilitating exacerbations and
ultimately death (38-40), and they also reduce the survival of CF patients after lung transplant
(41). B. cenocepacia possesses an arsenal of virulence determinants resulting in such aggressive
infections and poor prognosis of the infected patients [references in (37)].

1.3. Antimicrobial Heteroresistance: an emerging field in need of clarity
Infections by multi-drug resistant bacteria impose a serious encumber on the society and
economy worldwide and account for a soaring fraction of global morbidity and mortality.
Variable responses to the antibiotic from bacterial cells within the same population, a
phenomenon known as heteroresistance, further complicates the problem of antibiotic
resistance.Heterogeneous resistance to antibiotics was first described in 1947 for the Gramnegative bacterium Haemophilus influenzae (42), and almost 20 years later for Gram-positive
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staphylococci (43), but the first reported use of the term „heteroresistance‟ was in 1970 (44).
Clinical laboratory standards and recommendations for practices concerning antimicrobial
resistance are developed by organizations such as the Clinical and Laboratory Standards Institute
(CLSI), the British Society of Antimicrobial Chemotherapy (BSAC), and others. Therefore,
antimicrobial susceptibility testing methods, such as the minimum inhibitory concentration
(MIC) and disc-diffusion techniques, and standard guidelines to define isolates as susceptible,
resistant or intermediately resistant to any antibiotic are generally agreed upon world-wide. In
contrast, heteroresistance is poorly characterized and consensus-based standards to define and
identify heteroresistant bacteria are lacking.
The term „heteroresistance‟ is indiscriminately used in the literature to describe not only
population-wide variation in antibiotic resistance phenotype but also other observations.
Furthermore, methods to determine heteroresistance vary significantly among laboratories.
Together, this increases the confusion regarding this phenomenon, precluding establishing its
clinical significance and implementing proper therapeutic interventions and guidelines. Here, I
review the available literature on heteroresistance, to expose the contradictions and variations in
its definition.
1.3.1. Multiple definitions of heteroresistance
Heteroresistance broadly refers to a population-wide, variable response to antibiotics. Several
reports, including the earliest studies describing the phenomenon in 1964 and 1970, used this
definition without specifying a particular antibiotic concentration range (43-46). Figure 1
illustrates the notion of heteroresistance (A) in contrast to a bacterial population homogeneously
responding to an antibiotic (B). This phenomenon is distinct from bacterial persistence. Persisters
neither die nor grow in the presence of antibiotic (Fig. 1C), suggesting they are dormant (47).
These bacterial cells grow only after the antibiotic removal, and the progeny of persisters do not
exhibit increased resistance to the antibiotic; they rather show the pattern of sensitivity to the
antibiotic identical to that of the original bacterial population (48).
In other reports describing heteroresistance, specific concentration ranges were indicated. For
example, colistin heteroresistance in Acinetobacter baumannii was used to describe
subpopulations (less than 0.1% from 108 to 109 CFU/ml) growing in the presence of 3 to 10
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µg/ml colistin, while the MIC of the culture ranged from 0.25 to 2 µg/ml (49). In another report,
heteroresistance was described when a subset of the microbial population was considered
resistant to an antibiotic while the rest of the population was generally considered to be
susceptible to that antibiotic based on the concentration breakpoints used for traditional in-vitro
susceptibility testing (50). This definition does not encompass cases where the bacterial culture
comprises subpopulations with varying levels of resistance, and therefore the entire population
including the least resistant members is considered resistant to the antibiotic (Fig. 2).
Other definitions for heteroresistance were also used, which further contributed to misconception
about the nature of the phenomenon. Some of them were based on a single cut-off concentration,
which did not describe the pattern of resistance among various members of a bacterial
population. For example, heteroresistance was defined by growth of A. baumannii colonies on
plates containing 8 µg/ml of colistin, with confirmation of an MIC of 8 µg/ml by subsequent
broth microdilution test (51). Similarly, heterogeneously resistant staphylococci were defined as
any culture containing subpopulations at a frequency of 1 in 106 cfu/ml or higher with MIC > 4
μg/ml for vancomycin or ≥ 16 μg/ml for teicoplanin (52) or simply above the CLSI breakpoints
(53). A similar approach was adopted by setting a cut-off diameter of 10 mm in disc diffusion
assays below which the strain was considered heteroresistant rather than merely resistant (54).
While heteroresistance was properly recognized by population analysis profiling (PAP), the
improper definition misrepresented the phenomenon, giving rise to ambiguity in its
understanding at an early stage of its discovery (54). In another approach, high MIC of
Enterococcus faecium against vancomycin (>256 mg/L) determined by broth dilution but low
MIC (=1.8 mg/L) by Etest was suggestive of heteroresistance (55).
Other forms of bacterial heterogeneous behaviour against antibiotics have been reported. Certain
S. aureus strains displayed resistance to high concentrations of methicillin (64 to 512 mg/L) and
susceptibility to low concentrations of methicillin (2 to 16 mg/L) (56). This phenomenon, termed
"Eagle-type" resistance, was similar to the previously described Eagle killing by penicillin, in
which the bactericidal action of penicillin was paradoxically reduced at high
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Figure 1. Illustration of the phenomenon of heteroresistance to antibiotics.
(A) heteroresistant population; (B) homogeneous population; and (C) the phenomenon of
persistence. Bold cells denote alive cells, dotted cells denote dead cells, red bold cells denote
dormant persisters.
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Figure 2.Heteroresistant vs. homogenous response to antibiotics.
Dotted lines represent the breakpoints for resistance. Homogenous bacterial cultures (A-C) can
either be A, susceptible, B, of intermediate susceptibility, or C, resistant to an antibiotic
according to the traditional in vitro susceptibility testing. Heteroresistant bacteria (D-F) may be:
D, completely susceptible to an antibiotic, whereby all the different subpopulations respond to
antibiotic concentrations extending below the breakpoints. This form is less likely to be detected
and is probably the least clinically important (unless the least responsive subpopulations develop
resistance to the antibiotic). E, the more classical form of heteroresistance in which the majority
of the bacterial population is susceptible to an antibiotic with a highly resistant minority.
Antibiotic treatment guided by the traditional susceptibility testing breakpoints would select for
the resistant subpopulation, leading to therapeutic failure. F, the entire bacterial population,
including the least resistant subpopulations, is resistant to the antibiotic. Chemical
communication of antibiotic resistance from the more resistant members of the population
protecting less resistant bacteria is the major concern of such bacterial populations.
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concentrations (57). Similar pattern of 2-peaks of growth in population analysis profiles was
observed in A. baumannii with cefepime (58). Other S. aureus strains displayed 'thermosensitive'
heteroresistance (59), whereby cultures growing in the presence of high concentrations of
methicillin at 30°C lost this ability within 30 min after shifting the growth temperature to 37°C.
Shifting the temperature in the reverse direction resulted in an equally rapid expression of
methicillin resistance (59).
Adding to the confusion, 'heteroresistance' was often applied to describe incidences of infection
with bacterial strains exhibiting different levels of resistance to an antibiotic. Amoxicillinresistant and -susceptible Helicobacter pylori isolates (with MICs of 2 mg/L and 0.06 mg/L,
respectively) were observed in different biopsies from one patient, a case described as 'interniche' heteroresistance (60). More recently, pairs of H. pylori isolated from the same patients
showed different levels of resistance to levofloxacin, metronidazole and in only one case to
clarithromycin; the antibiotic resistant strains were mostly derived from a pre-existing sensitive
strain rather than from mixed infection (61). Similar cases were reported in Mycobacterium
tuberculosis as heteroresistance, defined as the coexistence of bacteria susceptible and resistant
to anti-tuberculosis drugs in the same patient (62, 63). More recently, heteroresistance in M.
tuberculosis was defined as the coexistence of populations with different mutations at drug
resistance locus within a sample of organisms (64).Therefore, it is clear that heteroresistance
does not have a uniformly consistent definition, making it difficult to compare studies
retrospectively to assess its clinical significance.

1.3.2. Measuring heteroresistance
1.3.2.1. Population analysis profiling (PAP).
Population analysis profiling (PAP) is considered the gold standard method for determining
heteroresistance. In this method, the bacterial population is subjected to a gradient of antibiotic
concentrations and the bacterial growth at each of these concentrations is quantified. The PAP
performed since the earliest description of the phenomenon adopted the format of standard MIC
determination techniques with antibiotic increments following a 2-fold difference pattern. PAP
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assays are mostly done by spread-plate techniques for cfu counting (43, 44, 46, 54, 56, 58, 59,
65-81). Cfu counting by dropping smaller aliquots showed similar efficiency as spread-plate
(82). Turbidimetric PAP assays are also performed using 2-fold antibiotic increments (83), and
antibiotic increments wider than 2-fold steps were also used (42, 84). However, in most of the
studies no criteria were set to define homogeneous vs. heterogeneous resistance. The lack of a
standardized method to perform PAP, in particular the selection of increments of antibiotic
concentration, has led to confounding observations. For example, several studies investigating
the response to glycopeptide antibiotics used PAP assays with narrow increments in antibiotic
concentrations, such as 1 µg/ml steps (49, 53, 85-105) and even as low as 0.1 µg/ml steps (106).
In these cases, a homogeneous strain could be inaccurately considered heteroresistant, and
sometimes the same strain appeared as homogenous in one curve and heterogeneous in another
(52).
A modified PAP assay comparing the area under the curve (PAP-AUC) of a given strain to that
of a strain previously shown to be heterogeneous was used to determine the heterogeneous
response of S. aureus to vancomycin (107-121). PAP-AUC ratios between test and control strain
of <0.9, 0.9 to 1.3, and >1.3 were considered indicative of vancomycin susceptible S. aureus,
heterogeneous vancomycin intermediate S. aureus (hVISA), and vancomycin intermediate S.
aureus (VISA), respectively. The concern with this method is its comparative nature that relies
on the response to vancomycin of the S. aureus control strain, whereby any instability in its
antibiotic resistance phenotype would cause significant changes in the results.
Another variation of PAP was used to screen clinical isolates for heteroresistance against
glycopeptides. The typical PAP method is time-consuming and labor intensive, which may not
be suitable for clinical laboratories that screen hundreds of isolates for heteroresistance. Thus,
screening of clinical isolates was performed on plates containing only one concentration of either
vancomycin or teicoplanin, hence called glycopeptides screening plates (96, 108-110, 115, 122124). The concentrations of glycopeptides and the medium type were slightly altered among
different laboratories. However, some comparative studies proved these methods not reliable and
showed poor performance in detection of heteroresistance (123, 125).
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1.3.2.2. Disc diffusion and Etest assays.
Disc diffusion assays were used early on to detect heteroresistance (43, 54, 58, 95, 126-132).
Later, Etest strips were similarly used at the same inoculum size as that recommended for the
traditional in vitro susceptibility testing (55, 58, 90, 103, 104, 106, 108, 111, 113, 116, 120, 126,
128-131, 133-141). Special Etest strips were developed for glycopeptides resistance detection
(GRD Etest) which are double-sided strips, one side contains vancomycin while the other
contains teicoplanin (109, 114, 115, 121, 142). As with PAP, the lack of guidelines hampers the
detection of heteroresistance using Etest and disc diffusion assays. The clear phenotype
indicating heteroresistance is the appearance of distinct colonies growing at the otherwise clear
zone of inhibition in the disc diffusion or Etest assays. However, many reports set cut-off
concentrations or inhibition zone diameters to decide based on which the heterogeneity of the
response of the bacterial population to antibiotics as discussed previously, but such cut-off values
cannot sufficiently describe the population-wide characteristics.

1.3.2.3. Additional methods to characterize heteroresistance.
Gradient agar plates, containing a linear gradient of antibiotic, were used to determine the
susceptibility of clinical isolates to antibiotics and identify antibiotic-resistant cells within
bacterial populations (143). Flow cytometry using a fluorescent penicillin derivative is another
approach employed to assess methicillin resistant S. aureus (MRSA) isolates with known
heteroresistance (144). However, this method was not compared to others used for
heteroresistance detection, thus its reliability cannot be assessed. Other methods to characterize
heteroresistant bacteria have included bacterial re-growth at later time points in time-kill assays
after an initial significant reduction in survivors (49, 80), and increase in MIC values of the same
strain on prolonging the incubation time (67). In both cases, these strategies provide time to the
less abundant more resistant members of the population to proliferate. On the other hand,
uninterpretable and irreproducible MIC results featured mainly in the form of „skipwells‟ (wells
exhibiting no growth although growth still occurs at higher concentrations of the antibiotic)
could suggest heteroresistance which was further confirmed by PAP in some of the tested
isolates of Enterobacter cloacae and Enterobacter aerogenes against polymyxin B (145).
18

1.3.3. Reports of heteroresistance in different bacteria
Heteroresistance denotes the presence of subsets in the population of bacterial cells with higher
levels of resistance to antibiotics. The more resistant bacterial cells were often isolated, but the
stability of such high level of resistance differed among bacteria. After 5 to 10 serial passages in
antibiotic-free medium some highly resistant cells reverted to the heterogeneous resistance
phenotype displayed by their original population (43, 70, 80), whereas others retained their high
level of resistance (68). On the other hand, bacteria exhibited a distinctive pattern of
heteroresistance; cultures showed fixed strain-specific frequencies of more resistant
subpopulations each time suggesting genetic control over this phenomenon (70).
Heteroresistance has been reported in several Gram-positive and Gram-negative bacteria. Most
of the reported incidences of heteroresistance involve bactericidal antibiotics including βlactams, glycopeptides, antimicrobial peptides, fluoroquinolones, aminoglycosides, and the
nitroimidazole antibiotic metronidazole, which acts on anaerobic bacteria (Tables 1 and 2). This
suggests that heteroresistance is more apparent with bactericidal antibiotics. However, no
systematic comparisons of the response of heteroresistant bacteria to bacteriostatic versus
bactericidal antibiotics have been reported. Only two studies report incidences of
heteroresistance against bacteriostatic antibiotics. In one of them, S. aureus strains showing
heteroresistance to fusidic acid were reported (85), but the PAP was performed using a narrow
range of fusidic acid concentrations in small increments. In the other study, Bordetella pertussis
showed heteroresistance to erythromycin (128), which could only be detected after 7 days of
incubation using Etest and disc diffusion techniques, as indicated by the appearance of discrete
colonies in the clear zones of inhibition.
For Gram-positive bacteria, the majority of heteroresistance cases were reported in S. aureus
although there are several reports concerning other Staphylococci, Enterococci and Clostridium
difficile. The earliest reports of heteroresistance in S. aureus were on the response to methicillin
(43, 44), but this extended to other β-lactams, which accounted for the majority of research
related to heteroresistance until late 1990s (Table 1).
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Table 1. Heteroresistance in Gram-positive bacteria
Organism
S. aureus (MRSA
isolates)
S. aureus
S. aureus

Staphylococcus
epidermidis and S.
haemolyticus
S. aureus
S. aureus
S. aureus

S. aureus
S. epidermidis
Streptococcus
pneumoniae

Antibiotic
Methicillin
Cephalexin& oxacillin
cephalothin,
methicillin,
and cephalexin
methicillin

nafcillin
Methicillin
“Thermosensitive”
Methicillin

Methicillin
"Eagle-type"
Methicillin/ oxacillin
Penicillin

Method
PAP by cfu (2 fold increments).
Disc diffusion (colonies in inhibition zone)
PAP by cfu (2-fold increments).
PAP by cfu (2 fold increments).
Disc diffusion.

Year, Ref.
1964(43)

PAP by cfu (2-fold increments).

1985 (66)

PAP by cfu (2 fold increments).
MIC (MICs at 48 h > at 24 h)
PAP by cfu (2 fold increments).

1985 (67)

PAP by cfu

1993 (70); 1994 (46);
1996 (71); 1996 (72);
1997 (73); 2003 (74);
2013 (146)
2001 (56)

PAP by cfu (2 fold increments).
PAP
Etest (complicated by zone of hemolysis);
PAP by cfu (very small increments, as low as
0.1 mg/L)

S. aureus
S. aureus
S. aureus

Oxacillin
Cefazolin; Methicillin
Methicillin

S. aureus

Methicillin/ oxacillin

S. pneumoniae
S. aureus
S. epidermidis

S. aureus

Penicillin
Ceftaroline
Methicillin;
Vancomycin;
Teicoplanin
Methicillin;
Vancomycin
Methicillin;
Vancomycin
Vancomycin

S. aureus

Vancomycin

S. aureus

Vancomycin

PAP
Disc diffusion: (Satellitism detected)
Cfu on Vancomycin (4 mg/L) plates.

Enterococcus
faecium
S. aureus

Vancomycin

E-tests (growth in zone of inhibition).

Vancomycin

PAP by cfu (narrow increments).

Coagulase
negative
staphylococci
S. aureus

Vancomycin;
Teichoplanin

PAP by cfu (narrow increments).

Vancomycin

Etest

Staphylococcus
spp.

Vancomycin;
Teichoplanin

BHI Agar screening method with 4 or 6 mg/L;
PAP (narrow increments)

S. aureus
S. aureus

PAP by cfu (2 fold increments)
Flow cytometry using Bocillin FL, known
heteroresistant MRSA used as reference.
PAP & selection of high resistance by
growing at subinhibitory concentration of
oxacillin.
PAP by cfu
PAP by cfu
PAP by cfu (2 fold increments)

1970(44)
1972 (54)

1986 (59)

2005 (147)
2007 (106)

2008 (45)
2008 (77)
2009 (144)
2009 (148)

2014 (149)
2014 (150)
1999 (86)

PAP by cfu (compared spread-plate to spotting
of 10 µl techniques):
PAP

2001 (82)

PAP (1 mg/L increments).

1997 (53); 2000 (87);
2001 (88); 2008 (151)
1999 (127)
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2004 (91)

1999 (125); 2000
(122)
2001 (133)
2002 (89); 2005 (92);
2005 (52); 2009
(152); 2011 (102)
2006 (93)

2007 (135); 2009
(140)
2007 (96)

S. aureus

Vancomycin and
Teicoplanin

BHI agar + 6 mg/L Vancomycin, Mueller
Hinton agar (MH) + 5 mg/L Vancomycin and
MH + 5 mg/L Teicoplanin); Etest
macromethod (using a 2 McFarland)
MIC by broth dilution; Etest (colonies in
inhibition zone).
Modified PAP by cfu on BHI agar +0.25, 0.5,
1, 1.5, 2, 4, 6 and 8 mg/L Vancomycin. The
area under the curve (AUC) was calculated.
PAP (1 mg/L increments) and calculating
(AUC test/AUC Mu3) ratios; Etest (colonies
in inhibition zone); BHI agar +4 mg/L
Vancomycin
Etest

2007 (123)

Enterococcus
faecium
S. aureus

Vancomycin

Staphylococcus
capitis

Vancomycin

Enterococcus
faecium
S. aureus

Teicoplanin

2008 (109)

Vancomycin

Etest GRD strips, with one incorporated with
nutrients to enhance the growth of hGISA;
BHI agar + 6 mg/L Vancomycin;
MH agar + 5 mg/L Teicoplanin; PAP-AUC.
PAP by cfu (2 fold increments)
PAP-AUC; Screening cascade: BHI agar +5
mg/L teicoplanin then MET for positive
isolates.
MET; PAP (narrow increments)

S. aureus
S. aureus

Vancomycin
Vancomycin

S. aureus
S. aureus

Vancomycin

Etest; PAP-AUC compared to Mu3.

S. aureus

Vancomycin

PAP-AUC

S. aureus

Vancomycin, but not
Telavancin
(bactericidal
lipoglycopeptide)
Vancomycin

PAP (narrow increments).

2009 (111); 2011
(113); 2011 (116);
2012 (104); 2013
(153)
2010 (112); 2011
(118); 2011 (119)
2010 (99)

S. aureus
S. aureus

Vancomycin

Glycopeptides

S. aureus

Vancomycin/
glycopeptides
Vancomycin

S. aureus

Vancomycin

S. aureus

Vancomycin

S. aureus

Vancomycin

S. aureus

Vancomycin

S. aureus

Vancomycin

S. aureus

Vancomycin

S. aureus

Vancomycin

PAP by cfu compared to the Mu3 (hVISA)
and Mu50 (VISA)
MET; PAP
PAP-AUC; MET; GRD Etest; broth
microdilution (MIC cutoff ≥ 2 mg/L); standard
Vancomycin Etest (MIC cutoff ≥ 2 mg/L)
PAP/AUC; MET; GRD Etest; BHI agars + 3
or 4 mg/L Vancomycin.
Broth microdilution; GRD Etest on 4,210
clinically significant isolates from 43 U.S.
centers; PAP-AUC for GRD-positive.
Broth microdilution; MET; Standard Etest on
220 clinical isolates (121 MSSA, 99 MRSA)
from bloodstream infections.
PAP-AUC; BHI agar +4 mg/L Vancomycin
PAP on 750 MRSA clinical strains isolated
from Japan in 1990, before the introduction of
injectable Vancomycin into clinical use in
Japan in 1991.
Etest; PAP-AUC on 288 MRSA isolates from
a Connecticut Veterans Hospital.
PAP on 268 MRSA isolates from Seoul,
Republic of Korea
GRD Etest; PAP-AUC on 43 MRSA isolates
from Malaysia.
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2008 (55)
2008 (107)

2008 (108)

2008 (137)

2009 (78)
2009 (110)

2009 (98)

2010 (100)
2010 (101); 2011
(117)
2011 (114)

2011 (115)
2011 (142)

2011 (124)

2012 (154)

2012 (120)
2012 (103)
2012 (121)

S. aureus MRSA
S. aureus
S. aureus
Toxigenic
Clostridium
difficile
Clostridium
difficile
Staphylococcus

Glycopeptides;
Daptomycin
Daptomycin
Daptomycin
Metronidazole

Etest.

2009 (138)

PAP by cfu (narrow increments)
PAP
Etest and disc diffusion

2006 (94)
2011 (155)
2008 (129)

Metronidazole
Ciprofloxacin but not
nalidixic acid
Fosfomycin

Streptococcus
pneumoniae
Bordetella
Erythromycin
pertussis
S. aureus
Fucidic acid
MET (Macro-Etest): an Etest in which higher

2010 (156)
PAP & MIC

1986 (69)

PAP (wide scale of increments higher than 2fold)
Disc diffusion and Etest.

2013 (84)
2002 (128)

PAP by cfu (narrow increments).
1998 (85)
inoculum sizes are used to increase the probability of detection of more resistant

members of the bacterial population.
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Heteroresistance to vancomycin and other glycopeptides was first detected in Japanese
vancomycin-resistant S. aureus (53). This also initiated a trend using the PAP format with a
narrow range of antibiotic concentrations with minor increments. These findings geared
heteroresistance studies towards glycopeptides and its clinical relevance and spread as
vancomycin was used to eradicate the notorious MRSA infections. With focus on the clinical
importance of the heterogeneous response to vancomycin, its prevalence was often assessed.
However, controversial findings, originating from similar time range and geographical
distribution, were reported with data showing that such heterogeneity in response to vancomycin
is common among S. aureus strains (87, 90, 101, 103, 110, 119, 135). Others reported that
heterogeneous response to vancomycin was not prevalent (91, 104, 112, 113, 120, 121, 142,
157). These studies aimed at identifying the need to assess heteroresistance in clinical
laboratories as a standard procedure. However, since they adopted different guidelines for
heteroresistance determination and in many cases, used improper methods to detect
heterogeneity, the results were conflicting.
Much fewer reports described heteroresistance in Gram-negative bacteria. Table 2 describes the
incidences of heteroresistance in Pseudomonas aeruginosa, Klebsiella, Acinetobacter, and B.
cenocepacia.
While antibiotic resistance in general could either be intrinsic or acquired (19), similar
observations apply to heteroresistance. Intrinsic heteroresistance occurs without the need to
previous exposure to the antibiotic; however, heteroresistance may be acquired or induced as a
result of initial exposure to antibiotics. For example, repeated exposure of homogenously
sensitive Staphylococci to methicillin resulted in mixed populations resembling the intrinsically
heteroresistant strains (43). A similar selection method was conducted in MRSA involving stepwise exposure to vancomycin leading to acquired heteroresistance (158).
Molecules other than antibiotics can induce heteroresistance. For example, exogenous glycine
led to heterogeneous response to methicillin in the highly homogeneous MRSA COL strain (71).
Increasing concentrations of glycine in the medium resulted in replacement of the D-alanyl-Dalanine terminus of the muropeptides with D-alanyl-glycine-terminating muropeptides of
bacterial peptidoglycan leading to decreased methicillin resistance and the appearance of a
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Table 2. Heteroresistance in Gram-negative bacteria
Organism
Type b Hemophilus
influenzae
Enterobacter
aerogenes; E. coli;
other Enterobacteria
E. coli

8 species of
Enterobacteriaceae

P. aeruginosa, and 7
strains from 5 genera
of Enterobacteriaceae
Helicobacter pylori
Acinetobacter
baumannii
A. baumannii
P. aeruginosa
Invasive nontypeable
H. influenzae
Enterobacter cloacae
and A. baumannii
A. baumanniicalcoaceticus complex
P. aeruginosa

Antibiotic
Streptomycin

Method
PAP by cfu count (concentrations <10-1000 U/ml)

Year, Ref.
1947(42)

Cefamandole;Cefoxitin,
Carbenicillin; nalidixic
acid.
Cefamandole;
Cefotaxime; Cefoxitin;
imipenem
Cefotaxime

PAP by cfu (2-fold increments)

1979 (65)

Turbidimetric PAP (2 fold increments or more)

1985 (83)

1985 (68)

Ciprofloxacin

PAP: E.coli and Proteus mirabilis: homogeneous;
Klebsiella oxytoca and Citrobacter koseri: less
homogeneous; Enterobacter cloacae, Citrobacter
freundii, Proteus vulgaris, and Morganella morganii:
heterogeneous.
PAP & MIC

Metronidazole
Imipenem;Meropenem

Etest and disc diffusion
Etest

1996 (126)
2005 (134)

Colistin
Carbapenems (Imipenem
and Meropenem)
Imipenem

2006 (49)
2007 (95)

Colistin

PAP by cfu (narrow increments); Time kill curves.
Disc diffusion; PAP by cfu: (narrow increments and
low initial inoculum)
PAP by cfu (2 fold increments); Etest (for MIC
determination)
Disk diffusion; Etest; agar dilution; broth microdilution

Colistin

PAP by cfu (2 fold increments).

2008 (76)

Carbapenems

2008 (97)

1986 (69)

2007 (75)
2007 (51)

Bartonella sp.
A. baumannii
A. baumannii
E. aerogenes

Ciprofloxacin
Ampicillin/Sulbactam
Carbapenem
Carbapenem

A. baumannii
Klebsiella pneumoniae
K. pneumonia
A. baumannii
Carbapenemaseproducing K.
pneumoniae
A. baumannii

Meropenem
Meropenem
Carbapenem
Imipenem
Colistin

Agar dilution according to CLSI. Increments of 2 mg/L
for concentrations ranging from 2 to 32mg /L and of
8mg/L from 32 to 64 mg/L
Etest
Etest (incubation for ≥48 h)
Disk-diffusion; Etest.
Etest; automated MicroScan WalkAway system (failed
to detect heteroresistance detected by Etest)
PAP by cfu (2 fold increments).
MIC & PAP (2 fold increments); Time kill assays
Etest; PAP.
Etest; disk diffusion (colonies in the inhibition zone)
PAP by cfu (2 fold increments) & MIC

Cefepime

Etest, disc diffusion, PAP by cfu (2 fold increments).

2012 (58)

A. baumannii
P. aeruginosa
E. cloacae; E.
aerogenes
H. pylori

Carbapenems
Polymyxin B
Polymyxin B

Disc diffusion
PAP by cfu (PmB concentrations from 0 to 8 mg/L).*
PAP

2012 (132)
2013 (105)
2013 (145)

2008 (136)
2009 (139)
2009 (130)
2009 (159)
2009 (79)
2010 (80)
2010 (141)
2011 (131)
2011 (81)

levofloxacin
(5/19),
clarithromycin (1/19) and
metronidazole (16/19)

MIC by Etest and agar dilution for 19 pairs of clinical
2014 (61)
isolates. Each pair was isolated from the same patient.
Heteroresistance was reported when pairs showed
difference in resistance.
Providencia rettgeri
Carbapenems
PAP by cfu
2014 (160)
*Isolates presenting subpopulations that exhibited growth at Polymyxin B concentrations ≥2 mg/L were considered
heteroresistant. Isolates containing subpopulations that grew at Polymyxin B concentrations at least twice as high as the original
MIC but <2 mg/L were considered heterogeneous.
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heterogeneous resistance phenotype. On the other hand, heteroresistance may originate from
genetic manipulation events such as transposition of resistance genes (161, 162) or conjugation
(163). The generated progenies included cells having different MIC values due to differences in
the number of copies of the inserted resistance genes or random disruption of genes involved in
the bacterial response to antibiotics.

1.3.4. Mechanisms of heteroresistance
Non-genetic individuality in bacterial populations has been observed in a wide range of
biological processes, including differentiation and cell division (164), chemotaxis (165),
enzymatic activity (166), sporulation (167), stress response and antibiotic resistance (48, 168,
169). However, the exact mechanism of heteroresistance is not clear and appears to be
multifactorial. In several cases, increased resistance was due to mutations or differential
expression of key resistance genes or regulatory systems. Long term infection was proposed to
result in instability of genomic DNA of bacteria potentially leading to heteroresistance; for
example, mutations in gene products having metronidazole nitroreductase activities, mainly
oxygen-insensitive NAD(P)H nitroreductase (RdxA) and NAD(P)H flavin oxidoreductase
(FrxA) occurred in H. pylori heteroresistant to metronidazole (61).

1.3.5. Significance and relevance of heteroresistance
The lack of standardized definition of heteroresistance, which may lead to misidentification of
homogenous strains as heteroresistant, hinders the proper assessment of the clinical relevance of
heteroresistance. While certain reports argued against the clinical significance of heteroresistance
observing no differences in the clinical outcome between heterogeneous populations and their
respective homogenously sensitive cultures (91, 103, 116, 152), others showed clear
deterioration in the clinical outcome due to bacteria displaying a heterogeneous phenotype of
resistance (86, 90, 104, 111, 117, 118, 170-173). Indeed, this controversy might be influenced by
the lack of standardized definition of heteroresistance as outlined in a previous section, thus the
lack of influence on the clinical outcome might reflect non-truly heteroresistant bacteria.
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Heteroresistance presents a risk of possible misinterpretations when only a single colony, picked
from the primary bacterial populations isolated from patients, is analyzed for its susceptibility to
antibiotics (126). The clinical impact of heteroresistance range between recurrence of infections
(86, 111), chronic infections (118) to increased mortality rates (104, 117, 171, 172). The
perceived main cause of such deterioration of the clinical picture and therapeutic failure is the
speculated selection of more resistant cells in the bacterial population by antimicrobial therapy;
this was directly detected in one study (170). However, the chemical communication and transfer
of resistance from the more resistant subpopulations to sensitive cells is another aspect that
would impede the therapeutic efficiency of antibiotics.

1.3.5.1. Selection of more resistant cells of the population
Therapeutic dosing of antibiotics determined without taking into consideration the highly
resistant subpopulations of a heteroresistant bacterial isolate would result in selection of such
subpopulations. This is particularly the case when the majority of the population is sensitive to
antibiotics while only a small subset, undetectable through the criteria set for the traditional in
vitro antibiotic susceptibility testing, display resistance to the antibiotic above the clinical
breakpoint (Fig. 2). In these situations, the net outcome of antibiotic therapy would be the
eradication of the more sensitive members of the bacterial population while the more resistant
cells proliferate and become predominant in the infection.
Colistin treatment of a patient with postneurosurgical meningitis harboring a colistinheteroresistant A. baumannii isolate resulted in the selection of colistin-resistant strains (170).
Moreover, A. baumannii isolates transitioned in vivo from susceptibility to full-resistance to
carbapenems, with heteroresistance as an intermediate stage in the same intensive care unit due
to administration of meropenem (130). Meropenem pressure can produce meropenemheteroresistant subpopulations of A. baumannii that could be selected for by the use of
suboptimal therapeutic drug dosages giving rise to highly resistant strains (79). Similarly,
evidence of in vivo development of heteroresistance as a result of antibiotic therapy was shown
in a patient with MRSA (138). Initial treatment with glycopeptides led to the development of
heterogeneous glycopeptide resistance, which transformed to full resistance following
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daptomycin treatment. A similar observation of switching from susceptibility to heteroresistance
occurred in A. baumannii in patients after prolonged exposure to imipenem (131).
1.3.5.2. Chemical communication of antibiotic resistance
Highly resistant subpopulations of heteroresistant bacteria could further complicate the clinical
picture of polymicrobial infections by providing protection to normally sensitive bacteria
through chemical signals. Although not truly heteroresistant owing to the lack of significant
variation in concentrations tolerated by the members of an E. coli bacterial population, more
resistant mutants arising from the continuous antibiotic treatment protected less resistant cells of
the same population from norfloxacin and gentamicin (174). Such mutants could maintain the
same level of indole production in the presence of antibiotic treatment, which could protect less
resistant cells that produced lower concentration of indole under antibiotic stress. These mutants,
although more resistant relative to the rest of the population, cannot be considered absolutely
highly resistant as their MIC is at or slightly above the MIC breakpoint for sensitive bacteria
especially for norfloxacin, hence questioning their survival in vivo at therapeutic doses of
antibiotics. Interestingly, indole production is not common among bacteria (175); nevertheless,
indole produced by E. coli was shown to confer antibiotic resistance to the indole-negative
intestinal pathogen Salmonella enterica serovar Typhimurium (176). Other chemical signals
normally produced by bacteria and that may modulate the antibiotic resistance profiles of
bacteria can potentially be similarly implicated in the communication of resistance among
different bacteria; hence, such signals will be further discussed in following sections.
Protection from antibiotics also occurred through antibiotic degrading enzymes. Protection of
sensitive bacteria was mediated by beta-lactamases produced from resistant E. coli cells against
beta-lactamase sensitive agents as cefamandole, but not cefotaxime, cefoxitin or imipenem
which are more resistant to beta-lactamases (83).
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1.4. Non-genetic mechanisms communicating antibiotic resistance
The alarming emergence of outbreaks by multidrug resistant clinical isolates pose a serious
challenge to the treatment of infections, often turning a mild infection into a life threat, and has
led to extensive worldwide studies on the mechanisms of antibiotic resistance and its genetic
transfer across bacterial populations (177). Unveiling the various mechanisms of genetic transfer
that contribute to the spread of antibiotic resistance has been a major breakthrough. However,
these findings have overshadowed other potentially important mechanisms of resistance
mediated by non-genetic factors. Indeed, the horizontal transfer of genetic determinants encoding
antibiotic resistance markers has been considered as the only mechanism of transfer of antibiotic
resistance across bacterial populations (178). However, bacteria possess signal transduction
machineries that rely on chemical signals enabling cell-to-cell communication and coordinating
multicellular behavior. The best examples are N-acyl-homoserine lactone and non-N-acylhomoserine lactone-based quorum sensing systems (179), which have been extensively reviewed
and will not be discussed here.
In this section, I will further challenge the traditional view of intrinsic resistance by focusing on
the current understanding of the small molecules that are capable of altering the antibiotic
susceptibility of bacterial cells by modulating cellular responses towards antibiotic stress. This
does not include mechanisms involving physical elimination of the antibiotics through
neutralization, or degradation, which would eventually lead to protection of other cells from the
antibiotic effect. The small molecules discussed in this section can be secreted by bacterial cells
or alternatively, by host cells in body fluids and tissues. They may also be secreted from plants
into the soil and thus present in the bacterial milieu. The interactions of bacteria with these
molecules occur in the context of intra-species, interspecies or interkingdom communication, and
contribute to the mechanism of intrinsic resistance to antibiotics. A better understanding of how
the small molecule-mediated interactions influence antibiotic resistance would eventually lead to
designing more effective inhibitors of such mechanisms and provide better therapeutic solutions
for combating multidrug resistant microbial infections.
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1.4.1. Chemical signals modulating antibiotic resistance
In this section, I will discuss various small molecules that act as infochemicals modulating the
susceptibility of bacteria to antibiotics (Table 3) and their potential mechanisms of action (Fig.
3). I will also attempt to expose new targets for developing lead compounds that could act as
inhibitors of the action of infochemicals to prevent increased resistance to antibiotics.

1.4.1.1. Indole
Indole is an aromatic heterocyclic organic compound derived from the amino acid tryptophan in
a reaction mediated by the TnaA tryptophanase. It is produced by around 85 species of Grampositive and Gram-negative bacteria (175). Indole has been recently recognized as an
intercellular signal molecule that controls diverse aspects of bacterial physiology including
biofilm formation (175).
Lee et al.revealed that few antibiotic resistant mutant cells that arise in an Escherichia coli
population in response to norfloxacin or gentamicin improved the overall response of the
bacterial population towards the antibiotics in part due to indole production (174). Indole
production was not induced in the more resistant mutant cells by the antibiotics but rather its
level was unchanged regardless of antibiotic exposure, as opposed to wild type bacteria in which
indole production was suppressed in response to the antibiotics (174).
Exogenous indole conferred resistance against norfloxacin and gentamicin to the less resistant
isolates (Table 3) (174). Moreover, E. coli cells treated with indole became rhodamine 6G and
sodium dodecylsulfate (SDS) resistant (180). Similar findings were reported in E. coli cells
exposed to ampicillin and kanamycin, in which a higher level of extracellular indole production
protected bacterial cells from antibiotic damage (181). Indole was also shown to influence
persister formation (182). Persisters neither die nor grow in the presence of antibiotic, as they are
dormant during antibiotic exposure (47). These persister bacterial cells grow after the antibiotic
removal, and their progeny does not exhibit increased resistance to the antibiotic. Therefore, their
pattern of sensitivity to the antibiotic remains identical to that of the original bacterial population
(48).
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Table 3.Effect of different small molecules on the activity of antibiotics.
Organism
Indole

Molecule

E. coli MG1655
E. coli MC4100

Indole

E. coli K-12 BW25113

Conc.

Antibiotic

300
µM

Norfloxacin and
gentamicin
Rhodamine 6G
and SDS

2 mM
1 mM

Ampicillin and
kanamycin

Method
MBC
Survival
rate assay
OD
growth
assay

Effect
Increased
resistance
Increased
resistance

Ref.
(174)
(180)

Increased
resistance

(181)

MIC

Increased
sensitivity

(183)

MIC

No effect

(183)

Polyamines
S. aureus strains Mu50
and N315, S. aureus
strain ATCC 35556.

P. aeruginosa PAO1and
10 clinical isolates

Spn

Spn
Spd

1mM

1 mM
20 mM

E. coli K-10, K-12,
C921-61 and S. enterica
serovar
Typhimurium LT2

Spn
Spd

1 mM
20 mM

P. aeruginosa PAO1

Spn
Spd
Put
Cad

1 mM
20 mM
20 mM
20 mM

P. aeruginosa PAO1

Spn
Spd
Put*
Cad*

1 mM
20 mM
20 mM
20 mM

E. coli GGB2600

Spd,
Put, or
their
equimolar
mix

0.1, 1
or 10
mM

E. coli RO91

Put

10 mM

E. coli BL21, P.

Spd

2 mM

15 different βlactams,
chloramphenicol,
polymyxin
B, and
tetracycline
Vancomycin,
ciprofloxacin, and
gentamicin

Increased
Sensitivity
(with few
exceptions)
Increased
resistance (with
few exceptions)

Carbenicillin,
chloramphenicol

MIC

Imipenem,
ciprofloxacin, and
Polymyxin B

MIC

Chloramphenicol
and 8 different βlactams

MIC

Increased
sensitivity

(183)

MIC

Increased
sensitivity

(184)

MIC

No effect

(184)

MIC

Increased
resistance (*
combinations:
no effect)

(185)

MIC

No effect

(185)

14 β-lactams,
chloramphenicol,
nalidixic acid and
trimethoprim
Erythromycin,
novobiocin and
fusidic acid
Polymyxin B*,
colistin*,
kanamycin,
gentamicin,
ciprofloxacin,
norfloxacin
Tetracycline
Levofloxacin,
netilmicin,
cefotaxime

Tetracycline,
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MIC

CFU
assay
Growth

Increased
resistance

(183)

(183)

(186)

(186)
Increased

(187)

aeruginosa Lm1, B.
subtilis and S. aureus
Xen36

Put

kanamycin

on
antibiotic
containin
g agar

resistance to
Tet, Increased
sensitivity to
Kan

Volatile signals
E. coli BL21, P.
aeruginosa Lm1, B.
subtilis and S. aureus
Xen36

Volatile
ammonia

Serratia rubidaea and
S. marcescens

Volatile
ammonia

E. coli

TMA

From
5-50
mM
NH4+
sol.
From
0.1%
sol.
From
0.5%
Sol.

2,3-BD and
glyoxylic acid
sulfur compounds,
Burkholderia ambifaria ketones, aromatic
compounds
Pseudomonas Quinolone Signal (PQS)
B. subtilis

P. aeruginosa PAO1

Tetracycline

Increased
resistance

Kanamycin

Increased
sensitivity

Ampicillin
Tetracycline

Growth
on
antibiotic
containin
g agar

Aminoglycosodes
; chloramphenicol
Ampicillin and
tetracycline

Increased
resistance
Increased
resistance
Increased
sensitivity
Increased
resistance

(187)

(188)

(189)

(190)

Gentamicin and
kanamycin

Discdiffusion
assay

Increased
resistance

(191)

Filterdisk
assay

Increased
sensitivity

(192)

CFU
assay

Increased
resistance

(193)

PQS

60
µM

Tetracycline,
chloramphenicol,
carbenicillin,
spectinomycin and
to a lesser extent
kanamycin

IAA

0.5
mM

Erythromycin,
rifampicin,
penicillin and
novobiocin

Indole Acetic Acid (IAA)
E. coli K-12

TMA: trimethylamine; 2,3-BD: 2,3-butanebione; Spn: spermine; Spd: spermidine; Put:
putrescine; Cad: cadaverine; PQS: Pseudomonas quinolone signal; IAA: indole acetic acid.
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The improved response to antibiotics mediated by indole was attributed to the stimulation of
certain drug efflux pumps (174, 180, 194) and oxidative stress protective mechanisms (174) (Fig.
3). Furthermore, indole is sensed in a heterogeneous manner across the bacterial population
(182), causing induction of OxyR and phage-shock pathways via a periplasmic or membrane
component, and triggering protective responses that result in the appearance of a persistent
subpopulation.

1.4.1.2. Polyamines
Natural polyamines consist of diamines (putrescine and cadaverine) and oligoamines (spermidine
and spermine) (195). The first description of a natural polyamine dates from more than 300 years
ago when spermine crystals were discovered in human semen (196). Since then, natural
polyamines were found in almost all living organisms. In plants, polyamines are involved in
growth, development, and modulation of defense responses to diverse environmental stresses. In
addition, polyamines have acid neutralizing and antioxidant properties, as well as membrane and
cell wall stabilizing abilities (197). Like in plants, polyamines also regulate cell growth and
proliferation in humans, as well as stabilize negative charges of DNA influencing RNA
transcription, protein synthesis, apoptosis, and immune responses (198). Spermidine enhances
autophagy, thus suppressing necrosis and enhancing cell longevity (199, 200). Spermine is
produced at higher levels by regenerating tissues, while injured or dying cells release spermine
into the extracellular milieu, so that tissue levels of spermine significantly increase at
inflammatory sites of infection or injury (201). Also, polyamines have anti-inflammatory and
immunosuppressive properties similar to those of glucocorticoid hormones (202). Spermine
accumulates at sites of infections such as mycobacteria-infected sites and pneumonia (201, 203).
Nearly all bacteria produce polyamines, with rare exceptions such as most Staphylococcus
aureus strains; polyamines, namely spermidine and spermine, are toxic to such strains as they
lack polyamines detoxifying enzymes (204). While polyamines play roles in growth and other
physiological processes in bacteria including incorporation into the cell wall, biosynthesis of
siderophores, acid resistance, scavenging free radical ion, signaling cellular differentiation and
biofilm formation (205), they also contribute to the bacterial responses to antibiotics
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demonstrated by the response of polyamine-deprived mutants and bacteria exposed to exogenous
polyamines to antibiotics.The two most common bacterial polyamines are putrescine and
spermidine (205). Cadaverine is usually synthesized only when putrescine synthesis is blocked
or in cases where there is excess lysine, its amino acid precursor, under anaerobic conditions at
low pH (206).
Both the inhibition of polyamine biosynthesis (207-210) and excess of exogenous polyamines
prevent bacterial growth (183, 211), as shown with certain strains of Staphylococcus aureus, E.
coli and Salmonella enterica (Table 4). These effects vary for the same strain under different
experimental conditions (183). On the other hand, Pseudomonas aeruginosa isolates are resistant
to the effects of the tested polyamines (183). These opposite effects of polyamines on bacterial
growth might indicate that a fine balance in their concentration within the cells is needed for the
proper homeostasis of the bacteria. This is supported by the observation that the polyamine
content of cells is highly regulated by biosynthesis, modification, uptake and excretion (212).

1.4.1.2.1. Effect of polyamines on bacterial susceptibility to antibiotics
Few studies reporting the effects of exogenous polyamines on the antibacterial activity of
different antibiotics against a variety of organisms (183-187) are summarized in Table 3. Results
vary from study to study depending on the polyamine used, its concentration, the strain tested,
and the test conditions. Despite some contradictory observations and the lack of systematic
studies on polyamine-antibiotic interactions, it appears that high concentrations of polyamines
approaching their inhibitory range (Table 4) increase the sensitivity to antibiotics, whereas lower
concentrations of polyamines increase resistance to antibiotics. Conversely, organisms that have
higher level of resistance to polyamines, such as P. aeruginosa, usually show increased
resistance to antibiotics in response to polyamines, whether at high or low concentration.

1.4.1.2.2. The mechanism of alteration of antibiotic response by polyamines
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It is not clear how polyamines mediate increased sensitivity to antibiotics. Polyamines do not
apparently affect the outer membrane as their effects are not abolished by divalent ions like
magnesium or calcium in contrast to the membrane-destabilizers polymyxin B and EDTA (184),
and they do not increase outer membrane permeability (213). Moreover, polyamines do not
inhibit efflux pumps, as for example they exert the same synergistic effects in AcrAB efflux
pump defective mutants and wild-type E. coli (183). On the other hand, the induced sensitivity to
aminoglycosides as a result of increased levels of intracellular polyamines is due to higher
translation of the oligopeptide binding protein OppA (Fig. 3) (187). OppA is a periplasmic
protein involved in aminoglycoside uptake and reduction in its level leads to aminoglycosides
resistance (214).
On the other hand, polyamines contribute to increasing the resistance to various antibiotics in
different bacterial species through multiple mechanisms (Fig.3). One mechanism involves
preventing the uptake of antibiotics by either blocking certain outer membrane porin channels or
competing with antibiotics for uptake through certain porins. For example, spermine can block
the porin OprD of P. aeruginosa resulting in increased resistance to imipenem (183, 215).
Similarly, the interaction of polyamines with the porin OmpF, and to a lesser extent OmpC,
resulted in reduced permeability to various antimicrobials (216-221). Tkachenko et al. (222)
demonstrated that polyamines increased the resistance of E. coli to antibiotics transported
through porin channels by decreasing the outer membrane permeability, and suggested three
mechanisms: (i) direct inhibition of the transport activity of porin channels, (ii) activation of the
transcription of micF whose product is an antisense RNA that inhibits the translation of porins,
and (iii) increase in the cell content of the stress resistance regulator S that suppresses the
transcription of ompF and induces cadaverine synthesis, thus leading to a decrease in the porin
transport.
Spermidine and other polyamines may also modulate efflux pump activity. In Burkholderia
pseudomallei, spermidine upregulates efflux pumps such as BpeAB-OprB, AmrAB-OprB and
BpeEF-OprC, contributing to aminoglycoside and macrolide resistance as well as biofilm
formation through the increased efflux of N-acyl homoserine lactones (223). Furthermore,
GeneChip experiments and promoter fusion studies have shown that spermidine induces the
expression of the P. aeruginosa oprH-phoPQ and PA3552-PA3559 operons encoding enzymes
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Table 4.Inhibitory effects of Polyamines.
Organism
E. coli strain B

Molecule
Spd
Spn
Spd
Spn
Spd

Conc.
390 µg/ml
17 µg/ml
12 µg/ml
2 µg/ml
Up to 16
mM

Method
MIC
MIC
MIC
MIC
MIC

Effect
Inhibition
Inhibition
Inhibition
Inhibition
No inhibition

Ref.
(211)
(211)
(211)
(211)
(183)

Spn

MIC

No inhibition

(183)

Spn

Up to 16
mM
1 to 2 mM

MIC

Inhibition

(183)

Spn

4 mM

MIC

Inhibition

(183)

Spn

10 mM

No effect

(183)

S. aureus Mu50

Spn

1 mM

Spn

1, 2 and 4
mM

Doubling time
increased from 39
min to 62 min
Concentrationdependent inhibition

(183)

E. coliK-12, E. coli K-10 and S.
enterica serovar Typhimurium LT2

OD
growth
curve
OD
growth
curve
OD
growth
curve

S. aureus
S. aureus strains Mu50 and N315,
S. aureus ATCC 35556
E. coli K-10 and K-12 and
enterotoxigenic strain C912-61
10 clinical isolates of P.
aeruginosa, P. aeruginosa PAO1.
S. enteric serovar Typhimurium
LT2
P. aeruginosa PAO1, E. coli K-12,
and E. coli C921-16
E. coli K-10 and Salmonella
enterica serovar Typhimurium LT2
S. aureus ATCC 35556
(MSSA/VSSA), N315,
(MRSA/VSSA), and Mu50,
(MRSA/VISA)
P. aeruginosa PAO1

Spn: spermine; Spd: spermidine
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(183)

for LPS modification and resulting in PhoPQ-mediated spermidine-induced resistance to cationic
antimicrobial peptides and quinolones (185). This study also suggests a possible spermidineresponsive sensor residing in the cytoplasmic membrane and modulating the phosphorylation
status of PhoP (185).
Another mechanism of polyamines to protect bacteria from antibiotic damage is preventing
oxidative stress. E. coli cells respond to oxidative stress induction by sublethal concentrations of
fluoroquinolones, aminoglycosides and cephalosporins with a 2-3 fold increase in cell polyamine
content (putrescine, and spermidine) due to upregulation of the ornithine decarboxylase (186).
Moreover, exogenous polyamines reduced intracellular reactive oxygen species production,
thereby preventing the damage to proteins and DNA, eventually increasing cell viability, growth
recovery and antibiotic resistance (186). This agrees with other studies showing the induction of
polyamines biosynthesis by reactive oxygen species and the role of polyamines in modulating
the cellular response to counter such stress (224, 225). Also, surface-localized spermidine is
produced under Mg2+-limiting conditions as an organic polycation and is proposed to bind
lipopolysaccharide (LPS) and to stabilize and protect the outer membrane against antibiotic and
oxidative damage (226).

1.4.1.3. Volatile signals
Bacteria can produce various volatile compounds as complex as those of plants and fungi, but the
ecological function of these compounds remains unknown (227). Volatile compounds may
modulate interactions within the microbial communities that can potentially result in the creation
of a favorable niche for some community members (228). The profiles of volatile compounds
produced by microorganisms are consistent, within the same cultural conditions, environment
and inputs (228), and have led to attempts to identify bacteria based on their volatile fingerprints
(229).While volatile compounds constitute a large class of potential infochemicals, their role in
bacteria–bacteria interactions remains unexplored. However, recent investigations have clearly
demonstrated that bacteria employ their volatiles during interactions with other organisms to
influence populations and communities (230). This phenomenon was considered to resemble
olfaction, or the sensing of airborne volatile compounds, a property of higher eukaryotes (231).
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Volatile-mediated transfer of antibiotic resistance to ampicillin in E. coli was first reported in
2002; however, the nature of the airborne signal was unknown (232). A more recent study
showed that exposure to gaseous ammonia, a catabolic product of L-aspartate, released from
stationary phase E. coli K12 cultures alters the antibiotic resistance profile of several Gramnegative and Gram-positive bacteria (187). Ammonia increased resistance to tetracycline in E.
coli BL21, P. aeruginosa Lm1, Bacillus subtilis, and Staphylococcus aureus Xen36 whereas it
increased sensitivity to the aminoglycoside kanamycin (Table 3). These effects resulted from
ammonia-dependent increase in polyamine levels,which altered the membrane permeability to
antibiotics and increased the resistance to oxidative stress (Fig.3); but whether or not the
ammonia release was induced in response to antibiotics was not determined (187). Similar
ammonia-mediated protection from ampicillin in Serratia rubidaea and S. marcescens was
attributed to antibiotic inactivation by alkalinization of the medium (188). Interestingly, volatiles
emitted from the tested Gram-positive and Gram-negative bacteria increased resistance of E. coli
to tetracycline; however, volatiles emitted from E. coli did not alter resistance to ticarcillin,
chloramphenicol, ofloxacin and vancomycin (187).
Trimethylamine (TMA) is another volatile compound produced by E. coli that can alter antibiotic
resistance patterns of E. coli, P. aeruginosa, S. aureus, and B. subtilis as a result of TMAmediated alkalinization of extracellular medium which would increase uptake of
aminoglycosides and chloramphenicol and reduce uptake of tetracycline (189). On the other
hand, 2,3-butanedione and glyoxylic acid emitted from B. subtilis increased resistance of E. coli
to ampicillin and tetracycline, a phenotype regulated by the previously uncharacterized ypdB
gene product through the downstream transcription factors soxS, rpoS or yjhU(190).
Burkholderia ambifaria emitted highly bioactive volatile blend (not regulated by quorum-sensing
systems) containing predominantly sulfur compounds, ketones, and aromatic compounds with
dimethyl disulfide being the most abundant compound. These volatile blends, and their
individual components, increased resistance to the aminoglycoside antibiotics gentamicin and
kanamycin in E. coli and induced significant biomass increase in the model plant Arabidopsis
thaliana as well as growth inhibition of two phytopathogenic fungi (Rhizoctonia solani and
Alternaria alternata) (191).
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1.4.1.4. Pseudomonas quinolone signal (PQS)
The Pseudomonas quinolone signal (PQS; 2-heptyl-3-hydroxy-4-quinolone), like the wellstudied N-acyl homoserine lactones, functions as a quorum-sensing signal that controls genes
required for virulence factor expression and biofilm formation (233, 234). Being hydrophobic, it
is difficult to explain how the PQS acts as an extracellular signal. However, outer membrane
vesicles can transport the PQS signal among P. aeruginosa cells (235). Furthermore, many of the
P. aeruginosa quinolones/quinolines packed into these vesicles have antibiotic activity against
Gram-positive cells such as S. aureus and B. subtilis, suggesting that the production of such
molecules might provide P. aeruginosa with an advantage to gain a niche by inhibiting the
growth of competing microorganisms (236).
Indirect evidences suggest the possibility that PQS-dependent cell-to-cell communication in P.
aeruginosa may be involved in controlling susceptibility to antimicrobial agents. For example,
exogenous PQS increased the susceptibility of the wild type P. aeruginosa PAO1 strain to
tetracycline, chloramphenicol, carbenicillin, spectinomycin, and to a lesser extent kanamycin
(Table 3). This was suggested to be a consequence of the PQS-dependent repression of other
multidrug efflux pumps, or direct regulation of genes involved in controlling cell envelope
permeability by PQS (Fig.3) (192). Overexpression of the MexEF-OprN multidrug efflux system
results in a delay in PQS production due to efflux of kynurenine, a PQS precursor, thus increased
antibiotic resistance was accompanied with lower intracellular levels of PQS (237).Other studies
also showed that overproduction of the MexEF-OprN pump results in increased resistance to
quinolone antibiotics and chloramphenicol, but hypersusceptibility to most β lactams (238).
Further work is still required to demonstrate a direct effect of PQS in modulation of antibiotic
susceptibility and its mechanism.

1.4.1.5. The phytohormone Indole-3-acetic acid
Indole-3-acetic acid (IAA) is the primary auxin in plants that regulates many plant
developmental and cellular processes and is capable of inducing changes in gene and protein
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Figure 3. Mechanisms of alteration of antibiotic susceptibility mediated by small molecules and
potential targets for drug design.
For detailed mechanisms of action of each molecule and their corresponding references, please
refer to the text. The potential targets for the design of novel therapeutics are marked by this sign
(

). AHL: N-acyl-homoserine lactone; EPS: exopolysaccharide; IAA: Indole-3-acetic acid;

LPS: lipopolysaccharide; OM: outer membrane; OMV: outer membrane vesicles; PQS:
Pseudomonas quinolone signal; ROS: reactive oxygen species.
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expressions, in prokaryotic and eukaryotic organisms, leading to different physiological
alterations (239). Auxin biosynthesis is also widespread among soil- and plant-associated
bacteria such as Streptomyces, Bacillus, Pseudomonas, Burkholderia, Erwinia, Flavobacterium,
and Stenotrophomonas as part of a system to communicate with their plant host (240). IAA
treatment of E. coli K-12 cells enhanced their resistance to various stress conditions including
exposure to antibiotics such as erythromycin, rifampicin, penicillin and novobiocin (Table 3)
(193). It seemed that IAA activates different protective pathways to synergistically enhance
stress tolerance. Treatment with IAA resulted in increased lipopolysaccharide (LPS) and
exopolysaccharide production, and enhanced synthesis of the chemical and molecular
chaperones, trehalose and DnaK respectively, which correlated with the higher resistance to
stress conditions (Fig.3) (193).
1.4.2. New targets for drug discovery
The successful therapeutic outcome of bacterial infections is impeded by the continuous
emergence of antibiotic resistant bacteria. This represents a major challenge that aggravates the
problems posed by microbial infections, especially when these infections further complicate
existing health-deteriorating conditions. The concept of using helper compounds that inhibit
certain features of pathogenic bacteria provides an appealing approach to reverse bacterial
resistance to antibiotics by targeting the bacterial membrane permeability to enhance penetration
of antibiotics or by inhibition of efflux pumps (241-244). Given the advances in our
understanding of the mechanisms of intrinsic resistance involving small molecular cues
modulating resistance to antibiotics, I propose that another target for potential inhibitors is
extracellular signaling, and various potential targets of this type for drug design are outlined in
Fig. 3. Interfering with biosynthetic pathways of the signaling molecules could not only
overcome increased antibiotic resistance (245), but also aid preventing the potential
communication and spread of antibiotic resistance to other bacteria mediated by these small
molecules. Such treatments would neither stop cellular division directly nor be toxic to the cells,
thus reducing the selective pressure to evolve mechanisms of resistance. In addition, targeting
small-molecule signaling pathways ensures that treatments will be directed specifically at the
pathogenic organism, rather than the entire microbiome (245).Overall, this direction for drug
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discovery could potentially expand further as our understanding of the mechanisms, biosynthetic
pathways and uptake of the different small molecules continues to increase.

1.5. Hypothesis and general objectives
Microbial infections are becoming more refractory to antibiotic therapy. The clinical outcome of
antibiotic treatment does not always correlate with the expectations based on in vitro
susceptibility testing performed on individual clinical isolates (246). Owing to the polymicrobial
nature of many infections (247), cross talk between the different bacterial species is probable
during infection. Hence, I hypothesize that bacteria displaying high-level intrinsic antibiotic
resistance, especially the more resistant members within a heteroresistant population, can
communicate such high level of resistance to other less resistant bacteria through chemical cues,
protecting them from the lethal action of antibiotics. To address this hypothesis, I will use B.
cenocepacia as a model organism to determine:
1. The population-wide response of B. cenocepacia to antibiotics whether it is a homogeneous
response or it displays heteroresistance.
2. If B. cenocepacia (the more resistant members of its population in case of heteroresistance)
can communicate its high level of resistance to less resistant bacteria.
3. The signals involved in the chemical communication of antibiotic resistance, in case B.
cenocepacia cells are capable of protecting other less resistant cells.
4. The mechanism by which the chemical signals involved in the phenomenon protects against
the action of antibiotics.
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Chapter 2

Chemical communication of antibiotic resistance by a highly
resistant subpopulation of bacterial cells
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El-Halfawy OM, and Valvano MA (2013).Chemical communication of antibiotic resistance by a
highly resistant subpopulation of bacterial cells. PLOS One 3;8(7):e68874. © 2013 El-Halfawy,
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2.1. Introduction
Treating infection caused by multidrug resistant bacteria is challenging, especially in
immunocompromised patients. These individuals often succumb from infections by opportunistic
bacteria that display intrinsic, high-level resistance to virtually all antimicrobials available for
clinical use. Reduced permeability of the bacterial cell envelope in conjunction with multidrug
efflux pumps are considered major determinants of intrinsic multidrug resistance (1). However,
the overall resistance of a bacterial population results from the combination of a wide range of
susceptibilities displayed by subsets of bacterial cells. Bacterial heteroresistance to antibiotics
has been documented for several pathogenic bacteria, but the mechanism of heteroresistance is
not always clear. Here, I use Burkholderia cenocepacia as a model opportunistic bacterium to
investigate the implications of heterogeneity in the response to the antimicrobial peptide
polymyxin B (PmB) and also other antibiotics. B. cenocepacia is an environmental, opportunistic
pathogen that causes serious infections in patients with cystic fibrosis and expresses high-level
multidrug resistance (2). Using the prototypic B. cenocepacia K56-2 strain, I observed a
population-wide variation in the response to PmB and more importantly, that the more resistant
members communicate higher level of resistance to less resistant members of the same
population, and to other bacterial species in co-culture, such as Pseudomonas aeruginosa and
Escherichia coli. Communication of increased resistance depended on overproduction by the
more resistant subpopulations of the polyamine putrescine and increased secretion of YceI, a
highly conserved small protein of unknown function. This rather general multifactorial
mechanism of communication of antibiotic resistance is distinct from previously reported
population-based resistance involving production of indole (3, 4), biogenic ammonia (5), and
intercellular nanotubes (6). My findings uncover a novel, non-genetic and cooperative
mechanism of transient increase in resistance that can be chemically communicated from more
resistant members of a heterogeneous population to less resistant bacterial cells of the same or
other species.
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2.2. Materials and Methods
2.2.1. Strains and reagents
Table 5 lists bacteria and plasmids used in this work. Bacteria grew in LB at 37°C.
Antibiotics (Sigma, St Louis, MO, USA) were diluted in water except for PmB, which was
diluted in 0.2% bovine serum albumin/0.01% glacial acetic acid buffer. For growth analyses,
overnight cultures were diluted to an optical density at 600 nm (OD600) of 0.0008 and incubated
at 37°C with medium continuous shaking in a Bioscreen C automated growth curve analyzer
(MTX Lab Systems, Vienna, VA, USA). Medium 121 containing 83 M phosphate was used to
test low phosphate conditions (7). Extracellular protease production was determined on dialyzed
Brain-Heart infusion milk agar plates (8). Lipopolysaccharide was extracted and visualized by
silver staining (9). Etest strips (AB bioMérieux, Solna, Sweden) were applied to agar plates
inoculated with test bacteria by swabbing overnight cultures diluted to OD600 of 0.04; plates were
then incubated at 37oC for 24 h. Unmarked non-polar deletions were performed as described
previously (10). Unmarked chromosomal single copy complementation of BCAL2641 was
performed using pMH447 (11). Complementation of yceI (BCAL3310 and BCAL3311) was
performed using pSCrhaB2 (12).

2.2.2. Population analysis profiling (PAP)
This involved treating bacterial cultures with doubling increments of antibiotic
concentrations and determining growth at each concentration by turbidimetry in LB broth (PAP
by broth dilution) or by cfu counting on agar plates (PAP by agar dilution). Heteroresistance was
considered when the antibiotic concentration exhibiting the highest inhibitory effects was 8-fold
or more higher than the highest non-inhibitory concentration.
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Table 5. Strains and plasmids used in Chapter 2
Strain or plasmid

Relevant characteristicsa

Source and/or reference

CF clinical isolate
ET12 clone related to J2315, CF clinical Isolate
Deletion of cciI in K56-2
Deletion of cepI in K56-2
Deletion of rpfF in K56-2
SAL65, Deletion of rpoE in K56-2
Deletion of hldA in K56-2
K56-2Prha-arnTarnBCamrAB, suppressor strain
OME2, Deletion of BCAL3390 in K56-2
OME3, Deletion of BCAM2086 in K56-2
OME4, Deletion of yceI (BCAL3310 and BCAL3311) in K56-2
OME5, Deletion of BCAM1679 in K56-2
OME7, Deletion of BCAM2086 in K56-2BCAL3390
OME8, Deletion of BCAL1281 in K56-2
OME11, Deletion of BCAL2641 in K56-2
OME12, Deletion of BCAM1111 and BCAM1112 in K56-2
OME19, K56-2 carrying pSCrhaB2, TpR
OME20, K56-2 yceI carrying pSCrhaB2, TpR
OME21, K56-2 yceI carrying yceI cloned into pSCrhaB2, TpR
OME29, Deletion of amrAB in K56-2
OME30, Deletion of amrAB in K56-2BCAL2641
OME31, Chromosomal BCAL2641 integration in amrAB
locus in K56-2BCAL2641

Cleveland
b
BCRRC,(13)
(14)
(14)
(14)
S. Loutet
(10)
(11)
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

Strains
Burkholderia cenocepacia
CP706-J
K56-2
cciI
cepI
rpfF
rpoE
hldA
arnBC
BCAL3390
BCAM2086
yceI
BCAM1679
BCAL3390BCAM2086
BCAL1281
BCAL2641
BCAM1111BCAM1112
K56-2 pSCrhaB2
yceI pSCrhaB2
yceIpyceI
amrAB
BCAL2641amrAB
amrAB::BCAL2641+
Escherichia coli
DH5α

GT115

HB101

F-80lacZ M15 endA1 recA1 supE44 hsdR17(rK- mK+)
deoR thi-1 nupG supE44 gyrA96relA1 ∆(lacZYA-argF)U169, λ– Laboratory
stock
F– mcrA∆(mrr-hsdRMS-mcrBC) 80∆lacZ∆M15 ∆lacX74
recA1rpsL (StrA) endA1∆dcm uidA(∆MluI)::pir-116
∆sbcC-sbcD
Invivogen, San Diego, CA
F-mcrBmrrhsdS20(rB-mB-) recA13 leuB6 ara-14 proA2
lacY1 galK2xyl-5 mtl-1 rpsL20(SmR) glnV44 λLaboratory Stock

SY327
BL21

araD Δ(lac pro) argE(Am) recA56 rifr nalA, λ pir
F−dcm ompT hsdS(rB−mB−) gal

(15)
Novagen

Pseudomonas aeruginosa
PAO1

Non-CF clinical isolate

(16)

oripBBR1, TetR, Pdhfr, mob+, expressing I-SceI, SacB
oriR6K, TpR , mob+, including an I-SceI restriction site
pGPI-SceI derivative used for chromosomal complementation
allowing gene integration in the gentamicin efflux pump
oricolE1, RK2 derivative, KanR, mob+, tra+
pOE2, pGPI-SceI with fragments flanking BCAL3390
pOE3, pGPI-SceI with fragments flanking BCAM2086
pOE4, pGPI-SceI with fragments flanking BCAL3310
and BCAL3311
pOE5, pGPI-SceI with fragments flanking BCAL1281
pGPI-SceI with fragments flanking BCAM1679
pOE6, pGPI-SceI with fragments flanking BCAL2641
pOE7, pGPI-SceI with fragments flanking BCAM1111
and BCAM112

(17)
(10)

Plasmids
pDAI-SceI-SacB
pGPI-SceI
pMH447
pRK2013
pDelBCAL3390
pDelBCAM2086
pDelyceI
pDelBCAL1281
pDelBCAM1679
pDelBCAL2641
pDelBCAM1111
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(11)
(18)
This study
This study
This study
This study
(19)
This study
This study

pSCrhaB2
pyceI
pBCAL2641
pET28a(+)
pExpBCAL3310
pExpBCAL3311
a

oripBBR1rhaR, rhaS, PrhaBTpRmob+
pOE8, yceI cloned in pSCRha-B2
pOE9, BCAL2641 cloned in pMH447 for chromosomal
complementation
pOE15, BCAL3310 without signal peptide encoding sequence
cloned in pET28a(+)
pOE16, BCAL3311 without signal peptide encoding sequence
cloned in pET28a(+)

(12)
This study
This study
Novagen
This study
This study

TpR, trimethoprim resistance, KanR, kanamycin resistance, TetR, tetracycline resistance.
BCRRC, B. cepacia Research and Referral Repository for Canadian CF Clinics.

b
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2.2.3. Co-culture
Co-culture was performed by mixing overnight cultures of P. aeruginosa PAO1 and B.
cenocepacia (treated with 500 g/ml PmB) diluted to OD600 of 0.004 at ratio 100:1 in LB broth
with or without PmB. Controls with the pure cultures at the same inoculum size were included in
the experiment. The mixtures were incubated at 37oC at 200 rpm and cfu of each species was
determined by using differential antibiotic selection on LB agar plates at 6 and 24 h. B.
cenocepacia was selected with PmB (50 g/ml) and PAO1 was selected with trimethoprim (100
g/ml). The total count was determined on LB agar plates.

2.2.4. Volatile-mediated protection
Overnight culture of B. cenocepacia was diluted 1 in 200 in LB containing 500 μg/ml
PmB and incubated at 37oC for 17 h at 200 rpm. The supernatant was collected at 4oC, filtered
using 0.2 m nylon membrane filters, and 10 ml aliquots were placed at one side of the septum
in septate Petri dishes. MIC by agar dilution was performed on test bacteria (B. cenocepacia
K56-2ΔarnBC, E. coli DH5α, HB101, and GT115) at the other side of the septum by spotting
(10 l) of their overnight cultures diluted to OD600 of 0.004 on LB agar containing PmB at
doubling increments. The plates were then incubated at 37oC for 24 h.

2.2.5. RNA extraction


rpoE/500 and rpoE cells were grown overnight and then diluted to OD600 of 0.05 in 50

ml of LB with 500 μg/ml PmB or vehicle control respectively. Cells were grown at 37oC for 30
min at 200 rpm then collected by centrifugation at 39,000 Xg for 30 min at 4oC. RNA was
prepared from approximately 5X108 cfu using the RiboPure-Bacteria kit (Ambion, Inc., Austin,
TX, USA) and treated with DNAse 1 (Ambion), followed by treatment with DNAse 1 (Qiagen
Inc., Mississauga, ON, Canada) following the manufacturer‟s protocol. Integrity of the RNA was
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assessed by agarose gel electrophoresis and by measuring the ratio of absorbance at 260 nm to
280 nm (values obtained between 2.0 and 2.2).

2.2.6. qRT-PCR
RNA was converted to cDNA and real-time PCR was performed as previously described
(20). Fold changes in gene expression were calculated using the Pfaffl Method (21) relative to
BCAS0175, an internal control used for microarray and real-time PCR analysis (22). Data were
calculated from 3 independent experiments each done in triplicate.

2.2.7. Ornithine decarboxylase (ODC) assay
Overnight cultures in LB broth were diluted to OD600 of 0.004 in the rapid ornithine broth
medium described by Fay and Barry (23) with or without PmB or the polyamine synthesis
inhibitors adjusted at pH 5.5. Aliquots (300 µl each) were transferred to 100-well Bioscreen C
plates and overlaid with 100 µl of mineral oil. The plates were incubated in the Bioscreen C
automated growth curve analyzer at 37oC without shaking and the color was monitored at 420
nm.

2.2.8. Thin-layer chromatography analyses of polyamines
Polyamine analysis was performed as previously described (24). Overnight cultures (~20
h) in M9 medium with or without PmB were used. M9 medium was used to eliminate potential
polyamine contamination in complex media such as LB medium. Supernatants, collected by
centrifugation at 16,100g for 5 min, corresponding to cultures of OD600 of 0.1 were used. HClO4
(4 N) was added to supernatants to reach a final normality of 0.4 N and incubated at 37oC for 1 h
with shaking. HClO4 extracts were centrifuged at 16,100g for 5 min. Fifty microlitres of the
supernatants were mixed with 50 µl of 2M Na2CO3 and 100 µl of 2.7 mg/ml dansyl chloride
(Sigma, St Louis, MO, USA) solution in acetone and incubated in the dark at 37oC for 2h with
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shaking. Standard solutions of putrescine, cadaverine, spermidine and spermine (0.2 mM each)
were treated similarly. The mixtures were evaporated to dryness under Nitrogen gas and
extracted with 200 µl benzene at 4oC for ~18 h with shaking. Fifty microlitres of the benzene
extracts of each of the samples and 5 µl of each of the standards were applied onto TLC silica gel
plates (20 × 20 cm, Merck, Darmstadt, Germany) and sequentially separated in two systems: I)
benzene–triethylamine (20 : 2 v/v); II) benzene–methanol (10 : 0.45 v/v). The dried plates were
photographed in ultraviolet light, which excites the green-blue fluorescence of dansyl polyamine
spots. The size and intensity of these spots were proportional to the polyamine concentration,
which was quantified using Image J 1.46r software.

2.2.9. Competition between putrescine and fluorescent PmB on surface binding
Overnight culture of B. cenocepacia K56-2 was centrifuged at 16,100 g for 1 min, and
cells were washed with PBS (3X) followed by dilution to OD600 of 1 in PBS. Polymyxin B
Oregon Green 514 conjugate, PmB-OG (Invitrogen) was added to 100 µl diluted cells at final
concentration of 25 µg/ml and incubated at 37oC for 10 min. Then, cells were washed with PBS
(3X), resuspended in 100 µl of PBS, and placed into 96-well white plates. Fluorescence was
measured at ex of 480 nm and em of 535 nm. Data was reported as a ratio of Fluorescence to
OD600.

2.2.10. Cloning, expression, and purification of YceI
Genes encoding the 2 YceI homologues (BCAL3310 and BCAL3311) were individually
amplified by PCR from K56-2 genomic DNA without the sequences encoding the signal
peptides. The constructs were cloned into the pET28a expression vector. The positive pET28a–
BCAL3310 or 3311 clones were verified by sequencing. The two YceI homologues were
overexpressed in E. coli (BL21 strain) using 0.05 mM isopropyl thio-β-D-galactoside, and the
expression was prolonged for 3 h at 25 oC. Bacterial cells were harvested and the cell pellet was
resuspended in 50 mM phosphate buffer pH 7.8 and lysis was achieved using one shot cell
disrupter (Constant Systems Ltd., Northants, UK) at 27 KPSI. The resulting supernatant was
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isolated from the insoluble fraction by centrifugation at 16,100 g for 60 min at 4 oC. His-tag
batch purification was performed using Ni++ coated beads. The purified proteins were detected
by Coomassie blue staining following 16% SDS-PAGE and quantified by Bradford assay using
bovine serum albumin (BSA) as standard.

2.2.11. Binding assay of YceI to PmB
Purified BCAL3310 and BCAL3311 were diluted to 10 µg/ml concentration, treated with
PmB-OG at final concentration of 1 µg/ml in a total volume of 100 µl and incubated at 37oC for
10 min with rotation. The fluorescence was measured at ex of 480 nm and em of 535 nm.
Background fluorescence of PmB-OG with the buffer control was subtracted. BSA was used as a
control for non-specific binding.

2.2.12. Statistical analyses
Unpaired student‟s t-tests were conducted with GraphPad Prism 5.0.

2.3. Results and Discussion

2.3.1. Heteroresistance of B. cenocepacia to PmB
The prototypic B. cenocepacia clinical strain K56-2 was assessed for heteroresistance by
performing population analysis profiling (PAP) of cultures exposed to serial dilutions of PmB.
The percent growth inhibition increased gradually at high concentrations of PmB but without
reaching complete bacterial inhibition, revealing residual subpopulations of more resistant cells
(Fig. 4A) and suggesting heteroresistance. However, the limited solubility of PmB in the culture
medium at concentrations higher than 2,048 µg/ml precluded the determination of the exact
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minimal inhibitory concentration (MIC) for PmB against K56-2. To investigate this phenomenon
in more detail, I performed PAP in isogenic mutants with intermediate sensitivity to PmB. K562ΔrpoE, which lacks an extracytoplasmic stress response regulator (25), showed evident
heteroresistance to PmB (Fig. 4A). A fraction of bacteria from the same culture was inhibited at
64 µg/ml despite that the MIC of PmB against the entire bacterial population was higher than
1,024 µg/ml. Gradual reduction in the resistant subpopulation was observed upon increasing
PmB concentrations over a 16-fold range. Heteroresistance to PmB was confirmed by E-test,
which demonstrated small colonies growing within the zone of inhibition surrounding the highest
concentrations of PmB on the E-test strips, both in K56-2 and K56-2∆rpoE (Fig. 4B and C
respectively). A similar pattern of heteroresistance was also previously observed for the K562ΔsuhB (26), which lacks an inositol monophosphatase and like K56-2∆rpoE, has intermediate
sensitivity to PmB. Heteroresistance to PmB was also observed in the B. cenocepacia clinical
isolate CP706-J, indicating that it is not a phenomenon unique to a single strain (Fig. 4D). In
contrast, P. aeruginosa PAO1 did not show heteroresistance to PmB, as demonstrated by the
abrupt drop in the bacterial growth on a two-fold increase of PmB concentration to reach
complete growth inhibition (Fig. 4E).
Heteroresistance to PmB was not related to the level of PmB resistance since mutants
displaying high sensitivity to PmB were also heteroresistant. K56-2ΔhldA, a strain lacking the
ability to produce a complete lipopolysaccharide (LPS) molecule as a result of the loss of the
hldA gene (27), demonstrated heteroresistance to PmB at concentrations ranging from 32 µg/ml
to 256 µg/ml (Fig. 4F). Furthermore, K56-2ΔarnBC carrying a deletion of genes required for 4amino-4-deoxy-L-arabinose (Ara4N) synthesis displayed similar heterogeneity in the response to
PmB despite its exquisite sensitivity to PmB (Fig. 4G). Since B. cenocepacia LPS modification
with Ara4N is the major determinant for the extreme resistance to PmB (11) my results suggest
that the heteroresistance of B. cenocepacia to PmB is not associated to LPS modifications and
therefore depends on a different mechanism.
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Figure 4.Heterogeneous response of B. cenocepacia to PmB.
(A) Population analysis profiling (PAP) of B. cenocepacia strains K56-2, K56-2∆rpoE, K562∆rpoE/500 by agar dilution at 24 h. (B) E-test of K56-2; and (C) E-test of K56-2∆rpoE
showing discrete colonies at otherwise clear zones of inhibition, indicating heterogeneous
response to PmB. (D) PAP of B. cenocepacia CF clinical isolate CP706-J by broth dilution at 18
h. (E) PAP of P. aeruginosa PAO1; (F) PAP of K56-2∆hldA; and (G) PAP of K56-2∆arnBC by
agar dilution at 24 h. n = 6. The shaded regions on the PAP graphs indicate ranges of antibiotic
concentrations over which the bacterial population transitions from lack of inhibition to maximal
inhibition by the antibiotic under the test conditions.
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2.3.2. A more resistant subpopulation of B. cenocepacia protects naïve bacteria from PmB
I investigated whether the more resistant subpopulations of B. cenocepacia could
influence the overall level of antibiotic resistance of naïve cells in mixed cultures. To test this
hypothesis I chose to focus on the K56-2ΔrpoE mutant, as this bacterium has a PmB resistance
profile that is similar to the parental strain but sufficiently less resistant to reach higher levels of
growth inhibition at testable concentrations of PmB (Fig. 4A). Based on the K56-2ΔrpoE PAP, I
selected the subpopulation of K56-2ΔrpoE exposed to 500 µg/ml (Fig. 4A, ∆rpoE/500), which
arose at a frequency of 2.48 x 10-4 and demonstrated uniform high-level resistance when reexposed to PmB (Fig. 4A). ∆rpoE/500 cells passaged for up to five days in the absence of PmB
displayed PAP identical to that of cells grown overnight in the presence of 500 µg/ml PmB,
indicating that the high-level resistance of ∆rpoE/500 was stable without selective pressure,
likely as a result of one or more mutations that confer increased PmB resistance. No differences
were found between ∆rpoE/500 and naïve ∆rpoE cells in LPS electrophoretic profiles (Fig. 5A).
Furthermore, the increased resistance of ∆rpoE/500 was not due to an increase in the Ara4N LPS
modification, since the differential expression of arnT and arnB genes, representing the 2
transcriptional units of the arn cluster (28), was 1.08 (+/-0.09) and -1.73 (+/-0.04) respectively,
as determined by qRT-PCR. This was expected since it was previously shown that the arn cluster
in B. cenocepacia is not regulated by PmB challenge (28). ∆rpoE/500 cells treated with PmB
also displayed reduced metabolic activity at 24 h relative to naïve ∆rpoE and K56-2 with or
without exposure to PmB, as revealed in the resazurin metabolic assay (Fig. 5B), suggesting that
increased PmB resistance in the ∆rpoE/500 subpopulation is associated with reduced metabolic
fitness.
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Figure 5.Characterization of the more resistant subpopulation ΔrpoE/500.
(A) LPS profiles; (B) Metabolic activity. Overnight cultures were diluted to OD600 of 0.02,
treated with PmB or vehicle control, incubated at 37°C with continuous medium shaking for 24 h
in a Bioscreen C automated growth curve analyzer. Cells were then collected, washed,
resuspended in PBS, transferred to white 96-well plate, and treated with resazurin at final
concentration 2.5 µg/ml. The plates were incubated in the dark at 37oC for 90 min, and the
fluorescence was measured at λex of 485 nm and λem of 600 nm, unpaired student‟s t-tests were
conducted comparing each condition to the control K56-2; (C) Secreted protease activity.
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Since ∆rpoE/500 represents ~1% of the ∆rpoE population in the turbidimetric PAP experiments
(not shown), ∆rpoE/500 was co-cultured in a 1:100 ratio with P. aeruginosa in the presence of 2
µg/ml of PmB. This concentration of PmB was based on the current clinical guidelines for P.
aeruginosa therapeutic breakpoints of the closely related antibiotic polymyxin E (colistin), which
is set at 2 µg/ml (29) and is equivalent to the MIC of PmB against P. aeruginosa. Co-culture
under these conditions resulted in more than a 3- to 5-log survival of P. aeruginosa at 6 and 24 h,
respectively, compared to P. aeruginosa grown alone (Fig. 6). There was no effect of P.
aeruginosa on the growth of B. cenocepacia cells in co-culture (Fig. 7). Protection by ∆rpoE/500
did not depend on secreted extracellular proteases since no differences were found between
∆rpoE/500 and naïve ∆rpoE cells in the amount of these proteases (Fig. 5C). Similarly,
protection did not depend on quorum sensing molecules, as mutants defective in the various
quorum systems of B. cenocepacia also showed heteroresistance to PmB and could protect P.
aeruginosa from PmB (Fig. 8A and B). Also, it could not be due to production of indole (3, 4)
since B. cenocepacia and Burkholderia in general are indole negative (30).
Furthermore, the filtered supernatant of an overnight culture of ∆rpoE/500 in PmB
communicated higher-level resistance in a volatile-mediated manner to physically separated
K56-2ΔarnBC and several E. coli strains. The MIC of the PmB-sensitive strains doubled due to
volatiles emitted from the supernatant of ∆rpoE/500 (Table 6), with the exception of E. coli
GT115, which only showed slight enhancement in the growth in the presence of PmB (not
shown). These results were consistent and reproducible. The protective effect of ∆rpoE/500 was
therefore not limited to the same species and could be communicated by one or more volatile
compounds in the bacterial supernatant.
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Figure 6. Protective effects of B. cenocepacia ∆rpoE/500 on P. aeruginosa PAO1, exposed to
PmB, in co-culture.
The dotted line represents the limit of detection (50 cfu/ml). Three independent experiments each
done in duplicate.
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Figure 7. The growth of B. cenocepacia∆rpoE/500 subpopulation was not impaired in co-culture
with P. aeruginosa PAO1except at 24 h in co-culture without PmB where its ratio relative to
PAO1 dropped 10 fold probably due to limiting nutrients as a result of the increased biomass of
both bacteria in the absence of PmB.
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Figure 8. Quorum sensing systems of B. cenocepacia are neither involved in the heterogeneity of
response to PmB nor in protection to naïve populations.
(A) PAP by agar dilution of the quorum-sensing mutants. (B) Direct co-culture of P. aeruginosa
PAO1 with subpopulations of the quorum-sensing mutants growing at 500 µg/ml in comparison
to ∆rpoE/500 subpopulation. The co-cultures were treated with 2 µg/ml PmB for 24 h; the
differences are not statistically significant based on unpaired student‟s t-tests.
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Table 6.MIC by agar dilution technique to determine the volatile-mediated protective effect
of the supernatant of ∆rpoE/500 from the effects of PmB on sensitive bacteria.
Sterile LB
Control (n)
Sensitive bacteria

Supernatant of
∆rpoE/500 (n)
MIC, µg/ml

B. cenocepacia K56-2ΔarnBC

0.25 (4)

0.5 (4)

E. coli DH5α

0.25 (4)

0.5 (4)

E. coli HB101

0.25 (3)/ 0.5
(1)

0.5 (4)

E. coli GT115

0.25 (4)

0.25 (4)
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2.3.3. The more resistant subpopulation releases higher amounts of a subset of proteins upon
exposure to PmB
To gain clues on the secreted molecules mediating the protective effects of B.
cenocepacia from PmB, I compared the profile of proteins released into the supernatant of PmBtreated ∆rpoE/500 with naïve K56-2∆rpoE and parental K56-2 treated or untreated with
PmB.The ∆rpoE/500 subpopulation and K56-2 treated with PmB showed a similar pattern of
overexpression of several polypeptide bands (Fig. 9), which were identified by mass
spectrometry. One of these bands corresponded to BCAM2827, which is a predicted periplasmic
component of an ABC transporter involved in the biosynthesis of hopanoids. Hopanoids,
bacterial substitutes of eukaryotic cholesterol that stabilize membranes and regulate membrane
fluidity and permeability, have been recently shown to be required for PmB resistance in B.
cenocepacia (31). Another protein band was identified as YceI, a conserved protein of unknown
function proposed to bind amphiphilic molecules and sequester toxic fatty acids or amides (32).
Two highly related YceI homologues, BCAL3310 and BCAL3311, are present in K56-2. Other
polypeptides were identified as flagellin, in agreement with the reported effects of PmB on the
flagellar assembly apparatus at the transcriptional level (33), and with the reduced motility in
parental K56-2 and ∆rpoE/500 upon exposure to PmB (not shown).
Three other polypeptide bands were identified as lysine-arginine-ornithine-binding
periplasmic proteins, which are involved in the import of these amino acids. I hypothesized that
increased import of lysine, arginine and ornithine could be utilized in the modification of the
membranes through the formation of lysylphosphatidylglycerol and ornithine-lipid derivatives,
since modification of bacterial membranes with cationic molecules reducing their overall
negative charge is one of the common mechanisms of increasing resistance to antimicrobial
peptides (34). However, deletion of BCAM1679 encoding a putative lysylphosphatidylglycerol
synthetase and olsB (BCAL1281), previously shown to render the cells incapable of synthesizing
the ornithine-lipid under low phosphate conditions (35), did not affect the resistance to PmB
when tested in LB medium or in low-phosphate containing medium in K56-2 background (not
shown).
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Figure 9. Proteins released into the supernatant of B. cenocepacia K56-2 and ∆rpoE/500 treated
with 500 µg/ml of PmB compared to those released from untreated K56-2 and naïve ∆rpoE.
Proteins were run on 14% SDS-PAGE and detected by silver staining and those that were
differentially expressed were further identified by LC-MS.
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2.3.4. A role for putrescine in PmB resistance
The increased import of lysine, arginine and ornithine suggested by the overexpression of
their periplasmic binding proteins in ∆rpoE/500 exposed to PmB could be also utilized for
synthesis of polyamines (Fig. 10A). Therefore, I tested the involvement of polyamines as
possible candidate molecules conferring increased PmB resistance. Spermidine, at concentrations
ranging from submicromolar to millimolar levels, had negligible effect on resistance of B.
cenocepacia to PmB (not shown). However, treatment of the parental K56-2 with 50 mM
putrescine increased the resistance to PmB since putrescine-treated cells survived better at 2,048
µg/ml PmB compared to control cells (Fig. 10B). Putrescine treatment of K56-2∆arnBC also
resulted in a 2-fold increase in the MIC of PmB, suggesting that putrescine plays a role in the
increased resistance to PmB and its transfer among the bacterial population.
To test this notion, I deleted the genes encoding key enzymes for polyamines
biosynthesis (Fig. 10A). Mutants with double deletions of both genes encoding spermidine
synthases (BCAL3390 and BCAM2086) showed a slight reduction in resistance to PmB and no
changes in growth rate (Fig. 11). However, the mutant lacking BCAL2641, which encodes an
ornithine decarboxylase, had a marked reduction in resistance to PmB and no growth rate defects
(Fig. 10C). PmB resistance was restored to parental level by single-copy complementation of
BCAL2641 (Fig. 10D). To further confirm these findings I used two polyamines synthesis
inhibitors, dicyclohexylamine and 3-(Methylthio)propylamine (Fig. 10E and Fig. 12).
Dicyclohexylamine, originally reported as a spermidine synthase inhibitor but also capable of
inhibiting the ornithine decarboxylase enzyme (Fig. 13), reduced resistance to PmB in K56-2 and
∆rpoE/500 cells in a concentration dependent manner (Fig. 10E and Fig. 12, respectively).
However, 3-(Methylthio)propylamine, which is more specific for spermidine synthase and lacks
any detectable inhibitory effect on the ornithine decarboxylase reaction (Fig. 13) had no effect on
resistance of ∆rpoE/500 (Fig. 12) and only caused a lower reduction of resistance of K56-2 to
PmB (Fig. 10E). Exogenous putrescine increased the resistance of K56-2 ∆BCAL2641 to PmB in
a concentration-dependent manner; full restoration of the level of resistance of the parental strain
was achieved at 50 mM putrescine (Fig. 10B). A comparison of the level of transcription of
BCAL2641 in both naïve ∆rpoE and ∆rpoE/500
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Figure 10.Contribution of the polyamine putrescine in the response to PmB.
(A) Polyamines biosynthetic pathway. (B) Exogenous putrescine increases the resistance of the
parental K56-2 to PmB and ΔBCAL2641 shows significant reduction in resistance to PmB which
was restored to the parental level using 50mM exogenous putrescine; n=6 (C) The deletion of
BCAL2641 leads to reduced resistance to PmB relative to the parental K56-2. (D) Single-copy
complementation of ∆BCAL2641. (E) The polyamine synthesis inhibitor dicyclohexylamine
(blue) reduces the resistance of B. cenocepacia K56-2 to PmB, with little to no effect of 3(methylthio)propylamine (red), shown in a turbidimetric PAP at 24 h; n=5. (F) TLC analysis of
polyamines released in the supernatants of 20 h old M9 cultures compared to standards
visualized under UV after derivatization to their dansylated derivatives. (G) Relative amounts of
putrescine released from the wild-type and mutants, n=4. Unpaired student‟s t-tests were
conducted to determine significance of differences among different test conditions.
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Figure 11.PmB resistance of the spermidine synthase double mutant, K56-2
∆BCAL3390∆BCAM2086.
(A) Growth curves in absence of PmB; (B) Effect of 2048 µg/ml PmB on growth.
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Figure 12. The polyamine synthesis inhibitor dicyclohexylamine (blue) reduces the
resistance of B. cenocepacia ∆rpoE/500 subpopulation to PmB, with no effect of 3(methylthio)propylamine (red), shown in a turbidimetric PAP at 18 h; n=5.
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Figure 13. Ornithine decarboxylase (ODC) activity of B. cenocepacia K56-2 either untreated or
treated with 1 mM of dicyclohexylamine or 3-(methylthio)propylamine at 24 h.
This concentration of the polyamine synthesis inhibitors did not affect the growth of the bacteria.
n=9. Unpaired student‟s t-tests were conducted comparing each condition with the control
untreated group.
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bacteria treated with PmB, demonstrated that the expression of this gene is upregulated by 2.9
(+/- 0.9) in ∆rpoE/500 in response to PmB. Moreover, higher levels of putrescine released in the
supernatant of ∆rpoE/500 treated with PmB were observed relative to ∆rpoE naïve population
(Fig. 14).
Putrescine is the most abundant polyamine secreted from B. cenocepacia, while much
less amounts of spermidine and cadaverine are secreted from K56-2 (Fig. 10F). The release of
putrescine was significantly reduced in the ∆BCAL2641 compared to the wild type K56-2 (Fig.
10G). However, B. cenocepacia possesses another predicted ornithine decarboxylase,
BCAM1111 and a putative arginine decarboxylase, BCAM1112. Deletion of genes encoding
both enzymes did not have an effect on resistance to PmB in K56-2 (not shown), and only a
small effect in the release of putrescine (Fig. 10G). In contrast, cadaverine was not detected in
the supernatant of ∆BCAL2641 and ∆BCAM1111∆BCAM1112 precluding the involvement of
cadaverine in increased PmB resistance (Fig. 10F). By qRT-PCR, BCAM1111 and BCAM1112
were 2000-fold less transcribed relative to BCAL2641 in naïve ∆rpoE and ∆rpoE/500 bacteria;
they were also not differentially transcribed in the more resistant subpopulation (∆rpoE/500)
relative to the naïve population, suggesting that their gene products are not preferentially used in
polyamines biosynthesis. In agreement, the ornithine decarboxylase (ODC) activity of
∆BCAL2641 was much more reduced relative to ∆BCAM1111∆BCAM1112 (Fig. 15). The
pattern of ODC activity corresponded to the levels of secretion of putrescine in the different
mutants relative to the wild type (Fig. 10G). Together, this shows that BCAL2641 is the primary
contributor of putrescine in B. cenocepacia explaining the phenotype observed upon its deletion.
K56-2 ∆BCAL2641 also lost the protective effects from PmB in co-culture with P. aeruginosa
PAO1 (Fig. 16A).These results implicated putrescine as a critical polyamine conferring
protection from PmB and communicating resistance to neighbouring bacterial cells.
The initial binding of antimicrobial peptides to the bacterial surfaces is crucial for their
subsequent antibacterial effects (34). Putrescine competed with PmB for binding to the surface of
B. cenocepacia K56-2, where treatment of cells with both putrescine and the fluorescent PmBOregon green 514 conjugate showed reduced binding of the fluorescent PmB derivative relative
to control cells (Fig. 16B). Putrescine also replaced already bound fluorescent PmB conjugate
(Fig. 16B). This agrees with previous findings showing that polyamines provide protection of
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Figure 14. Increased release of putrescine in the supernatant of ∆rpoE/500 subpopulation
treated with 500 µg/ml PmB relative to naïve ∆rpoE determined at 20 h from M9 cultures by
TLC analysis. n=6. Unpaired student‟s t-test was conducted.
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Figure 15. ODC assay of the parental strain K56-2 and different PAs biosynthetic mutants at 6 h.
n=9. Unpaired student‟s t-tests were conducted.
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Figure 16.Role of putrescine in the protective effects of B. cenocepacia against PmB.
(A) Involvement of putrescine in the protective effects of B. cenocepacia on P. aeruginosa
PAO1 shown by performing direct co-culture between PAO1 and K56-2 wild type or
∆BCAL2641 mutant at 24 h. The dotted line represents the limit of detection (50 cfu/ml). Three
independent experiments each done in duplicate. (B) Putrescine protects the bacterial surface
from binding to PmB; 50 mM of putrescine reduced binding of PmB-Oregon green 514
conjugate (25 µg/ml) when both added together, whereas it could replace already bound PmB;
n=6.
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the outer membrane of P. aeruginosa from PmB damage (36). However, this does not preclude
other mechanisms mediated by putrescine to protect against the effects of PmB. For example,
polyamines can reduce oxidative stress in E. coli exposed to bactericidal antibiotics (37) and
protect from membrane lipid peroxidation in P. aeruginosa (36). These additional mechanisms
of protection by polyamines are consistent with the notion that bactericidal antibiotics at
sublethal concentrations stimulate the production of hydroxyl radicals, which in turn may induce
mutations leading to various levels of antibiotic resistance (38).

2.3.5. The role of YceI protein
I also tested the involvement of YceI in heteroresistance. Mutants with a double deletion
of BCAL3310 and BCAL3311 had increased sensitivity to PmB, but no differences in growth rate
relative to K56-2 (Fig. 17A). Complementing the double deletion mutant
∆BCAL3310∆BCAL3311 (K56-2∆yceI) with both genes restored resistance to PmB to the
parental level (Fig. 17B). Moreover, YceI contributed to the protective effects of B. cenocepacia
towards P. aeruginosa PAO1 cells exposed to 1.5 µg/ml PmB (Fig. 17C). The level of
transcription of BCAL3310, determined by qRT-PCR in both naïve ∆rpoE and the more resistant
subpopulation ∆rpoE/500 treated with PmB, indicated that this gene was upregulated by 2.5 (+/0.6) in the more resistant subpopulation in response to PmB. Together, these experiments reveal
that the YceI homologues contribute to the increased resistance to PmB in ∆rpoE/500 and the
protective effects on other cells against PmB. Purified YceI BCAL3310 and BCAL3311 (Fig.
17D), were both capable of binding PmB-Oregon green 514 conjugate, although BCAL3311
being more potent than BCAL3310 (Fig. 17E). This supports their role in sequestering PmB thus
protecting other cells from the toxic effects of the antibiotic.

2.3.6. B. cenocepacia is heteroresistant to other bactericidal antibiotics
I determined whether heteroresistance in K56-2 is exclusive to PmB. Turbidimetric PAP
using various antibiotics indicated that K56-2 is heteroresistant to gentamicin (protein synthesis
inhibitor), norfloxacin (DNA replication inhibitor), rifampicin (mRNA transcription inhibitor)
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Figure 17.Contribution of YceI in the response to PmB and its role in protection against
PmB.
(A) The deletion of BCAL3310 and BCAL3311 (∆yceI) leads to reduced resistance to PmB
relative to the parental K56-2. (B) PAP by agar dilution showing complementation of the
reduced resistance in ∆yceI mutant by yceI (using both BCAL3310 and BCAL3311) under
the control of the rhamnose promoter on pSCrhaB2 to the parental level at 0.4% rhamnose.
(C) Involvement of YceI in the protective effects of B. cenocepacia on P. aeruginosa PAO1
shown after 24 h of direct co-culture of PAO1 and K56-2 wild type or ∆yceI. Three
independent experiments each done in duplicate. (D) Purified YceI homologues,
BCAL3310 and BCAL3311. (E) Binding of BCAL3310 and BCAL3311 to PmB-Oregon
green 514 conjugate. BSA was used as a control for binding. n=6.
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and ceftazidime (cell wall peptidoglycan synthesis inhibitor), all of which belong to different
classes of bactericidal antibiotics (Fig. 18). In contrast, the response of K56-2 was homogeneous
to tetracycline, chloramphenicol, novobiocin, trimethoprim, which are all bacteriostatic
antibiotics (Fig. 19). Polyamines play a role in the heterogeneity of response to the bactericidal
antibiotics. ∆BCAL2641 displayed a more homogeneous response to the different bactericidal
antibiotics, except for gentamicin (Fig. 18). Similarly, YceI was involved in the heterogeneous
response to the amphiphilic bactericidal antibiotics rifampicin and norfloxacin; however, the
∆yceI mutant only showed minor reduction in the percentage of the more resistant fractions of
the population in response to ceftazidime (Fig. 18).

2.4. Conclusions
I show that (i) B. cenocepacia is heteroresistant to PmB and different classes of
bactericidal antibiotics; (ii) a more resistant subpopulation of B. cenocepacia communicates
high-level resistance to less resistant cells; (iii) the protection extends to other bacterial species
and is chemically mediated by putrescine, a polyamine, and the secretion of YceI. Since
putrescine is volatile (39), resistance can also be communicated to physically separated bacteria
in a volatile-mediated manner. Natural polyamines, discovered more than 300 years ago, occur in
almost all living organisms; they are involved in growth, development, and other important
functions related to modulation of defence responses to diverse environmental stresses and
modulation of immune responses in plants and humans respectively (40, 41). Polyamines are
significantly increased at inflammatory sites of infection or injury (42, 43); they are also
produced by a wide range of bacteria, playing roles in growth and other functions including
incorporation into the cell wall, biosynthesis of siderophores, acid resistance, scavenging free
radical ion, signaling cellular differentiation and biofilm formation (44). The two most common
bacterial polyamines are putrescine and spermidine (44). I show here that the most abundant
polyamine in B. cenocepacia is putrescine, while spermidine and cadaverine are produced in
much lower amounts. Polyamines were previously shown to increase the resistance of P.
aeruginosa to antimicrobial peptides (36, 45, 46). Heteroresistance of B. cenocepacia K56-2 was
common to bactericidal antibiotics regardless of their site of action. I speculate that bacterial
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Figure 18.Heterogeneous response of B. cenocepacia K56-2 to bactericidal antibiotics.n = 6.
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Figure 19.Homogenous response of B. cenocepacia K56-2 to bacteriostatic antibiotics.n = 6.
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cells may be exposed to greater stress in case of bactericidal agents, relative to bacteriostatic
antibiotics, which might result in variation across the bacterial population in their capabilities to
withstand and respond to such hostile insult. The involvement of polyamines in heteroresistance
to the different classes of bactericidal antibiotics and of YceI in the response to amphiphilic
bactericidal antimicrobials leads me to propose that these mediators serve as "danger"
infochemicals. These chemical signals may be employed in the non-genetic communication of
resistance among members of heteroresistant bacterial populations against the different
bactericidal antibiotics. The action of YceI on amphiphilic antibiotics fits with its proposed
mechanism sequestering toxic amphiphiles with acyl fatty chains, such as PmB, as I have shown
in this study. However, this does not preclude other mechanisms in the response of B.
cenocepacia to bactericidal antibiotics, especially the aminoglycoside gentamicin, which still
requires further investigation.
The proposed danger infochemicals can serve as a general mechanism of protection of
other bacterial species in a polymicrobial infection such as that found in patients with cystic
fibrosis. YceI would reduce available amphiphilic antibiotics from the medium thus protecting
any organism; whereas putrescine could interact with most of the bacterial species, since
polyamines are produced by most bacteria, with rare exceptions such as Staphylococcus aureus
strains, which do not tolerate polyamines as they lack the necessary detoxifying enzymes (47).
In conclusion, I show that antibiotic heteroresistance leads to a cooperative behaviour
such that the more antibiotic-resistant members of the population protect the less resistant ones
as well as less resistant members of other species. A similar observation has been made
previously with indole production by E. coli strains (3). However, indole production in the more
resistant cells was at the exact same level as in naive cells with no antibiotic treatment and unlike
putrescine, indole was neither induced by antibiotics nor over-secreted by the more resistant
cells. I believe my findings are relevant in the clinical setting, particularly for intrinsically
resistant opportunistic Gram-negative bacteria. Attempts to modulate these interactions using
polyamine synthesis inhibitors may contribute to disrupting heteroresistance so the bacterial
population will have a more uniform response to the antibiotic, reducing the window of
therapeutic failure.
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Chapter 3

Putrescine reduces antibiotic-induced oxidative stress as a
mechanism of modulation of antibiotic resistance in
Burkholderia cenocepacia

A version of this chapter has been published:

El-Halfawy OM, and Valvano MA (2014). Putrescine reduces antibiotic-induced oxidative stress
as a mechanism of modulation of antibiotic resistance in Burkholderia cenocepacia.Antimicrob
Agents Chemother. 58(7):4162-4171; doi: 10.1128/AAC.02649-14. Copyright © American
Society for Microbiology.
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3.1. Introduction
The relentless increase in multidrug resistance, particularly intrinsic, high-level resistance,
undermines new treatments improving health and extending the life of patients especially of
those with chronic conditions (1). For example, respiratory failure secondary to chronic
pulmonary bacterial infection in patients with cystic fibrosis hinders the dramatic improvements
in survival achieved over the last several decades and remains the primary cause of death (2).
The emergence of growing numbers of cystic fibrosis pathogens with intrinsic, multidrug
resistance such as Burkholderia cepacia complex, Stenotrophomonas maltophilia,
Achromobacter xylosoxidans, and nontuberculous mycobacteria creates a further need for novel
therapies (2). I investigate the mechanisms of high-level intrinsic multidrug resistance using
Burkholderia cenocepacia as a model bacterium. B. cenocepacia is an environmental,
opportunistic pathogen that belongs to the B. cepacia complex and causes serious respiratory
infections in CF patients (3). These infections are associated with faster decline in lung function,
debilitating exacerbations and ultimately death (4-6), and they also reduce the survival of CF
patients after lung transplant (7).
While genetic mechanisms are considered the quintessential means of transfer of
antibiotic resistance traits among bacteria, small molecules are also capable of modulating the
antibiotic response of bacteria (8). The clinical outcome of antibiotic treatment does not always
correlate with the expectations based on in vitro susceptibility testing performed on individual
clinical isolates (9). Owing to the polymicrobial nature of many infections (10), cross-talk
between the different bacterial species is likely to occur during infection. Such chemical
communication of antibiotic resistance among bacteria may aggravate the problem of antibiotic
resistance by potentially causing transient reduction in the susceptibility to antibiotics,
potentially leading to therapeutic failures. For example, a transient increase in resistance to
antimicrobial peptides by exposure to host polyamines was shown for the urogenital pathogen
Neisseria gonorrhoeae (11). Identifying chemical communicators of antibiotic resistance and
their mechanism of protection would provide another avenue for intervention to combat the
increase and spread of antimicrobial resistance. Recently, we demonstrated that B. cenocepacia
exhibits a non-genetic mechanism to reduce antibiotic susceptibility that is chemically mediated
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by putrescine and YceI, a small secreted protein of unknown function that is highly conserved in
bacteria (12). Putrescine is a polyamine produced by almost all living organisms (13). When
released from B. cenocepacia, putrescine protects less resistant cells from the same and different
species from the antimicrobial peptide polymyxin B (PmB) (12).
The mechanism of protection is partly due to the ability of putrescine to compete with
PmB for binding to the surface of B. cenocepacia (12). However, polyamines can also quench
oxidative species (14) and protect membranes from lipid peroxidation (15). Various classes of
antibiotics induce oxidative stress and increased production of reactive oxygen species (ROS)
(16-19). Although the specific lethal role of ROS generated in response to antibiotics remains
under discussion (16, 20, 21), oxidative stress constitutes a burden on the bacterial cells (22).
Therefore, it is conceivable that protection from oxidative stress accompanying antibiotic
exposure would improve the bacterial response to antibiotics, thus increasing resistance.
Here I show that when present at sub-lethal concentrations, PmB and other bactericidal
antibiotics induce oxidative stress in B. cenocepacia. My findings revealed that exogenous and
endogenous putrescine protects against antibiotic-mediated oxidative stress. This work exposes
another mechanism of putrescine-mediated protection from antibiotics alongside with protection
of cell surface from binding of PmB previously described (12). By examining the expression
patterns of the different putrescine synthesizing enzymes in response to antibiotics, I discovered
that the ornithine decarboxylase BCAL2641 is a plausible target for designing inhibitors that
would block putrescine-mediated communication of antibiotic resistance among different
bacteria, ultimately reducing the window of therapeutic failure in treating bacterial infections.
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3.2. Materials and Methods
3.2.1. Strains and reagents.
Table 7 lists bacteria and plasmids used in this study. Bacteria grew in LB at 37°C. Antibiotics
(Sigma, St Louis, MO, USA) were diluted in water except for PmB, which was diluted in 0.2%
bovine serum albumin/0.01% glacial acetic acid buffer. Rifampicin was dissolved in dimethyl
sulphoxide (DMSO).
3.2.2. General molecular techniques.
DNA manipulations were performed as previously described (23). T4 DNA ligase (Roche
Diagnostics, Laval, Quebec, Canada), Antarctic phosphatase (New England Biolabs, Pickering,
Ontario, Canada) and restriction endonucleases (Roche or New England Biolabs) were used as
recommended by the manufacturers. Transformation of Escherichia coli GT115 was performed
using the calcium chloride method (24). Mobilization of plasmids into B. cenocepacia was
conducted by triparental mating (25) using E. coli DH5α carrying the helper plasmid pRK2013
(26). DNA amplification by polymerase chain reaction (PCR) was performed using a C1000
Thermal cycler (Bio-Rad Laboratories Ltd., Mississauga, Ontario, Canada) with Taq or HotStar
HiFidelity DNA polymerases (Qiagen, Mississauga, Ontario, Canada) and optimized for each
primer pair. DNA sequencing was carried out at the DNA sequencing Facility of York
University, Toronto, Canada or at Eurofins MWG Operon, Huntsville, Alabama, USA. The DNA
sequences were analyzed with the BLAST computer program and compared to the sequenced
genome of B. cenocepacia strain J2315.
3.2.3. Fluorometric determination of ROS.
Overnight cultures of the parental B. cenocepacia K56-2 and the appropriate mutants in LB
medium were diluted to an optical density at 600 nm (OD600) of 0.1 in fresh medium. Five-ml
aliquots were incubated at 37oC for 3 h at 200 rpm. Antibiotics and/or putrescine were added at
the specified concentrations and the cultures were further incubated at 37oC for 2 h at 200 rpm.
After incubation, the OD600 was measured and aliquots containing cells equivalent to an OD600 of
0.4 were pelleted, washed with phosphate buffered saline (PBS), and resuspended in 1 ml of
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PBS. Superoxide radicals and other ROS were determined by diluting the obtained suspension
100 fold in 1 ml PBS and adding 2‟,7‟-dichlorofluorescein diacetate (DCF) to a final
concentration of 2 µM. The reaction mixture was then incubated at 37oC for 30 min with
rotation. After incubation, the fluorescence was measured in 200-µl aliquots placed into 96-well
white plates (Microfluor-2 White, Thermo Scientific) at λex= 480 nm and λem= 521 nm, using
Cary Eclipse fluorescence spectrophotometer (Varian, Inc., Mississauga, Ontario, Canada). In
addition, the OD600 of the same suspensions were measured and used to normalize the
fluorescence values. Hydroxyl radical production was determined in 600 µl bacterial suspensions
without dilution using 3‟-(p-hydroxyphenyl) fluorescein (HPF) at a final concentration of 5 µM.
Fluorescence was measured at λex= 495 nm and λem= 530 nm in 200 µl aliquots placed into 96well white plates. Background fluorescence of each probe in buffer control was subtracted.
Autofluorescence of the bacterial suspensions, without adding the probes, was measured and
corrected for by subtraction from the fluorescence signals. Data were normalized to the OD600 of
the bacterial suspensions. The suspensions were protected from light throughout the assays to
avoid photo-oxidation.
3.2.4. Antibiotic susceptibility testing.
Overnight cultures of the parental B. cenocepacia K56-2 and the appropriate mutants in LB
medium were diluted to an optical density at 600 nm (OD600) of 0.0008 (low inoculum) or 0.04
(high inoculum) in fresh LB medium and 0.04 in fresh M9 minimal medium with or without the
antibiotic and incubated at 37°C with medium continuous shaking in a Bioscreen C automated
growth curve analyzer (MTX Lab Systems, Vienna, VA, USA). Bacterial growth was assessed
turbidimetrically at 600 nm.
3.2.5. In vitro antioxidant activity assay.
The ability of putrescine to scavenge free radicals was determined using a system of in vitro
generation of superoxide radicals containing phenazine methosulfate (PMS)-NADH as
previously described (27). Briefly, the reaction mixture consisted of 21 mM phosphate buffer
(pH 8.3), 0.7 mM NADH, 17 µM nitro blue tetrazolium, and the corresponding quantity of
putrescine.The reaction was initiated by adding 4 µM PMS. The reaction mixtures were mixed
and the amount of formazan formation was measured immediately using the spectrophotometer
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Table 7. Strains and Plasmids used in Chapter 3
Strain
or plasmid

Relevant characteristicsa

Source and/or
reference

Strains
Burkholderia cenocepacia
K56-2
ET12 clone related to J2315, CF clinical Isolate, bBCRRC
OME11
K56-2, ∆BCAL2641
OME12
K56-2, ∆BCAM1111-∆BCAM1112
OME49
OME12 Prha::BCAL2641
OME50
K56-2, PBCAL2641::pGSVTp-luxCDABE; TpR
OME51
OME12, PBCAL2641::pGSVTp-luxCDABE; TpR
OME52
K56-2, PBCAM1111::pGSVTp-luxCDABE; TpR
OME53
OME11, PBCAM1111::pGSVTp-luxCDABE; TpR
OME54
K56-2, PBCAM1112::pGSVTp-luxCDABE; TpR
OME55
OME11, PBCAM1112::pGSVTp-luxCDABE; TpR
OME56
K56-2, PoxyR::pGSVTp-luxCDABE; TpR
OME57
OME11, PoxyR::pGSVTp-luxCDABE; TpR
OME58
OME12, PoxyR::pGSVTp-luxCDABE; TpR
Escherichia coli
DH5α
GT115

(28)
(12)
(12)
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

F-80lacZ M15 endA1 recA1 supE44 hsdR17(rK- mK+)deoR
Laboratory
thi-1 nupG supE44 gyrA96relA1 ∆(lacZYA-argF)U169, λstock
F– mcrA∆(mrr-hsdRMS-mcrBC) 80∆lacZ∆M15 ∆lacX74
Invivogen
recA1rpsL(StrA) endA1∆dcm uidA(∆MluI)::pir-116 ∆sbcC-sbcD

Plasmids
pRK2013
pGSVTp-lux
pSC200
pOE14
pOE17
pOE18
pOE19
pOE20
a

oricolE1, RK2 derivative, KanR, mob+, tra+
Mobilizable suicide vector containing the lux operon,
derivative from pGSV3-lux(29); OriT; TpR
oriR6K, PRhaB rhamnose-inducible promoter, TpR, mob+
PBCAL2641::luxCDABE transcriptional fusion in pGSVTp-lux
Prha::BCAL2641 in pSC200
PBCAM1111::luxCDABE transcriptional fusion in pGSVTp-lux
PBCAM1112::luxCDABE transcriptional fusion in pGSVTp-lux
PoxyR::luxCDABE transcriptional fusion in pGSVTp-lux

TpR, trimethoprim resistance, KanR, kanamycin resistance, TetR, tetracycline resistance.
BCRRC, B. cepacia Research and Referral Repository for Canadian CF Clinics.

b
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(26)
(30)
(31)
This study
This study
This study
This study
This study

at 560 nm. The percentage of inhibition of formazan formation by putrescine was calculated
relative to the control lacking putrescine.
3.2.6. Transcriptional fusions to luxCDABE.
The promoter regions from BCAL2641, BCAM1111, BCAM1112 and OxyR were PCR
amplified. The PCR products were digested with EcoRI and cloned into the EcoRI digested and
dephosphorylated pGSVTp-lux plasmid. The orientation of the promoter region was checked by
PCR and luminescence of E. coli GT115 colonies carrying the plasmids. The resulting plasmids
contained the promoter region of the genes of interest fused to the luxCDABE reporter system.
The plasmids were mobilized into K56-2 and the appropriate mutants by triparental mating.
Transconjugants (carrying the chromosomal promoter-reporter fusions) were selected on LB agar
plates containing 100 µg/ml of trimethoprim (Tp), 200 µg/ml ampicillin and 10 µg/ml
gentamicin.
3.2.7. Luminescence expression assays.
Overnight cultures in LB containing 100 µg/ml Tp were diluted into fresh LB medium to
OD600=0.04. After addition of the antibiotics and/or putrescine, 300 µl of sample were loaded in
triplicate, for each time-point, in a 100-well honeycomb microtitre plate. The plates were
incubated at 37°C with medium continuous shaking in a Bioscreen C automated growth curve
analyzer (MTX Lab Systems, Vienna, VA, USA). Growth was followed by measuring the OD600
at 37°C every 30 min. At pre-determined time points post-inoculation, the Bioscreen was paused
and three 200 µl aliquots for each condition tested were transferred into a flat bottom 96-well
microtiter plate (Microfluor-2 White, Thermo Scientific) and luminescence (in relative light
units, RLU) was measured using a Fluoroskan Ascent FL Microplate Fluorometer and
Luminometer (Thermo Scientific, Ottawa, Ontario, Canada). Expression levels of each gene of
interest in the different strain backgrounds were calculated as RLU/OD600 for each time-point.
3.2.8. Construction of a conditional mutant.
A fragment (~300-bp) spanning the 5′ region of BCAL2641 was PCR amplified, digested by
NdeI and XbaI and cloned into the NdeI and XbaI digested and dephosphorylated pSC200
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plasmid. The plasmids were mobilized into OME12 (∆BCAM1111-1112) by triparental mating.
Transconjugants were selected on LB agar plates containing 100 µg/ml of trimethoprim (Tp),
200 µg/ml ampicillin, 10 µg/ml gentamicin and 0.5% (wt/vol) rhamnose. This strategy creates
conditional mutants in which the expression of the targeted gene depended on the rhamnose
concentration in the medium (31).
3.2.9. Thin-layer chromatography analyses of polyamines.
The conditional mutant and the wild type were grown at 37°C in M9 minimal medium
supplemented with final concentrations of Tp 100 μg/ml and rhamnose 0.4% (wt/vol),
permissive condition of expression. An aliquot of an overnight culture in M9 medium with
rhamnose was spun down and washed three times with sterile phosphate-buffered saline (PBS),
resuspended in PBS, and adjusted to an OD600 of 1. Drops (10 μl) of undiluted suspension and
10-fold serial dilutions were plated onto M9 agar plates supplemented with 0.4% (wt/vol)
glucose and incubated at 37°C (non-permissive condition of expression). Bacteria growing on
the plates were collected, suspended in sterile PBS, and the OD600 was adjusted to 0.1.
Polyamines were extracted, derivatized to their dansyl derivatives, sequentially separated on
TLC silica gel plates (20×20 cm, Merck, Darmstadt, Germany) in two solvent systems: I)
benzene–triethylamine (20:2 v/v); II) benzene–methanol (10:0.45 v/v) and visualized under
ultraviolet light as previously described (12). Standard solutions of putrescine, cadaverine,
spermidine and spermine (0.2 mM each) were treated similarly and included as controls.
3.2.10. Catalase enzyme activity assay.
Overnight cultures of the wild type B. cenocepacia K56-2 in LB were diluted to OD600=0.04 into
30 ml fresh LB medium, with or without antibiotics, and incubated at 37oC, 200 rpm for 16 h.
Bacterial cells were pelleted, washed with sterile PBS and resuspended in 300 µl (or less if
necessary depending on bacterial inhibition of growth by antibiotics) of PBS. The OD600 of the
bacterial suspensions was measured. The catalase enzyme activity was evaluated using the
method described by Iwase et al. (32). Briefly, 100 µl of bacterial suspension or bovine liver
catalase solution at different concentrations were added in a glass tube followed by the addition
of 100 µl of 1% Triton X-100. Finally, 100 µl of undiluted hydrogen peroxide (30%) were added
to the solutions, mixed thoroughly and incubated at room temperature. The height of O2-forming
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foam that remained constant for 15 min in the test tube was finally measured using a ruler. The
catalase activity of bacterial suspensions was determined using calibration curves constructed
using the standard catalase solutions with different concentrations and normalized to the OD600
of the tested suspensions.
3.2.11. Statistical Analyses.
Unpaired student‟s t-tests were conducted with GraphPad Prism 5.0.

3.3. Results And Discussion
3.3.1. Putrescine reduces ROS production induced by PmB.
Treatment of B. cenocepacia K56-2 with 1 mg/ml PmB led to significantly increased production
of intracellular ROS, as detected by 2‟,7‟-dichlorofluorescein diacetate (DCF) (Fig. 20). DCF is
a colorless, nonfluorescent fluorescein derivative which passively diffuses into cells where the
two acetate groups are cleaved by intracellular esterases to yield the non-cell permeable 2‟, 7‟dichlorofluorescein (33). This cleaved product becomes trapped within the cells and becomes
oxidized by intracellular ROS resulting in the formation of a highly fluorescent product; hence it
is a measure of generalized oxidant production rather than that of any particular reactive species
(33). Lower concentrations of PmB (0.5 mg/ml or less) did not alter the intracellular DCFdetectable ROS pool (data not shown), whereas due to its reduced solubility in the culture
medium higher concentrations of PmB could not be reliably tested. Since putrescine protects B.
cenocepacia from PmB (12), I assessed whether it also alleviates PmB-induced ROS production.
Compared to control cells, exogenous putrescine reduced DCF-detectable ROS generation in
PmB-treated bacteria (Fig. 20). This effect was assessed at 2 h incubation with PmB and/or
putrescine to avoid potential interference from putrescine degradation or metabolic by-products
at prolonged incubation times. It should be noted that putrescine did not decrease the background
ROS levels produced by bacterial cells not exposed to PmB, but rather caused a slight but
significant increase in DCF-detected ROS levels compared to control cells at 20 mM (Fig. 20,
white bars). I attributed these results to polyamines catabolism, which also generate ROS (34).
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Figure 20. Putrescine reduces ROS production induced by PmB in B. cenocepacia K56-2.
ROS were detected by DCF.n= 6 from 2 independent experiments. Unpaired student‟s t-tests
were conducted between each condition and its respective control.
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To assess whether endogenous putrescine also has the ability to reduce ROS levels in
PmB-treated B. cenocepacia, I employed deletion mutants in the putrescine biosynthesis
pathway. Putrescine can arise through the action of either ornithine decarboxylase or arginine
decarboxylase (12). B. cenocepacia has two ornithine decarboxylase homologues, BCAL2641
and BCAM1111, and one arginine decarboxylase protein, BCAM1112 (Fig. 21A). The ornithine
decarboxylase BCAL2641 is encoded by a gene located on chromosome 1 of B. cenocepacia;
whereas both the ornithine decarboxylase BCAM1111 and the arginine decarboxylase
BCAM1112 are encoded by genes located adjacent to each other, but in opposite orientation, on
chromosome 2. In a previous study, we have shown that ∆BCAL2641 had a greater reduction in
the amount of secreted putrescine compared to wild type than ∆BCAM1111-BCAM1112 (12).
Here, I confirmed that these three enzymes are the only contributors to putrescine production in
B. cenocepacia. A conditional mutant of BCAL2641 in the ∆BCAM1111-BCAM1112
background did not produce detectable levels of putrescine at the non-permissive conditions of
expression compared to the wild type strain (Fig. 21B). With respect to the response to PmB, the
ornithine decarboxylase BCAL2641 was the only enzyme, among the 3 putrescine synthesis
enzymes, involved in resistance against PmB. ∆BCAL2641, but not ∆BCAM1111-BCAM1112,
had increased susceptibility to PmB compared to wild type when tested in LB medium (Fig. 21C
and 21D) or M9 medium (Fig. 21E). Although the growth of ∆BCAM1111-BCAM1112 was not
impaired in LB medium regardless of the initial inoculum size (Fig. 21C and 21D), it exhibited
significant reduction in growth compared to the wild type cells in M9 medium (Fig. 21E).
Nevertheless, this mutant did not show increased susceptibility to PmB in M9 medium in which
its growth was retarded (Fig. 21E). On the contrary, ∆BCAL2641 showed slight reduction in
growth in LB medium only at low inoculum size (Fig. 21C) but not at high inoculum size (Fig.
21D) or in M9 medium (Fig. 21E). This suggests that these genes involved in putrescine
synthesis are not functionally redundant; they seem to be stimulated under different conditions
and regulated differently with BCAL2641 only involved in resistance to antibiotics. Next,
detection of ROS by DCF was assessed after incubation of ∆BCAL2641 and ∆BCAM1111BCAM1112 mutants with PmB for 16 h to allow the different enzymes to reach their maximum
expression levels which occurred at about 12 h in the luminescence expression assays (not
shown). No differences were observed in PmB-untreated cells between the wild type and the
deletion mutants (Fig. 22, white bars). In contrast,
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Figure 21. BCAL2641 is the only putrescine synthesis enzyme in B. cenocepacia involved in
reduced susceptibility to PmB.
A. Putrescine synthesis pathway in B. cenocepacia K56-2 together with the enzymes involved.
ADC, arginine decarboxylase; ODC, ornithine decarboxylase. B. TLC plate showing the lack of
production of putrescine in ∆BCAM1111-1112Prha-BCAL2641conditional mutant under nonpermissive conditions. Put, putrescine; Cad, cadaverine; Spd, spermidine; Spn, spermine. C-E.
Sensitivity of wild type and putrescine synthesis mutants ∆BCAL2641 (OME11) and
∆BCAM1111-1112 (OME12) to 2048 µg/ml PmB determined turbidimetrically. n=3 from a
representative experiment. C, low initial inoculum in LB medium; D, high initial inoculum in
LB medium; D, in M9 minimal medium.
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Figure 22. BCAL2641 is the main ornithine decarboxylase responsible for reduction of ROS
accumulation.
ROS production in response to 1 mg/ml PmB in wild type K56-2, compared to putrescine
synthesis mutants ∆BCAL2641 (OME11) and ∆BCAM1111-1112 (OME12) detected by
DCF.n=6 from 2 independent experiments. Unpaired student‟s t-tests were conducted.
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∆BCAL2641 exhibited a significant increase in levels of superoxide and other ROS detected by
DCF in response to PmB compared to wild type, whereas ∆BCAM1111-BCAM1112 produced
the same level as that in the parental strain (Fig. 22). Together, these results support the notion
that putrescine reduces the level of PmB-induced ROS production and this reduction contributes
to protection of bacteria from the bactericidal effects of PmB.
Hydroxyl radical is another ROS that may be produced upon oxidative stress. Others
have used hydroxyphenyl fluorescein (HPF) to fluorometrically detect hydroxyl radicals upon
antibiotic stress (16). Using HPF in similar experiments as above, I found a comparable pattern
of reduction of PmB-induced ROS by putrescine (data not shown). However, the fluorescence
signal detected by HPF was too low compared to that detected by DCF, and required 100-fold
higher inoculum than that for the DCF experiments to detect signal above the background noise
of fluorescence. Such high inoculum of cells led to high autofluorescence compared to the actual
fluorescence signal detected upon adding HPF, which was not the case with the DCF assays (Fig.
23). Thus, I disregarded the results of HPF assays. Similar criticism to the use of HPF was raised
recently concerning the interference between the autofluorescence of cells with the actual
fluorescence in the presence of the probe especially upon antibiotic treatment (35).
Although the DCF fluorometric assay is a well established method and has many advantages
over other techniques developed for measurement of intracellular ROS (33), the probe may be
nonselective reacting with other oxidants such as hydroxyl radicals and lipid peroxides (36).
Hence, to provide additional evidence supporting the DCF fluorometric assays results, I
measured the expression of OxyR as an independent indicator of oxidative stress. OxyR belongs
to the LysR family of transcription factors whose regulon is involved in the cellular response to
oxidative stress (22). OxyR is very sensitive to ROS, and is activated at very low hydrogen
peroxide concentrations, leading to upregulation to its regulon (37). Moreover, an oxyR::lacZ
promoter fusion is also upregulated in response to hydrogen peroxide (38). Similarly, another
LysR-type transcription regulator involved in the response to oxidative stress is also
overexpressed in response to ROS (39). Therefore, I constructed derivatives of wild type and
mutant strains carrying an oxyR::lux promoter fusion to measure oxyR gene expression at
chromosomal levels. PmB stimulated the oxyR expression (Fig. 24A), which was consistent with
the induction of intracellular ROS detected by DCF (Fig. 20 and 22). Likewise, catalase
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Figure 23. Comparison of the autofluorescence of cells relative to fluorescence signals of
fluorescent probes detecting reactive oxygen species in B. cenocepacia K56-2.
(A) Emission signal following treatment with HPF without correction for autofluorescence
background; (B) Autofluorescence of cells at the same inoculum size and under the same
conditions used for HPF assay; (C) Emission signal following treatment with DCF without
correction for autofluorescence background; (D) Autofluorescence of cells at the same inoculum
size and under the same conditions used for DCF assay. n=3 from one representative
experiment.
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activity, regulated by OxyR (22), increased in response to PmB (Table 8). This further confirms
the induction of intracellular ROS in response to PmB and validates the findings of DCF
fluorometric and oxyR expression assays as measures of intracellular ROS. oxyR expression was
significantly higher in ∆BCAL2641 compared to the parental strain both in the presence or
absence of PmB. In contrast, no difference in oxyR expression between the wild type and
∆BCAM1111-BCAM1112 was detected in response to PmB (Fig. 24A). No differences in the
growth rate of the different strains were noted in absence of PmB; whereas ∆BCAL2641 was
more susceptible to PmB compared to the wild type and ∆BCAM1111-BCAM1112 (Fig. 25).
These results follow the same pattern of ROS generated in response to PmB in the mutants
compared to the wild type strain (Fig. 22).
Next, I investigated the mechanism by which putrescine protects from oxidative stress.
Putrescine stimulated the expression of oxyR (Fig. 24A), probably as a result of a slight induction
of ROS accumulation as detected by DCF (Fig. 20). However, putrescine alleviated the increase
in oxyR expression in response to PmB (Fig. 24A), suggesting a protective effect against ROS.
Nevertheless, putrescine did not induce a statistically significant difference in growth of the wild
type in the presence or absence of PmB at this early time point of incubation (3 h) under the
conditions of this test (Fig. 25). Supporting the protective role of putrescine from oxidative
stress, I confirmed the antioxidant properties of putrescine by demonstrating that it could
scavenge superoxide radicals generated in vitro from a phenazine methosulfate-NADH system in
a concentration dependent manner (Fig. 24B). Together, the results of this section reveal a link
between reduced susceptibility to PmB, induction of ROS production, and expression of OxyR
with the intracellular level of putrescine, which can be attributed to the antioxidant properties of
this polyamine.
3.3.2. Expression of the putrescine synthesis enzymes in response to PmB.
To better understand the role of the different putrescine synthesizing enzymes in response to
oxidative stress and consequently to PmB, I investigated the expression profiles of their
corresponding genes also using lux promoter fusions as before. BCAL2641::lux gene expression
was stimulated by exposure to PmB (Fig. 26A); whereas neither BCAM1111::lux nor
BCAM1112::lux fusions were responsive to PmB (Fig. 26B and 26C respectively). This agrees
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Figure 24. A. Induction of OxyR expression as an indicator of ROS accumulation in the wild
type (OME56) compared to putrescine synthesis mutants ∆BCAL2641 (OME57) and
∆BCAM1111-1112 (OME58) in response to 500 µg/ml PmB with or without 10 mM Put
determined by luciferase expression assay at 3 h. Results are shown as percentage of relative
light units RLU/OD600 relative to the OME56 control (K56-2 background). The mean
RLU/OD600 of the control is 0.09567. The percentages of OD600 are shown in Fig. 25. n=9 from
3 different clones. * p<0.05, ** p<0.01 and *** p<0.001 from unpaired student‟s t-tests. B. In
vitro antioxidant activity of putrescine. n=6 from 2 independent experiments.
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Figure 25. The relative growth of cells in the luminescence expression assay for oxyR
expression in the wild type (OME56) compared to putrescine synthesis mutants (ΔBCAL2641
background, OME57; and ΔBCAM1111-1112 background, OME58) at 3 h shown in Figure
24A. Results are shown as percentage of OD600 relative to the control (untreated K56-2
background). The mean OD600 of the control is 0.1663. * p<0.05, ** p<0.01 and *** p<0.001
from unpaired student‟s t-tests.
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Table 8. Catalase enzyme activities.
Antibiotic Concentration
(µg/ml)

Catalase Activity*
% Units/OD600 (SEM)

Difference from control
(P-value)

None

100 (1.3)

Not applicable

Polymyxin B (500)

120.1 (4.2)

0.0002

Norfloxacin (8)

110.6 (1.2)

0.0012

Rifampicin (16)

134.5 (5.2)

<0.0001

Ceftazidime (32)

99.8 (12.4)

0.978 (Not significant)

Gentamicin (1000)

48.0 (7.1)

<0.0001

* Results from 2 independent experiments, n=6. r2 of calibration curves was: 0.9644 and 0.9544.
Significance of differences from control was determined using unpaired student‟s t-tests.
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Figure 26. Luciferase expression assay of the different putrescine synthesizing enzymes in
response to 500 µg/ml PmB at 3 h.
Results are shown as percentage of relative light units RLU/OD600 relative to the control
(untreated K56-2 background). The percentages of OD600 are shown in Fig. 27. A, Expression of
BCAL2641 in the wild type (OME50) and ∆BCAM1111-1112 (OME51) backgrounds.n=6 from
2 different clones. The mean RLU/OD600 of the control is 1.4829. B, Expression of BCAM1111
in the wild type (OME52) and ∆BCAL2641 (OME53) backgrounds.n= 6 from 2 different clones.
The mean RLU/OD600 of the control is 1.5585. C, Expression of BCAM1112 in the wild type
(OME54) and ∆BCAL2641 (OME55) backgrounds.n= 7 from 2 different clones. The mean
RLU/OD600 of the control is 0.2423. * p<0.05, ** p<0.01 and *** p<0.001 from unpaired
student‟s t-tests.
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Figure 27.The relative growth of cells in the luminescence expression assay for the different
putrescine synthesizing enzymes in response to 500 μg/ml PmB at 3 h shown in Figure 26.
Results are shown as percentage of OD600 relative to the control (untreated K56-2 background).
(A) Expression of BCAL2641 in the wild type (OME50) and ΔBCAM1111-1112 (OME51)
backgrounds. n=6 from 2 different clones. The mean OD600 of the control is 0.1422. (B)
Expression of BCAM1111 in the wild type (OME52) and ΔBCAL2641 (OME53) backgrounds.
n= 6 from 2 different clones. The mean OD600 of the control is 0.1523. (C) Expression of
BCAM1112 in the wild type (OME54) and ΔBCAL2641 (OME55) backgrounds. n= 7 from 2
different clones. The mean OD600 of the control is 0.1017. * p<0.05, ** p<0.01 and *** p<0.001
from unpaired student‟s t-tests.
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with the behaviour of ∆BCAL2641 and ∆BCAM1111-BCAM1112 mutants to PmB in terms of
antimicrobial resistance (Fig. 21C-21E) and ROS production (Fig. 22). Moreover, this is
consistent with our previous data showing increased transcription of BCAL2641, but not
BCAM1111 or BCAM1112, in response to PmB (12). BCAL2641 also appears to regulate by an
unknown mechanism the gene expression of BCAM1111 and BCAM1112 putrescine synthesis
enzymes, since the expression of both genes was significantly reduced in the ∆BCAL2641
background (Fig. 26B and 26C, respectively). This regulation is not mediated through the action
of putrescine since 10 mM of putrescine did not stimulate the gene expression of BCAM1111 or
BCAM1112 (not shown). Other indirect regulatory pathways may be involved which will require
further investigation. On the other hand, the gene expression of BCAL2641 increased in the
absence of BCAM1111 and BCAM1112 (Fig. 26A), which may explain the slight increase in
survival of the ∆BCAM1111-BCAM1112 when exposed to PmB shown in Fig. 21E. This might
be due to compensation of the reduced synthesis of putrescine by these enzymes being normally
stimulated by BCAL2641. Alternatively, BCAM1111 and BCAM1112 might provide feedback
inhibition to BCAL2641; thus their absence would lead to increased BCAL2641 gene
expression. Notably, the expression of BCAM1112 (RLU/OD600 0.2423) is much lower than that
of the other 2 enzymes (RLU/OD600 1.4829 and 1.5585 for BCAL2641 and BCAM1111
respectively). This suggests that B. cenocepacia does not preferentially utilize the arginine
decarboxylase BCAM1112. This agrees with the fact that B. cepacia can degrade arginine only
through the use of the succinyl transferase pathway, despite the possession of an arginine
decarboxylase homologue (40, 41). Except for ∆BCAL2641, which exhibited reduced growth in
the presence of PmB, no differences in growth were observed in the other strains tested
regardless of PmB exposure (Fig. 27). Together, these findings expose BCAL2641 as a crucial
contributor of putrescine synthesis in the response against antibiotics.
3.3.3. ROS production in response to other bactericidal antibiotics.
To evaluate whether the induction of oxidative stress and its amelioration by putrescine is a
general phenomenon, I tested other bactericidal antibiotics. Exposure of B. cenocepacia to
gentamicin, norfloxacin, ceftazidime and rifampicin led to increased ROS production as detected
by DCF (Fig. 28) at sub-lethal concentrations; i.e. concentrations below but more specifically
near the MIC of these antibiotics (Fig. 29). Putrescine reduced the antibiotic-induced elevation
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Figure 28. Effect of different bactericidal antibiotics on superoxide radical at different
concentrations determined using DCF.
n=6 from 2 independent experiments.
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Figure 29.The relative growth of cells in the luminescence expression assay for BCAL2641, (in
OME50), oxyR (in OME56), and BCAM1111 (in OME52) in response to different bactericidal
antibiotics at 3 h shown in Fig. 31.
Results are shown as percentage of OD600 relative to the control (untreated K56-2 background).
n= a minimum of 6 from at least 2 different clones. The mean OD600 of the control is 0.1943 for
BCAL2641; 0.1816 for OxyR and 0.2166 for BCAM1111. * p<0.05, **p<0.01 and ***
p<0.001.

125

in ROS levels only for norfloxacin and rifampicin (Fig. 30), and this correlated with induction of
BCAL2641 gene expression (Fig. 31A and 31B, respectively). This agrees with the contribution
of BCAL2641 in resistance to both antibiotics that we have previously reported (12). Moreover,
oxyR transcription was also upregulated in response to both norfloxacin and rifampicin (Fig. 31A
and 31B, respectively), which was reflected in an increase in the catalase activity (Table 8),
supporting the notion that both antibiotics lead to increased ROS production (Fig. 30 and Fig.
28). In contrast, neither antibiotic affected BCAM1111 gene expression (Fig. 31), indicating that
this gene and its product are not directly involved in the response to antibiotic-mediated
oxidative stress. It should be noted that higher rifampicin concentrations resulted in great
reduction in the expression of BCAL2641, oxyR, and BCAM1111 (Fig. 31B), which might be
attributed to non-specific inhibition of transcription by rifampicin, especially at 512 µg/ml where
expression from these genes was almost completely inhibited.
Putrescine did not reduce ROS production generated in response to ceftazidime, but
rather further increased the generated ROS at 10 mM but not at 20 mM concentration of
putrescine (Fig. 30). Ceftazidime did not affect the expression of BCAL2641, oxyR or
BCAM1111 (Fig. 31C), and did not alter the catalase enzyme activity (Table 8). However, in a
previous study we reported that BCAL2641 is involved in the response of B. cenocepacia to
ceftazidime (12). This may suggest another role of BCAL2641 in the protective actions against
ceftazidime not related to the oxidative stress.
Concerning the response to gentamicin, exogenous putrescine did not affect the level of
gentamicin-induced superoxide anion (Fig. 30). Moreover, gentamicin did not alter the
expression of BCAL2641 (Fig. 31D). This agrees with the previously reported lack of
involvement of this enzyme in the response to gentamicin in B. cenocepacia (12). Furthermore,
gentamicin did not affect the expression of oxyR (Fig. 31D). However, the highest tested
concentrations of gentamicin did reduce the expression of both BCAL2641 and oxyR (Fig. 31D).
Similarly, gentamicin reduced the catalase enzyme activity (Table 8). Such inhibition might be
due to the mechanism of action of the aminoglycoside inhibiting translation and protein synthesis
in general, since it also inhibited the expression of BCAM1111, which consequently might have
led to increased ROS levels at high concentration (Fig. 30).
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Figure 30.The role of putrescine in the bactericidal antibiotics-mediated ROS accumulation in B.
cenocepacia K56-2.
n= 9 from 3 independent experiments. The 4 tested antibiotics alone significantly (p<0.001)
induced the accumulation of ROS compared to control cells. * p<0.05, ** p<0.01 and ***
p<0.001 from unpaired student‟s t-tests compared to the respective control conditions.
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Figure 31. Effect of different antibiotics on the expression of BCAL2641 (in OME50), oxyR (in
OME56), and BCAM1111 (in OME52) determined using a luciferase expression assay at 3 h.
Results are shown as percentage of relative light units RLU/OD600 relative to the control
(untreated K56-2 background). The percentages of OD600 are shown in Fig. 29. n= a minimum of
6 from at least 2 different clones. The mean RLU/OD600 of the control is 1.0759 for BCAL2641;
0.1087 for oxyR and 1.4723 for BCAM1111. * p<0.05, ** p<0.01 and *** p<0.001 from
unpaired student‟s t-tests compared to the respective control conditions.
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3.4. Conclusions
In this Chapter, I show the following: (i) Sub-lethal concentrations of different bactericidal
antibiotics (PmB at 1 mg/ml, rifampicin at 256 and 512 µg/ml and norfloxacin at 32 and 64
µg/ml) induce oxidative stress in B. cenocepacia that is manifested as induction of ROS
formation as detected by DCF, stimulation of expression of the transcription regulator OxyR
involved in response to oxidative stress (at antibiotic concentrations similar to or even lower than
those inducing ROS formation; PmB at 0.5 mg/ml, rifampicin at 16 and 32 µg/ml and
norfloxacin at 16-64 µg/ml), and increased catalase enzyme activity (PmB at 0.5 mg/ml,
rifampicin at 16 µg/ml and norfloxacin at 8 µg/ml). (ii) This response does not apply to
gentamicin and ceftazidime which do not induce OxyR expression or increase catalase enzyme
activity, suggesting that not all bactericidal antibiotics induce oxidative stress. (iii) Putrescine
protects against oxidative stress induced by several bactericidal antibiotics (PmB, norfloxacin
and rifampicin). (iv) Protection by putrescine correlates with increased BCAL2641 gene
expression. (v) BCAL2641, in addition to synthesizing putrescine, regulates the other putrescine
biosynthetic enzymes BCAM1111 and BCAM1112 by an unknown mechanism that does not
directly involve putrescine. Together, these observations suggest a model (Fig. 32) by which B.
cenocepacia responds to antibiotic stress by overproducing putrescine and in turn, this
polyamine protects bacterial cells by a surface effect blocking antibiotic binding (12) as well as
by reducing oxidative damage.
Putrescine was previously shown to communicate antibiotic resistance among different
bacteria (12). Its increased production in B. cenocepacia occurs in response to a subset of
bactericidal antibiotics (12), which induce oxidative stress in bacterial cells at near lethal
concentration ranges. It is still controversial whether the generation of ROS is the cause of
lethality of antimicrobial agents or a consequence of antibiotic stress (16, 20, 21). However, it is
conceivable that the oxidative stress accompanying antibiotic treatment imposes a metabolic
burden on the bacterial cells at near death conditions. Thus, my results demonstrating a
protective role for putrescine in the response to the oxidative stress generated in B. cenocepacia
during antibiotic exposure represent another mechanism of protection from the antibacterial
effects of bactericidal antibiotics. This agrees with previous reports on the antioxidant properties
and protective effects of putrescine against antibiotic induced ROS formation in E. coli (17).
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Figure 32. Model summarizing the role of putrescine in protecting B. cenocepacia from
antibiotic-induced stress.
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While little is known about the physiological levels of putrescine, it seems that its level
varies in different body sites. For example, putrescine concentration was reported to be 3 mM in
urine (11), but was no greater than 0.2 mM in sputum samples from CF patients (42, 43).
However, it is difficult to predict the local concentration of putrescine and other polyamines in
the lung of CF patients, as infection alters the rheology of the mucus and the lung environment
(44). Moreover, putrescine levels increase dramatically (by 10 fold or more) during
exacerbations of bacterial infections in CF patients (42, 43). Hence, the concentrations used in
this study could potentially resemble the physiological situation in certain body compartments.
Furthermore, a direct relationship exists between increased putrescine concentration during
infection and the proliferation of lung microbiota and specific pathogens such as P. aeruginosa
in the lungs of CF patients (43). Also, putrescine and other polyamines in genital mucosal fluids
increase the resistance of N. gonorrhoeae to antimicrobial peptides (PmB and LL-37), possibly
enhancing its survival during infection by reducing bacterial susceptibility to host-derived
antimicrobials (11). Interestingly, the expression of the ornithine decarboxylase BCAL2641 is
induced in B. cenocepacia in CF conditions compared to soil environmental like conditions
shown by comparative transcriptomics, underscoring the importance of putrescine, and this
enzyme in particular, during infection (45).
This study also provides new information on the regulation of the putrescine synthesis
enzymes. The ornithine decarboxylase BCAL2641 gene responds to the external antibiotic
signals, while the other ornithine decarboxylase BCAM1111 or the arginine decarboxylase
BCAM1112 do not. Also, BCAL2641 regulates the expression of BCAM1111 and BCAM1112
since their expression depends on the presence of BCAL2641. This suggests that upon antibiotic
stress maximal production of putrescine is required, which arises from the upregulation of
BCAL2641 and by maintaining the expression of the other two enzymes in a BCAL2641dependent manner. The molecular mechanism of this regulation awaits further investigation.
In conclusion, this study broadens our understanding on the mechanism of chemical
communication of antibiotic resistance mediated by putrescine. In addition, it provides a clear
target for the design of inhibitors targeting the ornithine decarboxylase BCAL2641 that is
critically implicated in this phenomenon. Such inhibitors would not only reduce the resistance to
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antibiotics in B. cenocepacia but also would reduce its ability to communicate high-level
resistance to other less resistant bacteria.
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Chapter 4

A novel mechanism of resistance and protection from the action
of hydrophobic antibiotics mediated by secreted bacterial
lipocalins
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4.1. Introduction
Communication among bacteria via small molecules is implicated in the transient increase of
bacterial resistance to antibiotics, which could lead to therapeutic failures, thereby aggravating
the problem of antibiotic resistance. The extremely antibiotic resistant bacterium Burkholderia
cenocepacia protects Pseudomonas aeruginosa, in direct co-culture, from the lethal action of
polymyxin B (PmB) (1).YceI is a small, secreted protein implicated in this protection (1).YceI
constitutes a large family of conserved bacterial small proteins that share a common tertiary fold,
similar to lipocalin proteins found in many prokaryotic and eukaryotic organisms, including
humans. Bacterial lipocalin or “bacteriocalin” genes are present in 1524 bacterial species both
Gram-positive and negative (according to SMART research tool (2)). The bacteriocalin structure
has been elucidated in a few cases and consists of an extended, eight-stranded, antiparallel betabarrel that resembles the lipocalin fold, although no sequence homology exists with lipocalins
(3).
Bacteriocalin gene expression was induced in response to bases in Escherichia coli (4),
and oxidative stress in Pseudomonas aeruginosa (5), and the protein was predicted to bind
polyisoprenoid chain within the pore of the barrel via hydrophobic interactions in Thermus
thermophilus based on its crystal structure (3). More recently, I have shown that YceI is involved
in the bacterial response to several amphiphilic bactericidal antibiotics; the transcription of YceI
was upregulated in B. cenocepacia in response to PmB and the purified YceI proteins were able
to bind PmB (1). Interestingly, the structure of bacteriocalins resembles that of human α-1-acid
glycoprotein (AGP), which was shown to bind polymyxin B in serum (6). However, until now,
there has been no direct demonstration of bacteriocalin function. Here I hypothesize that
bacteriocalins are involved in the bacterial response to stress conditions, including exposure to
antibiotics and oxidative stress by binding toxic and undesired compounds. B. cenocepacia
possesses 2 bacteriocalin homologues, BCAL3310 and BCAL3311. In this study, I characterized
their individual roles in antibiotic resistance, their binding affinity to compounds of different
chemical characteristics, and their expression profiles in response to antibiotic stress. I further
investigated the functional conservation of bacteriocalins among different bacterial species and
whether bacteriocalins secreted from one bacterium can protect other bacterial species in vitro
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and in vivo. Herein, I present the first report of a defined function for bacteriocalin proteins in the
communication of transient antibiotic resistance in B. cenocepacia.

4.2. Materials and methods
4.2.1. Strains and reagents
Table 9 lists bacteria and plasmids used in this study. Bacteria grew in LB (supplemented with
0.4% rhamnose when required) at 37°C. Escherichia coli cultures were supplemented as required
with the following antibiotics (final concentrations): tetracycline (30µg/ml), kanamycin (40
µg/ml), and trimethoprim (50 µg/ml). B. cenocepacia cultures were supplemented as required
with trimethoprim (100 µg/ml), and tetracycline (100 µg/ml). Antibiotics (Sigma, St Louis, MO,
USA) were diluted in water except for PmB, which was diluted in 0.2% bovine serum
albumin/0.01% glacial acetic acid buffer. Rifampicin was dissolved in dimethyl sulphoxide
(DMSO).
4.2.2. General molecular techniques
DNA manipulations were performed as previously described (7). T4 DNA ligase (Roche
Diagnostics, Laval, Quebec, Canada), Antarctic phosphatase (New England Biolabs, Pickering,
Ontario, Canada) and restriction endonucleases (Roche or New England Biolabs) were used as
recommended by the manufacturers. Transformation of Escherichia coli GT115 and DH5α was
performed using the calcium chloride method (8). Mobilization of plasmids into B. cenocepacia
was conducted by triparental mating (9) using E. coli DH5α carrying the helper plasmid
pRK2013 (10). DNA amplification by polymerase chain reaction (PCR) was performed using a
C1000 Thermal cycler (Bio-Rad Laboratories Ltd., Mississauga, Ontario, Canada) with Taq or
HotStar HiFidelity DNA polymerases (Qiagen, Mississauga, Ontario, Canada) and optimized for
each primer pair. DNA sequencing was carried out at Eurofins MWG Operon, Huntsville,
Alabama, USA. The DNA sequences were analyzed with the BLAST computer program and
compared to the sequenced genome of B. cenocepacia strain J2315. Cloning, expression, and
purification of B. cenocepacia bacteriocalins was performed as previously described (1).
Transcriptional fusions to luxCDABE and the subsequent luminescence expression assays were
performed as previously described (11).
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Table 9. Strains and Plasmids used in Chapter 4
Strain or plasmid

Relevant characteristicsa

Source and/or
reference

Strains
Burkholderia cenocepacia
K56-2
ET12 clone related to J2315, CF clinical Isolate
OME19
K56-2 pSCrhaB2; TpR
OME37
K56-2 pOE12; BCAL3310 with C-terminus FLAG tag; TetR
OME40
K56-2 pOE13; BCAL3311 with C-terminus FLAG tag; TetR
OME59
K56-2, PBCAL3309::pGSVTp-luxCDABE; TpR
OME60
K56-2, PBCAL3310::pGSVTp-luxCDABE; TpR
OME61
K56-2, PBCAL3312-3311::pGSVTp-luxCDABE; TpR
OME62
K56-2, ∆BCAL3311
OME63
K56-2, ∆BCAL3312
OME65
K56-2, ∆BCAL3310
OME66
K56-2 pDA17; TetR
OME67
OME62 pDA17; TetR
OME68
OME62 pOE13 (BCAL3311); TetR
OME69
OME62 pOE31 (PA0423); TetR
OME70
OME62 pOE32 (PA4340); TetR
OME71
OME62 pSCrhaB2; TpR
OME72
OME62 pOE33 (BCAL3311); TpR
OME73
OME62 pOE34 (PA0423); TpR
OME74
OME62 pOE35 (PA4340); TpR
OME75
OME62 pOE36 (PA4345); TpR
OME76
OME62 pOE37 (Rv1890c); TpR
Escherichia coli
DH5α
F-80lacZ M15 endA1 recA1 supE44 hsdR17(rK- mK+)deoR thi-1
nupG supE44 gyrA96relA1 ∆(lacZYA-argF)U169, λ–
GT115
F– mcrA∆(mrr-hsdRMS-mcrBC) 80∆lacZ∆M15 ∆lacX74 recA1
rpsL (StrA) endA1∆dcm uidA(∆MluI)::pir-116 ∆sbcC-sbcD
BL21
F−dcm ompT hsdS(rB−mB−) gal
Pseudomonas aeruginosa
PAO1
Non‐CF clinical isolate
Salmonella typhi
SARB63
Shigella flexneri
SF51571
Serotype 1a, antigenic formula 1:4
Acinetobacter species
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b

BCRRC,(12)
(1)
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
Laboratory
stock
Invivogen,
San Diego,
CA
Novagen
(13)
(14)

Clinical isolate
A. baumannii
(AB1)
A. lwoffi (AB2)
Clinical isolate
A. junni (AB3)
Clinical isolate
Klebsiella pneumoniae
Kpn18
Staphylococcus aureus
USA300
Community acquired MRSA
Plasmids
pRK2013
oricolE1, RK2 derivative, KanR, mob+, tra+
pGSVTp-lux
Mobilizable suicide vector containing lux operon, derivative from
pGSV3-lux(15); OriT; TpR
pSCrhaB2
oripBBR1rhaR, rhaS, PrhaBTpRmob+
pDAI-SceI-SacB
oripBBR1, TetR, Pdhfr, mob+, expressing I-SceI, SacB
pGPI-SceI
oriR6K, ΩTpR , mob+, including an I-SceI
restriction site
pDA17
oripBBR1, TetR, mob+, Pdhfr, FLAG epitope
pOE12
pOE13
pOE15
pOE16
pOE22
pOE23
pOE25
pOE26
pOE27
pOE31
pOE32
pOE33
pOE34
pOE35
pOE36
pOE37

pDA17, BCAL3310, C-terminus FLAG, TetR
pDA17, BCAL3311, C-terminus FLAG, TetR
BCAL3310 without signal peptide encoding sequence cloned in
pET28a(+)
BCAL3311 without signal peptide encoding sequence cloned in
pET28a(+)
PBCAL3310::luxCDABE transcriptional fusion in pGSVTp-lux, TpR
PBCAL3312-3311::luxCDABE transcriptional fusion in pGSVTp-lux, TpR
pGPI-SceI with fragments flanking BCAL3310, TpR
pGPI-SceI with fragments flanking BCAL3311, TpR
pGPI-SceI with fragments flanking BCAL3312, TpR
pDA17, PA0423, C-terminus FLAG, TetR
pDA17, PA4340, C-terminus FLAG, TetR
pSCrhaB2, BCAL3311, TpR
pSCrhaB2, PA0423, TpR
pSCrhaB2, PA4340, TpR
pSCrhaB2, PA4345, TpR
pSCrhaB2, Rv1890c, TpR

a

LHSCc
LHSCc
LHSCc

(10)
(16)
(17)
(18)
(19)
D. Aubert,
unpublised
This study
This study
(1)
(1)
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

TpR, trimethoprim resistance, KanR, kanamycin resistance, TetR, tetracycline resistance.
b
BCRRC, B. cepacia Research and Referral Repository for Canadian CF Clinics.
c
LHSC, London Health Science Centre, London, Ontario, Canada.
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4.2.3. Protein analysis and Western Blotting
Overnight cultures were diluted to OD600 0.03 in 30 ml fresh LB medium with or without PmB
and incubated for 3.5 h at 37oC, 200 rpm. Following incubation, cells equivalent to OD600 ~0.2
were pelleted, resuspended in 30 µl SDS-PAGE protein loading dye, and boiled to obtain whole
cell lysates. Secreted proteins were precipitated from the supernatant of the rest of the cultures
using 10% trichloroacetic acid as previously described (20). The precipitated proteins were
resuspended by Tris buffer, 1M, pH 7.5. The volume of protein samples loaded to the 16% SDSpolyacrylamide gel was normalized to the OD600 value. After SDS–PAGE, proteins were
transferred onto nitrocellulose membranes and the membranes were blocked overnight at 4°C
with Western blocking reagent (Roche Diagnostics, Laval, QC, Canada) in TBST (50 mM TrisHCl pH 7.5, 150 mM NaCl, 0.1 % Tween-20). The primary antibodies, anti-FLAG M2
monoclonal antibody (Sigma) or anti-α-subunit RNA Polymerase (E. coli) (Neoclone, Madison,
WI, USA), were diluted to 1:15,000 in TBST and applied for 1.5 h. Secondary antibody, goat
anti-mouse Alexa Fluor 680 IgG antibodies (Invitrogen), was diluted to 1:15,000 and applied for
1 h. Western blots were developed using LI-COR Odyssey infrared imaging system (LI-COR
Biosciences, Lincoln, NE, USA)

4.2.4. Antibiotic susceptibility testing.
Overnight cultures of the parental B. cenocepacia K56-2 and the appropriate mutants in LB
medium were diluted to an optical density at 600 nm (OD600) of 0.0008 in fresh LB with or
without the antibiotic and incubated at 37°C with medium continuous shaking in a Bioscreen C
automated growth curve analyzer (MTX Lab Systems, Vienna, VA, USA). Bacterial growth was
assessed turbidimetrically at 600 nm.
Etest strips (AB bioMérieux, Solna, Sweden) were applied to agar plates (17 ml agar in
85 mm Petri dish) inoculated with test bacteria by swabbing overnight cultures diluted to OD600
of 0.04; plates were then incubated at 37oC for 24 h. Alternatively, population analysis profiling
(PAP) was performed turbidimetrically or by cfu counting as previously described (1). For in
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vitro protection assays, B. cenocepacia bacteriocalins were added to LB broth at a final
concentration of 1.5 µM.

4.2.5. Fluorometric binding assays
These assays were performed as previously described (6) with few modifications. Purified
bacteriocalins, 8-Anilino-1-naphthalenesulfonic acid (ANS) and Auramine O were prepared in
phosphate buffered saline (PBS, pH 7.4). Phospholipids and Nile Red were prepared in DMSO.
The binding of each fluorescent probe to bacteriocalins was measured by titrating 100 µl of
bacteriocalins (1.5 µM) in a flat bottom 96-well microtiter plate (LUMITRAC 200 White,
Greiner bio-one, Monroe, North Carolina, United States) with aliquots of increasing
concentrations of probe until fluorescence intensity reached plateau. All spectra were corrected
for background fluorescence determined from probe into buffer titrations. Fluorescence was
measured using a Cary Eclipse Fluorescence spectrophotometer (Varian, Mississauga, ON,
Canada) set at an excitation wavelength (λex) specific for each probe, as follows: ANS (400 nm),
Auramine O (428 nm), Nile Red (550 nm), and BODIPY phospholipids (500 nm for fatty acyl
BODIPY labeled phosphocholine and 505 nm for head group BODIPY labeled
phosphoethanolamine). The emission spectrum for each probe was collected across the following
wavelengths (λem): ANS (420–600 nm), Auramine O (460–660 nm), Nile Red (590–750 nm),
and BODIPY phospholipids (510–665 nm). The background-corrected binding fluorescence with
each probe was fitted to a one-site binding model. The dissociation constant for the probe–
bacteriocalin complex at a probe concentration equivalent to half the saturation concentration at
which the maximum specific fluorescence enhancement occurs (Kd), was determined by nonlinear least square regression analysis of the binding isotherms using GraphPad Prism V5.0
software (GraphPad software, San Diego, CA, USA).
For probe displacement experiments, antibiotic solutions diluted in PBS, pH 7.4 were titrated
against bacteriocalin–probe complex at a saturating concentration necessary to obtain the
maximum fluorescence when bound. Displacement of probe was measured as the corresponding
decrease in fluorescence upon the progressive increase of antibiotic concentration.
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4.2.6. Galleria mellonella larvae in vivo infection models
These assays were performed as described in Harding et al. (21). Overnight cultures were diluted
to OD600 in PBS, pH 7.4 with or without B. cenocepacia bacteriocalins at 1.5 µM final
concentration as follows: P. aeruginosa PAO1 to 0.00004, K. pneumoniae Kpn18 to 0.04, A.
baumannii AB1 to 0.4 and S. aureus USA300 to 0.004. The larvae were injected with 10 µl of
the bacterial suspensions or sterile PBS (10 larvae/group in each experiment) using 10 µl
Microliter syringes (Hamilton Company, Reno, Nevada, USA). The larvae were incubated at
30oC and their viability was checked at regular time intervals. In similar assays, 5 larvae/group
were sacrificed at 200 min post-infection and the hemolymph was extracted as previously
described (21). The hemolymph was immediately serially diluted in PBS, plated on LB agar
supplemented with 0.3% cetrimide to quantify the cfu of P. aeruginisa PAO1 recovered from the
infected larvae.
4.2.7. Statistical Analyses
Unpaired student‟s t-tests and other statistical analyses were conducted with GraphPad Prism
5.0.

4.3. Results and discussion
4.3.1. Secretion of B. cenocepacia bacteriocalins
To confirm the release of bacteriocalins into the extracellular milieu from B. cencocepacia,
plasmid-encoded Flag-tagged versions of each bacteriocalin homologue were used. This revealed
that BCAL3311, but not BCAL3310, was only secreted from the wild type K56-2 irrespective of
exposure to PmB (Fig. 33). BCAL3310 was not detected in the supernatant even upon treatment
with PmB at 2 µg/ml (Fig. 33) or 500 µg/ml (not shown).

4.3.2. The role of the different B. cenocepacia bacteriocalins in response to antibiotics
The function of the individual bacteriocalin homologues (BCAL3310 and BCAL3311), and the
associated cytochrome b561 (BCAL3312) was assessed by performing individual deletions.
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Figure 33. BCAL3311 is the only secreted B. cenocepacia bacteriocalin.
Proteins (carrying a C-terminal Flag-tag) were detected in whole cell lysates and supernatants of
control untreated cultures or cultures treated with 2 µg/ml PmB by Western blot using anti-Flag
antibody. The α-subunit of the RNA polymerase was used as a control for cell lysis.
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The deletion mutant of only BCAL3311 showed increased susceptibility to PmB, rifampicin,
norfloxacin and ceftazidime, but not the hydrophilic antibiotic gentamicin (Fig. 34). Etest
revealed that ∆BCAL3311 has more homogenous response to ceftazidime observed as fewer
discrete colonies at the otherwise clear zone of inhibition relative to the parental strain (Fig.
34F). This matches with previously reported antibiotic susceptibility phenotypes of double
deletion mutant of YceI homologues (1). However, BCAL3310 deletion did not affect the
susceptibility to antibiotics (Fig. 34), which is consistent with being not secreted (Fig. 33).
Similarly, the cytochrome b561 BCAL3312 was not involved in the response to any of the tested
antibiotics (Fig. 34).
4.3.3. Fluorometric assays of binding interaction of B. cenocepacia bacteriocalins
To test the binding preference of bacteriocalins, I used fluorescent compounds that probe binding
sites of proteins. These fluorophores have different chemical features enabling them to probe
different binding sites of proteins. I used Nile Red (consisting of a hydrophobic multi-cyclic
structure and a tertiary amine) which tests hydrophobic binding sites, Auramine O (consisting of
a bridged bi-phenyl structure with a tertiary amine on each phenyl and a central basic group),
which tests basic binding sites, and 8-Anilino-1-naphthalenesulfonic acid, ANS (consisting of
three hydrophobic phenyl groups, a secondary amine and an acidic sulfonate group) which tests
acidic binding sites (6). I determined the binding affinity of purified recombinant bacteriocalin
homologues for each of the 3 probes in PBS buffer by measuring the increase in fluorescence
intensity upon probe–protein complex formation (Fig. 35A-F). The rise in fluorescence at the
specific emission wavelengths of each probe was monitored with a series of concentrations of
probes until no further increase in the fluorescence intensity was detected, indicating all binding
sites were occupied. A one-site binding model was fit to the binding isotherms to derive the
dissociation constant for each probe–BCAL3311 complex as previously described for human
AGP (6). Auramine O and Nile Red exhibited higher binding affinity for BCAL3311 relative to
ANS (Fig. 35). This suggests that BCAL3311 binds with higher affinity to hydrophobic and
basic molecules, whereas it binds acidic compounds with lower affinity. However, Auramine O
interaction with BCAL3311 yielded fluorescence emission with low signal to noise ratio, and
hence a low correlation coefficient compared to that of Nile Red-BCAL3311 interaction. The
interaction of BCAL3310 with the same fluorophores was compared
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Figure 34. BCAL3311 is the only B. cenocepacia bacteriocalin involved in resistance to
hydrophobic but not hydrophilic antibiotics.
Mutants carrying markerless deletions of individual genes encoding the 2 bacteriocalins
BCAL3310 (OME65) and BCAL3311 (OME62) and the associated cytochrome b561 BCAL3312
(OME63) were compared to the parental strain K56-2 in turbidimetric assays the results of which
are expressed as %OD600 relative to control untreated culture of the corresponding mutant (A-E)
and by Etest (F) in their response to the antibiotics: A, PmB 1 mg/ml at 18 h, from 3 independent
experiments, n=9; B, rifampicin 16 µg/ml at 18 h, from 2 independent experiments, n=6; C,
norfloxacin 4 µg/ml at 24 h, from 3 independent experiments, n=9; D, gentamicin 512 µg/ml at 24
h, from 2 independent experiments, n=6; E, ceftazidime 16 µg/ml at 24 h, n=3; F, ceftazidime
Etest. * p<0.05, ** p<0.01 and *** p<0.001 from unpaired student‟s t-tests compared to the
respective control conditions.
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Figure 35. Bacteriocalins bind with higher affinity to hydrophobic molecules; BCAL3311 shows
superior binding affinity relative to BCAL3310.
Fluorometric assays were used to determine the binding affinity of 1.5 µM recombinant B.
cenocepacia bacteriocalins lacking their signal peptide sequences to fluorophores having
different chemical characteristics in PBS. Binding affinity of BCAL3311 to Nile Red (A),
Auramine O (B), and ANS (C) was determined from 3 independent experiments, n=5. The
binding affinity of BCAL3310 was compared to that of BCAL3311 with 1.5 µM Nile Red (D),
1.5 µM Auramine O (E), and 150 µM ANS (F). Displacement assays of the fluorophores from
BCAL3311-fluorophore complex by antibiotics were performed with PmB and PmBN against
1.5 µM Nile Red (G) and 150 µM ANS (H) and with rifampicin, norfloxacin, ceftazidime and
gentamicin against 1.5 µM Nile Red (I); n=2. * p<0.05, ** p<0.01 and *** p<0.001 from
unpaired student‟s t-tests.

148

to that with BCAL3311 (Fig. 35D-F). While there was no difference in the interaction at basic or
acidic binding sites, BCAL3310 bound Nile Red with much lower affinity than BCAL3311 (Fig.
35D). This suggests that binding hydrophobic moieties is critical to the function of BCAL3311.
This agrees with my previous study showing that BCAL3310 binds with lower affinity to a
fluorescent derivative of PmB compared to BCAL3311 (1). To further test the binding
preference of BCAL3311 to hydrophobic moieties as opposed to hydrophilic ones, I measured
the binding of two fluorescent phospholipid analogs labeled with the BODIPY fluorophore on
the head group (BODIPY-phosphoethanolamine) and fatty acyl chain (BODIPYphosphocholine). There was no fluorescence emission observed upon titration of BCAL3311
with BODIPY-phosphoethanolamine, whereas titration of BCAL3311 with BODIPYphosphocholine resulted in high fluorescence emission suggesting high affinity interaction
comparable to that with Nile Red (Not shown). This indicates that the hydrophilic head group
segment of the molecule with the fluorescent label does not bind to BCAL3311 whereas the fatty
acyl segment of the molecule with the fluorescent label is responsible for binding.
Next, the ability of different antibiotics to compete with each probe in complex with BCAL3311
was examined by incremental titration with each antibiotic to gain insights on the basis of
interaction between BCAL3311 and the different antibiotics (Fig. 35G-I). Probe displacement
assay for Auramine O was not feasible due to the low signal-to-noise ratio. Initially, I compared
the probe displacement ability of PmB to its nonapeptide derivative (PmBN). PmBN only lacks
the fatty acyl tail of PmB, which results in a significant loss of its bactericidal activity (22). The
fatty acyl tail of PmB seemed critical for binding to hydrophobic binding sites of BCAL3311
where its loss led to significant reduction of its Nile Red displacement ability (Fig. 35G).
Moreover, neither PmB nor PmBN could displace ANS (Fig. 35H), further supporting the notion
of hydrophobic interaction between PmB and BCAL3311. Similarly, rifampicin and, to a lower
extent, norfloxacin could displace Nile Red (Fig. 35I). Slight Nile Red displacement was
observed only at the highest tested concentrations of ceftazidime, whereas no displacement of
Nile Red from its interaction with BCAL3311 was observed with any of the tested gentamicin
concentrations (Fig. 35I).
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4.3.4. Luciferase expression assays of B. cenocepacia bacteriocalins
The role of the two B. cenocepacia bacteriocalin homologues in response to antibiotics was
further assessed by testing the expression of these proteins. I created chromosomal promoterluxCDABE transcriptional fusions for BCAL3310 (Fig. 36A) and the transcriptional unit
BCAL3311-BCAL3312 (Fig. 36B). The expression of BCAL3311 and the associated
cytochrome b561 (BCAL3312) was upregulated in response to PmB, rifampicin, and norfloxacin
(Fig. 36B). The expression was not altered in response to ceftazidime whereas it was slightly
reduced in response to gentamicin probably due to the mode of action of this aminoglycoside
targeting protein expression (Fig. 36B). This agrees, in the most part, with the antibiotic
susceptibility phenotypes observed for the ∆BCAL3311 mutant. Conversely, BCAL3310
expression was overexpressed by norfloxacin and ceftazidime only whereas it was slightly
inhibited by rifampicin and gentamicin probably due to their general mechanism of action
targeting transcription and translation respectively (Fig. 36A). Interestingly, the expression of
BCAL3311 only was upregulated by paraquat (Fig. 36), which is an inducer of the superoxide
anion. This suggests that BCAL3311 is also involved in the response to oxidative stress. A
similar link between the response to antibiotics and oxidative stress was recently shown in case
of putrescine released from B. cenocepacia (11).

4.3.5. Bacteriocalins from different bacterial species are involved in antibiotic resistance
As bacteriocalins are conserved among bacteria, I sought to determine if bacteriocalins from the
YceI family of proteins from different bacteria are also involved in response to antibiotics. To
address this, I attempted to complement ∆BCAL3311 with bacteriocalin homologues from
different bacterial species. I tested the B. cenocepacia K56-2 yceIBc BCAL3311, P. aeruginosa
PAO1 yceIPa PA0423, PA4340 and PA4345, the Mycobacterium tuberculosis H37Rv yceIMtb
Rv1890c and the S. aureus USA300 SAUSA300_2620. Cloning genes encoding BCAL3311,
PA0423 and PA4340 with C-terminal Flag-tag did not complement the ∆BCAL3311 phenotype,
potentially due to interference of the tag at this position with function of the proteins (Not
shown). Next, I cloned all tested genes from the different species under the control of the
rhamnose-inducible promoter in pSCRhaB2. PAP by agar dilution against PmB revealed that the
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Figure 36. Luciferase expression assay of the different B. cenocepacia bacteriocalins in response
to antibiotics at 3 h.
Results are shown as percentage of relative light units RLU/OD600 relative to the control
(untreated K56-2 background). The percentages of OD600 are shown in Fig. 37. A, Expression of
BCAL3310 (OME60).n=6 from 2 different clones. The mean RLU/OD600 of the control is 0.5531.
B, Expression of BCAL3311 and the associated cytochrome b561 BCAL3312 (OME61).n= 6
from 2 different clones. The mean RLU/OD600 of the control is 1.3464. * p<0.05, ** p<0.01 and
*** p<0.001 from unpaired student‟s t-tests compared to the respective control conditions.
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Figure 37. The relative growth of cells in the luminescence expression assay of the different B.
cenocepacia bacteriocalins in response to antibiotics at 3 h shown in Fig. 36.
Results are shown as percentage of OD600 relative to the control (untreated K56-2 background).
A, Growth in the expression assay of BCAL3310 (OME60).n=6 from 2 different clones. The
mean OD600 of the control is 0.0963. B, Growth in the expression assay of BCAL3311 and the
associated cytochrome b561 BCAL3312 (OME61).n= 6 from 2 different clones. The mean OD600
of the control is 0.0998. * p<0.05, ** p<0.01 and *** p<0.001 from unpaired student‟s t-tests
compared to the respective control conditions.
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B. cenocepacia BCAL3311 significantly increased the resistance of ∆BCAL3311 to PmB (Fig.
38A). Moreover, the M. tuberculosis yceIMtb fully complemented the deletion of BCAL3311,
whereas the 3 P. aeruginosa yceIPa homologues and the S. aureus USA300 bacteriocalin
homologue significantly increased resistance to PmB in the ∆BCAL3311 relative to the control
vector (Fig. 38A). MIC determined by Etest showed that all tested bacteriocalin homologues
from B. cenocepacia, P. aeruginosa, M. tuberculosis and S. aureus increased resistance to
Rifampicin in the ∆BCAL3311 to the wild type level (Fig. 38B). Together, this shows that
bacteriocalins from different pathogens are involved in antibiotic resistance and suggests that the
function of bacteriocalins is conserved among bacteria.

4.3.6. Bacteriocalins protect different bacterial species in vitro and in vivo
I sought to determine if bacteriocalins secreted from one bacterial species can protect other
bacteria from the action of antibiotics. In vitro assays showed that P. aeruginosa PAO1 treated
with purified recombinant yceIBc BCAL3311 had reduced sensitivity to PmB, an effect that was
not observed with the less active BCAL3310 (Fig. 39A). However, both proteins protected
Salmonella typhi SARB63, Shigella flexneri SF51571, Acinetobacter baumanni AB1,
Acinetobacter lwoffi AB2, and Acinetobacter junni AB3 (Fig. 39B-F) at concentrations ~10-20
folds lower than that where protection was observed in case of P. aeruginosa (Fig. 39A). This
difference in concentrations at which protection is observed for the different bacteria corresponds
to difference in magnitude of affinity to Nile Red between BCAL3310 and BCAL3311 (Fig.
35D), which could explain the protective effect of BCAL3310 in case of the different bacterial
species and its lack with P. aeruginosa PAO1.
Next, I used Galleria mellonella larvae infection model. BCAL3311-treated P. aeruginosa
PAO1 cells were more virulent than the control PAO1 cells or BCAL3310-treated cells (Fig.
39G). After 200 minutes post-infection with ~700-900 cfu of P. aeruginosa, I recovered
significantly higher numbers of BCAL3311-treated cells compared to the control untreated cells
or the BCAL3310-treated group from the hemolymph of G. mellonella larvae plated on LB agar
supplemented with 0.3% cetrimide (Fig. 39H). This suggests that the increased virulence due to
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Figure 38. The function of bacteriocalins in the response to hydrophobic antibiotics are
conserved among different bacteria.
Bacteriocalins from B. cenocepacia K56-2 (BCAL3311), P. aeruginosa PAO1 (PA0423,
PA4340, PA4345), M. tuberculosis H37Rv (Rv1890c) and S. aureus USA300
(SAUSA300_2620) were cloned in pSCRhaB2 under the control of the rhamnose promoter and
used to complement the ∆BCAL3311 mutant in the presence of 0.4% rhamnose. A, PAP by agar
dilution against PmB, from 3 independent experiments, n=6, asterisks are color coded and
denotes difference from ∆BCAL3311 pSCRhaB2 mutant. * p<0.05, ** p<0.01 and *** p<0.001
determined by unpaired student‟s t-tests. B, MIC determined by Etest against rifampicin, a
representative of 3 independent experiments. Discrete colonies in the otherwise clear zone of
inhibition indicating heteroresistance similar to those in Fig. 34 panel F were not taken into
consideration for MIC determination.
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Figure 39. B. cenocepacia bacteriocalins, mainly the secreted BCAL3311, protect different
bacterial species in vitro and in vivo.
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(A-F) In vitro protection assays against PmB with 1.5 µM of BCAL3310 or BCAL3311: A, P.
aeruginosa PAO1, n=8 from 4 independent experiments; B, S. typhi SARB63, n=7 from 3
independent experiments; C, S. flexneri SF51571, n=7 from 3 independent experiments; D, A.
baumanni AB1, n=6 from 2 independent experiments; E, A. lwoffi AB2, n=5 from 2 independent
experiments; F, A. junni AB3, n=5 from 2 independent experiments.
(G-K) In vivo protection assay using G. mellonella infection model. Each larva was injected with
10 µl of suspensions of different bacteria in PBS with or without B. cenocepacia bacteriocalins.
The survival was monitored over time and compared to control group injected with sterile PBS.
Each group included 10 larvae. (G) P. aeruginosa PAO1, the results are obtained from 3
independent experiments; the survival of both PAO1 and PAO1-BCAL3310 treated larvae is
significantly different from that of PAO1-BCAL3311 treated group at p= 0.0165 and 0.0303
respectively. (H) In an independent experiment, larvae were sacrificed 200 min post-infection
and the hemolymph was collected and plated on 0.3% cetrimide agar to quantify the recovered P.
aeruginosa PAO1; n=10 from 2 independent experiments. (I) K. pneumoniae Kpn18, from 2
independent experiments; (J) A. baumannii AB1 from 3 independent experiments; and (K) S.
aureus USA300, from 2 independent experiments. * p<0.05, ** p<0.01 and *** p<0.001 from
unpaired student‟s t-tests compared to the respective control conditions.
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treatment with BCAL3311 is a result of protection from killing of P. aeruginosa cells inside the
host. G. mellonella larvae possess a humoral immune response where the hemolymph of
bacteria-challenged larvae contains several antimicrobial peptides among them are members of
linear α-helical peptides (cecropins and moricin-like peptides), cysteine-stabilized peptides
(defensins), proline-rich peptides, and glycine-rich peptides in addition to lysozyme (23). Similar
phenotype of increased virulence upon treatment with BCAL3311 was observed in K.
pneumoniea Kpn18, A. baumannii AB1, and S. aureus USA300 (Fig. 39 I-K).

4.4. Conclusions
I show that bacteriocalins are involved in the bacterial response to hydrophobic or amphiphilic
antibiotics (PmB, rifampicin, norfloxacin and ceftazidime), but not hydrophilic ones (such as
gentamicin). This effect is attained by their preferential binding affinity to hydrophobic moieties.
Bacteriocalins are functionally conserved among different bacteria and those secreted from one
bacterial species can protect bacteria from other species from the effects of antibiotics whether in
vitro or in vivo. Interestingly, the expression of both B. cenocepacia bacteriocalins is induced in
CF conditions compared to soil environmental like conditions shown by comparative
transcriptomics, underscoring the importance of bacteriocalins during infection (24). On the
other hand, bacteriocalins could be involved in the response to oxidative stress. BCAL3311
expression was induced in response to paraquat. This is consistent with the overexpression of P.
aeruginosa PAO1 bacteriocalin PA0423 in response to hydrogen peroxide and paraquat (5).
Furthermore, Mammalian Odorant binding protein (OBP), a soluble lipocalin, when
overexpressed in E. coli, protected the bacterial cells from oxidative stress induced by hydrogen
peroxide (25). In conclusion, I report for the first time a novel mechanism of antibiotic
resistance, based on physical binding of antibiotics, that is conserved among large number of
bacteria whether Gram-positive or Gram-negative and that can non-specifically protect various
clinically relevant pathogens from the action of antibiotics. These findings offer a new avenue
for intervention against antibiotic resistance and its spread among different bacteria by
developing inhibitors against bacteriocalins.
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Chapter 5

General Discussion
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5.1. General Overview
At the present time, existing pipelines of novel antibiotic drug development are
insufficient to bridge the widening gap that is inherent in the global dissemination of multi-drug
resistant bacteria versus the effectiveness of available antibiotic therapy to treat microbial
infections. This dilemma is further complicated by confusion regarding a closely related
phenomenon, namely heteroresistance, which would complicate the overall therapeutic outcome.
Despite the recognition of this phenomenon since 1947, the field is plagued with misconceptions
and confusion about heteroresistance. In this thesis, I aimed at providing better characterization
of heteroresistance and one of its major implications, which is the possibility of chemical
communication of antibiotic resistance.

5.2. Heteroresistance: the current understanding
The term „heteroresistance‟ is sometimes used indiscriminately to describe other
observations not related to population-wide response to antibiotics. Moreover, no clear definition
or globally standardized methods to determine heteroresistance are available. The lack of
standardization of test formats and the guidelines to decide heteroresistance led to the lack of
agreement between outcomes of different methods and between different laboratories (1-3).
Various studies showed that heteroresistance could have serious implications in therapy of
microbial infections as discussed in Chapter 1. Hence, the harmonization and standardization of
definitions and methods to describe heteroresistance is of utmost importance.
Based on my study (Chapter 2) and upon extensive and critical review of the available
literature (Chapter 1), I recommend defining heteroresistance as the population-wide variation of
antibiotic resistance whereby different subpopulations within an isolate exhibit varying
susceptibilities to a particular antimicrobial agent. With respect to the methods of detection, PAP
remains the gold standard for detection of heteroresistance preferably by cfu counts, while
turbidimetric PAP is an acceptable alternative, provided that the antibiotic increments are set at
2-fold. A strain can be considered heteroresistant when the lowest antibiotic concentration
exhibiting maximum inhibition of the bacterial population is equal to or greater than 8-fold
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higher than the highest non-inhibitory concentration. A 4-fold difference may be regarded as
intermediate heterogeneity while a lower difference indicates homogenous response to an
antibiotic. An alternative to PAP would be disc diffusion or Etest assays, whereby the growth of
discrete colonies at the otherwise clear zone of inhibition is indicative of heteroresistance. This
method can be used for faster screening of clinical isolates rather than using the laborious PAP
assays. With standard criteria to define and assess heteroresistance world-wide, the prevalence of
heteroresistant bacteria as well as their clinical relevance and impact on healthcare can be better
assessed. Consequently, effective therapeutic strategies should be explored to counteract
heteroresistance. This may include testing synergistic combinations of antibiotics (4), or using
antibiotic adjuvants inhibiting key pathways involved in antibiotic resistance in conjunction with
front-line antibiotics (5).
On the other hand, elucidation of the mechanisms of heteroresistance when this
phenomenon is properly defined will help understand whether a common mechanism exists
among the different bacteria and against the different antibiotics or these mechanisms are
antibiotic-specific, species-specific or both. In B. cenocepacia, heteroresistance to polymyxin B
depends on putrescine and YceI secretion, being differentially expressed across the different
subpopulations as shown in Chapter 2. Moreover, a periplasmic component of an ABC
transporter involved in the biosynthesis of hopanoids was overexpressed in the more resistant
subpopulation exposed to polymyxin B. While the role of this transporter in heteroresistance was
not directly evaluated, hopanoids have been shown to contribute to polymyxin B resistance in B.
cenocepacia (6). Putrescine and YceI were similarly implicated in heteroresistance to rifampicin,
norfloxacin and ceftazidime to various extents but not gentamicin. Identifying the mechanisms of
heteroresistance would potentially aid in finding new targets for disruption of this phenomenon,
thus reducing the window of therapeutic failure.
It is also essential to determine thoroughly whether heteroresistance is only restricted to
the response to bactericidal antibiotics, or bacteria can display heteroresistance to bacteriostatic
antibiotics as well. No systematic comparisons of the response of heteroresistant bacteria to
bacteriostatic versus bactericidal antibiotics have been reported. Here I showed that B.
cenocepacia exhibited heteroresistance to bactericidal antibiotics from different classes and
homogenous responses to bacteriostatic antibiotics.
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Interestingly, the same strain can display both intrinsic and acquired heteroresistance.
Here I showed that B. cenocepacia wild type and several less resistant isogenic mutants,
including ∆hldA, displayed intrinsic heteroresistance to several bactericidal antibiotics including
polymyxin B (5). Previously, heteroresistance was induced in the same hldA mutant possessing
truncated LPS where it developed subpopulations resistant to higher concentrations of the
antibiotic that are not tolerated by even the most resistant members of the original population
after exposure to multiple rounds of selection in polymyxin B (7).
In conclusion, global organizations concerned with antimicrobial resistance are urged to
advocate for harmonized recommendations and coordinate general consensus concerning the
phenomenon of heteroresistance. This is of utmost importance especially in clinical practice
where currently thousands of clinical isolates are screened for heteroresistance, but rather using
non-standardized methods that differ from one laboratory to another, further puzzling the global
picture. Such efforts can be better directed to more accurate and standardized detection of
heteroresistance, leading to superior therapeutic outcomes based on improved identification of
heteroresistant bacteria and optimized strategies to eradicate them.

5.3. Chemical communication of antibiotic resistance
Highly resistant subpopulations of heteroresistant bacteria could further complicate the
clinical picture of polymicrobial infections by providing protection to normally sensitive bacteria
through chemical signals. Here I showed in Chapter 2 an example of such chemical
communication of resistance in which P. aeruginosa was protected from the action of the
antimicrobial peptide polymyxin B by highly resistant subpopulation of the heteroresistant
pathogen B. cenocepacia. Simultaneous infection of both organisms is not uncommon; cystic
fibrosis patients are among the groups having high potential of contracting such polymicrobial
infection (8). This provides high potential for clinical relevance of such interaction between
microorganisms given this particular example. This chemical communication of antibiotic
resistance was mediated by the release of excessive amounts of the polyamine putrescine, and
YceI, a small conserved protein with a lipocalin fold, from B. cenocepacia and resulted in P.
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aeruginosa surviving polymyxin B treatment equivalent to the recommended therapeutic
breakpoint instead of being completely killed in its pure culture. This was shown in an in vitro
direct co-culture experiment and awaits further in vivo confirmation. In chapter 4, I showed an in
vivo evidence of protection of P. aeruginosa PAO1 by the bacteriocalin BCAL3311 in G.
mellonella larvae infection model. On the other hand, putrescine and other polyamines in genital
mucosal fluids increased the resistance of N. gonorrhoeae to antimicrobial peptides (PmB and
LL-37), possibly enhancing its survival during infection by reducing bacterial susceptibility to
host-derived antimicrobials (9). Together, this supports the clinical relevance of putrescine and
bacteriocalins as communicators of antibiotic resistance.
Putrescine protected the surface of the bacteria from the initial binding of polymyxin B
[Chapter 2 and (5)] and reduced antibiotic-induced oxidative stress [Chapter 3 and (10)];
however, this does not preclude other mechanisms by which putrescine modulate the antibiotic
response (11). On the other hand, YceI could bind and sequester polymyxin B and other
hydrophobic antibiotics thus potentially reducing their levels in the bacterial milieu [Chapters 2
and 4, and (5)]. Given that the mechanism of such chemical communication could be universal
among bacteria; i.e. the signals involved could be sensed and benefited from by almost all
bacteria, extra caution should be in effect while dealing with heteroresistant B. cenocepacia
infections (or by other bacteria displaying similar phenotype of extreme antibiotic resistance) in
particular when associated with other bacteria in mixed infection.

5.4. New targets for drug discovery
Unveiling these mechanisms contributing to intrinsic antibiotic resistance and
communication of resistance among bacteria provides novel targets for therapeutic interventions.
A promising avenue for potential synergists is inhibition of biosynthesis of polyamines,
putrescine in particular. In this study (Chapter 3), I identified the ornithine decarboxylase
BCAL2641 as a critical player in response to antibiotics despite the presence of other putrescine
synthesizing enzymes (BCAM1111 and BCAM1112), which seemed to have other physiological
functions not related to antibiotic resistance. Therefore, these findings suggest BCAL2641 as a
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plausible target for inhibitors that would potentiate the effects of antibiotics. Interestingly, certain
inhibitors of key enzymes in the biosynthetic pathway of polyamines, such as ornithine
decarboxylase and spermidine synthase, are available (12-15). Such inhibitors have been
effective in the treatment of parasitic infections such as different types of trypanosomiases (16,
17). The uptake of putrescine and other polyamines may present another potential target for
inhibition potentially blocking the chemical communication among bacteria. Certain anthraceneand benzene-polyamine conjugates that inhibit polyamine transport were also effective for
treatment for Pneumocystis pneumonia (18). Together, the identification of specific bacterial
targets such as BCAL2641 in addition to the clinical implementation of interfering with
polyamine synthesis and uptake in parasitic infections supports the feasibility of this approach in
bacterial infections.
Similarly, bacteriocalins can provide another plausible target for inhibition. One strategy
for inhibition is to design or search for molecules capable of binding to bacteriocalins with
higher affinity than antibiotics thus preventing sequestration of antibiotics. Overall, this direction
for drug discovery could potentially expand further as our understanding of the mechanisms,
biosynthetic pathways and uptake of the different small molecules continues to increase.

5.5. Ongoing and future research
Indeed this study revealed novel observations in terms of the heteroresistance of B. cenocepacia
to different bactericidal antibiotics as well as the chemical communication of antibiotic
resistance and the signals involved in this interaction. However, much remains to be learned
about antimicrobial heteroresistance and new avenues for drug development has been generated.
Thorough investigation of the mechanisms of heteroresistance in B. cenocepacia is still
required. Although I have showed the implication of putrescine and bacteriocalins in this
phenomenon through differential expression among the different bacterial subpopulations;
however, the stability of the high level of resistance in the more resistant subpopulation implies
the presence of underlying mutations contributing to such level of antibiotic resistance. Whole
genome sequencing of the more resistant subpopulations is currently underway. This would
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increase our understanding of the mechanisms of heteroresistance in B. cenocepacia and would
potentially identify novel mechanisms of antibiotic resistance in general.
To better exploit our knowledge of chemical communication of antibiotic resistance,
better understanding of the mechanisms involved in the mediator infochemicals is essential. For
example, while surface competition and protection from ROS has been revealed as mechanisms
of protection by putrescine from the action of various antibiotics, other mechanisms of protection
by putrescine needs to be identified as well. Two-dimensional gel electrophoresis is currently
optimized to compare between the response of wild type and ∆BCAL2641 to antibiotics in a
non-biased manner. On the other hand, since BCAL2641 was proven to be central in the
putrescine-mediated response to antibiotics, it is desirable to explore its regulatory pathways, in
particular those involved in its stimulation in the presence of antibiotics. This will be pursued
through creating transposon libraries. Regulators important in such antibiotic response could
serve as targets for inhibitors as well. Equally important, understanding the affinity of
BCAL2641 to the available inhibitors of polyamines biosynthesis would aid in the rational drug
design of novel specific inhibitors against this ornithine decarboxylase enzyme.
With respect to bacteriocalins, mapping of the binding sites through in silico binding
modeling is underway. This can be validated by site-directed mutagenesis and in vitro binding
assays. This could be coupled with determination of the 3D structure of bacteriocalins by NMR.
This would ultimately aid in identifying the favorable parameters for effective inhibitors for
bacteriocalins.

5.6. Significance and Concluding Remarks
Using B. cenocepacia as a model opportunistic bacterium, I reported heteroresistance
against PmB and other bactericidal antibiotics. Population analysis profiling identified B.
cenocepacia subpopulations arising from a seemingly homogenous culture that are resistant to
higher levels of PmB than the rest of the cells in the culture, and can protect the more sensitive
cells from killing, as well as sensitive bacteria from other species, such as P. aeruginosa and E.
coli. Communication of resistance depended on upregulation of putrescine synthesis and YceI, a
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widely conserved low-molecular weight secreted bacterial lipocalin (bacteriocalin). Polyamines
and bacteriocalins were also required for heteroresistance of B. cenocepacia to various
bactericidal antibiotics. This work proposes that putrescine and bacteriocalins resemble "danger"
infochemicals whose increased production by a bacterial subpopulation, becoming more resistant
to bactericidal antibiotics, communicates higher level of resistance to more sensitive members of
the population of the same or different species.
Putrescine protects less resistant cells from PmB partly due to its ability to compete with
PmB for binding to the surface of bacteria. In addition, it protects against oxidative stress induced
by PmB and other antibiotics. On the other hand, I report for the first time a new mechanism of
antibiotic resistance, based on physical binding of antibiotics, mediated by bacteriocalins. Shown
in B. cenocepacia, M. tuberculosis, P. aeruginosa, and S. aureus, this mechanism can be
conserved among a large number of bacteria that are predicted to possess bacteriocalins as well.
Furthermore, bacteriocalins can non-specifically protect various clinically relevant pathogens
from the action of antibiotics.
In conclusion, the findings of this thesis uncover a novel, non-genetic and cooperative
mechanism of transient increase in resistance that can be chemically communicated from more
resistant members of a heterogeneous population to less resistant bacterial cells of the same or
other species. This multifactorial mechanism of communication of antibiotic resistance is distinct
from previously reported population-based resistance, hence expanding our knowledge on
intrinsic antibiotic resistance mechanisms and offering novel targets for antimicrobial
intervention.
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Appendix A

Characterization of regulators of polymyxin B resistance in
B. cenocepacia
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A.1. Background and rationale
Pathogens respond to various insults in the host environment for infection to be
successful. Integration of the signals generated into coherent messages, which the organism can
counter with both transcriptional and post-translational responses is paramount. These responses
involve several global regulatory systems. This also applies to survival of pathogens in the
environment (1). Several envelope stress response systems have been characterized in other
Gram-negative bacteria such as Escherichia coli, and investigated individually and globally (26); however, little is known about the regulation of extracytoplasmic stress response pathways in
B. cenocepacia. Thus, it is important to study the regulation mechanisms, which would enhance
our understanding of the extreme resistance of B. cenocepacia to APs.
Outer membrane permeability is controlled in part by the master regulator of the
extracytoplasmic stress responses, RpoE (7). RpoE has a similar role in E. coli in which many of
the genes identified in its regulon are involved in membrane biogenesis or repair, protein folding
or degradation, and they include rpoE itself along with its regulatory proteins (8). It has been
shown that RpoE is required in B. cenocepacia for PmB resistance at 37oC (9) but not at 30oC
(7). The MIC50 of Polymyxin B (PmB) at 37oC for the ∆rpoE mutant is 64 µg/ml versus more
than 1024 µg/ml for the wild type strain (9). Therefore, characterization of the RpoE regulon in
B. cenocepacia is essential to understand its contribution in resistance to APs.
A

relatively

more

recently

identified

two

component

regulatory

system

(BCAL2831/BCAL2830) (10) has been shown to contribute to resistance of B. cenocepacia to
PmB (9). This two-component system might correspond to the PmrA/PmrB system in
Pseudomonas aeruginosa. Indeed, the gene encoding the putative response regulator, BCAL2831
encoded a protein that exhibited a certain level of similarity (53% identity) at the primary amino
acid sequence level with PmrA of P. aeruginosa (10). Previous reports have shown that the P.
aeruginosa PmrA/PmrB system regulates resistance to APs in part by modifications of LPS,
mainly through the addition of 4-L-aminoarabinose (Ara4N) (11, 12). Interestingly, the pmrApmrB operon is activated by a number of cationic peptides (11). In striking contrast to other
bacteria, the Ara4N modification of LPS in B. cenocepacia is essential for viability (13). This
could imply that the regulation of this pathway would be different in B. cenocepacia than other
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bacteria in which it is non-essential. Thus, I investigated whether the BCAL2831/BCAL2830
system is involved in the regulation of the modification of lipid A or not.

A.2. Characterization of the RpoE regulon in B. cenocepacia
Initially, I performed a bioinformatic analysis to identify genes potentially regulated by
RpoE in B. cenocepacia by analogy to the previously characterized RpoE regulon of Escherichia
coli K12 (3). Some predictions were tested by comparing the gene expression in wild type K56-2
and the ∆rpoE mutant SAL65 using real-time PCR upon subjecting the cultures to PmB stress.
The bioinformatic analysis performed by analogy to the RpoE regulon in E. coli K12
resulted in a list of ~ 60 genes potentially regulated by RpoE in B. cenocepacia J2315. Selected
genes from these predictions were tested by comparing the gene expression in wild type B.
cenocepacia K56-2, which is clonally related to J2315 and proven to be more amenable to
genetic manipulation (14), and the ∆rpoE mutant SAL65 using real-time PCR. The preliminary
results show that compared to the RpoE-regulated operons in E. coli, RpoE regulates some of
them in B. cenocepacia while others are not. The differential expression of genes between wild
type and SAL65 was different in the case of 30oC and 37oC (Table 10), which could explain the
different patterns of resistance to PmB at those temperatures (7, 9). Among the tested genes,
most of those that are significantly regulated by RpoE in B. cenocepacia at 37oC are genes
encoding periplasmic proteases [BCAM1695 and BCAL0326], enzymes involved in lipid A
synthesis [genes in the same operon with rseP as lpxABD genes], LPS transport and assembly
[lptA and bamA present in the same operon with rseP], in addition to the rpoE operon itself
[rseA] and its regulatory machinery [rseP]. However, previous studies showed that the
periplasmic proteases are not involved in resistance to PmB mediated by RpoE (9). Furthermore,
I have tested other genes of interest as those involved in Ara4N modification [arnT and arnB]
and phosphoethanolamine binding [peb]; however, none of them was regulated by RpoE (Table
10). In the previous experiment, the cultures were exposed to PmB for 15 minutes prior to RNA
extraction. However, on prolonging this period to 30 minutes, I could see differences in the
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Table 10. Differential expression of selected genes in wild type K56-2 versus the ΔrpoE
mutant at 30oC and 37oC subjected to 1 mg/ml PmB for 15 min determined by qPCR.
Gene ID

Gene
name

Function

BCAL0999
BCAL2084

rseA
rseP

Anti-RpoE sigma factor
Inner membrane zinc metalloprotease; activates
RpoE by degrading RseA

BCAM1695
BCAL0326
BCAL2829
BCAL0634
BCAL1881
BCAL3091
BCAL0163
BCAL0815
BCAL0203
BCAL1929

degQ/degP
degQ/htrA
degP/htrA

Periplasmic, membrane-associated serine
endoproteases

BCAL1931

arnB

BCAL0508
BCAL1459
BCAL1659
BCAL2694
BCAL1861

lpxL

yfgL
uppP/bacA
yraP
lptA
Peb
arnT

phbB

Fold change
normalized to BCAS0175

Putative lipoprotein
Putative OM assembly lipoprotein
undecaprenyl pyrophosphate phosphatase
Putative phospholipid-binding lipoprotein
LPS transport periplasmic protein
Phosphatidylethanolamine-binding protein
putative undecaprenyl phosphate-α-4-amino-4deoxy-l-arabinose arabinosytransferase
putative UDP-4-amino-4-deoxy-l-arabinoseoxoglutarate aminotransferase
lipid A biosynthesis lauroyl acyltransferase
Calcineurin-like phosphoesterase
Ribose transport permease
Putative dehydrogenase
Acetyl-CoA reductase

174

37oC

30oC

13.87
7.37

1.69
1.01

10.5
10.2
2.56
-2.3
-2.38
-2.17
2.14
3.93
-2.16
1.67

2.8
-2.2
2.17
-18.4
2.14
-1.81
-1.93
3.21
-6.37

1.24
1.49
-2.83
-17.3
-2.08
-4.23

-3.32
-2.08
-1.38
1.26

Table 11. Differential expression of selected genes in wild type K56-2 versus the ∆rpoE
mutant at 37oC subjected to 1 mg/ml PmB for either 15 or 30 min determined by qPCR.
Gene

Fold Change normalized to BCAS0175
Duration of PmB Stress
15 min
30 min
BCAL1929 (arnT)
1.678
2.08
BCAL1931 (arnB)
1.240
6.01
BCAL0203 (peb)
-2.158
1.35
BCAL2829 (degP/htrA)
2.563
-4.63
BCAL0999 (rseA)
13.875
7.16
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differential expression profiles of most of the tested genes to variable extents (Table 11). This is
consistent with previous studies performed on rpoE in E. coli that showed that different genes in
the regulon were upregulated at different time points along the course of stress (3). It was
interesting to see that prolonging the PmB stress showed that the arnB gene involved in the
Ara4N modification pathway was upregulated in the wild type compared to SAL65. This points
out that characterizing the RpoE regulon at a single time point might be misleading as we
observed in the subset of genes tested after two durations of stress.
To further investigate this, the differential expression of genes as a function of the
duration of stress and the optimal stress conditions for expression of rpoE should be tested.This
can be tested in a strain with luxCDABE reporter genes downstream of the promoter of the rpoE
operon by monitoring the level of expression by determining the luciferase activity as a function
of stress condition and time. Different variables should be tested such as concentration of PmB
and duration of exposure to it under different conditions of culture (in nutrient rich or minimal
media). Also, other conditions may be tested such as the effect of heat shock, osmotic stress or a
combination of different stresses; RpoE is required by B. cenocepacia for survival under those
stressful conditions (7). Next, whole transcriptome sequencing using mRNA-enriched RNA
samples extracted from K56-2 and SAL65 after exposure to the previously determined optimal
stress condition for expression of rpoE should be performed followed by validation of selected
genes by qRT-PCR.

A.3. Study of the BCAL2831/BCAL2830 two-component system.
Due to its similarity to PmrAB system, I expected that the BCAL2831/BCAL2830
regulatory system might regulate LPS modification pathways such as those involving the
addition of either Ara4N or phosphoethanolamine. It has been reported that the disruption of this
system reduces the MIC50 of PmB by about 4 fold (9). I speculated that this low contribution to
resistance to PmB may be due to the fact that a proportion of the OM in B. cenocepacia is
already constitutively decorated with Ara4N, which is essential for viability (13), or that the
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disruption of this regulatory system might stimulate RpoE thus compensating for the reduced
resistance to APs.
I first tested the susceptibility to PmB in the medium 121 (15) that is reported to induce
LPS modifications in E. coli (16). This was performed in deep rough mutants due to their higher
susceptibility to PmB (17). Deep rough mutants lack O-antigen as a result of the deletion of the
hldA gene which encodes a heptokinase involved in the modification of heptose sugars prior to
their incorporation into the LPS core oligosaccharide (17). I compared the susceptibility to PmB
of the deep rough mutant to that of other mutants with further disruptions in rpoE or BCAL2831
genes (Table 12). It may be expected that if a system regulates the modification of LPS, the
mutant with its functional gene will have increased MIC values in the medium 121 relative to LB
medium, as opposed to the case in the mutant with disrupted gene of this regulator. Growth of
the tested mutants was retarded in the medium 121, which was reflected in their lower MIC50
values. The relative susceptibilities to PmB of the different mutants were the same under the
different conditions, suggesting no significant modifications in LPS profile. This might indicate
that neither RpoE nor the two-component system under study regulates LPS modifications, or
that the medium 121 does not have LPS modifying properties in B. cenocepacia as those exerted
in E. coli.
Then I compared the expression of selected genes in wild type B. cenocepacia K56-2 and
RSF29 by qRT-PCR after subjecting them to 1 mg/ml PmB for 15 minutes. However, under the
tested condition, this system did not affect the expression of arnB or arnT involved in Ara4N
modification, peb involved in phosphoethanolamine modification, rseA present in the rpoE
operon, or even the htrA BCAL2829 present in its own operon (Table 13). However, other
conditions of stress should be tested before making a definitive conclusion on its role in
resistance to PmB.

A.4. Significance
The significance of these studies is that they will advance our understanding of the
resistance of B. cenocepacia to APs in terms of its genetic basis and regulation and will provide
insights for enhanced treatment of this pathogen‟s severe infections.
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Table 12. MIC50 of PmB against different B. cenocepacia mutants in different culture
media.
Strain

RSF34

SAL47

SAL55

Medium
LB
121 LP
121 XP
LB
121 LP
121 XP
LB
121 LP
121 XP

MIC50, g/ml
24 hr
48 hr
128
256
<4
8
8
32
16
64
<4
≤4
<4
8
64
128
<4
4
<4
16

Note:
RSF34: K56-2, hldA
SAL47: RSF34, with disrupted rpoE
SAL55: RSF34, with disrupted BCAL2831
LP: Limiting phosphate conditions (K2HPO4: 8.3 x l0-5M)
XP: excess phosphate conditions (K2HPO4: 8.3 x l0-4M)
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Table 13. Differential expression of selected genes in wild type K56-2 versus mutant with
disrupted BCAL2831, RSF29, at 37oC subjected to 1 mg/ml PmB for 15 min determined by
qPCR.
Gene

Fold Change
normalized to BCAS0175

BCAL1929 (arnT)
BCAL1931 (arnB)
BCAL0203 (peb)
BCAL2829 (degP/htrA)
BCAL0999 (rseA)

1.69
-1.05
-1.17
1.18
-1.15

Note:
RSF29: K56-2, with disrupted BCAL2831
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Appendix B

Search for synergistic inhibitors potentiating the action of
Polymyxin B against B. cenocepacia

182

The concept of using helper compounds that could inhibit certain features of pathogenic
bacteria has been investigated as an appealing approach to reverse resistance of bacteria to
antibiotics (1-3). Such attempts targeted the membrane permeability of bacteria to enhance
penetration of antibiotics (1) or the inhibition of efflux pumps (2). Another target for potential
inhibitors is extracellular signaling where interfering with it would prevent the release of
virulence factors, the formation of biofilms or increased antibiotic resistance (4). Such treatments
targeting signaling systems neither arrest cellular division directly nor are they toxic to the cells,
which means the selective pressure to evolve mechanisms of resistance is likely to be
substantially reduced. In addition, targeting small-molecule signaling pathways ensures that
treatments will be directed specifically at the pathogenic organism, rather than the entire
microbiome (4). In the largest sense, the helper compounds or antimicrobial adjuvants inhibit a
bacterial resistance mechanism to an antibiotic, thus rendering the bacterium susceptible to that
antibiotic (5).
In this study, I attempted to identify inhibitors of the outer membrane (OM) barrier effect,
which would permeabilize the cells to APs thus reducing resistance towards them and increasing
their antimicrobial effectiveness. This would provide a therapeutic solution to the extremely high
level of intrinsic resistance of B. cenocepacia to APs.
The library consisted of 448 compounds derived from Sea life (obtained from Instituto
Biomar, Leon, Spain). Solutions of these compounds were seeded in pairs of 100-well Bioscreen
C plates and the solvent was evaporated. Overnight cultures of the wild type B. cenocepacia
K56-2 diluted to OD600 0.0002 in fresh LB medium were added to the plates (300 µl/well)
dissolving the compounds at final concentration of 1 µg/ml. Plate pairs were incubated in the
Bioscreen C automated growth curve analyzer at 37oC with continuous medium shaking. After
two hours, polymyxin B was added to one plate at a final concentration of 500 µg/ml and the
vehicle control in which polymyxin B is dissolved (0.2% bovine serum albumin, 0.01% acetic
acid) was added to the other plate. Wells that received no compounds were also included in each
plate of the pairs. The plates were further incubated at 37oC and OD600 was read every 30
minutes. This experimental design allows the identification of compounds that have direct
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antibiotic activity against B. cenocepacia as well as those that synergize the antimicrobial
activity of polymyxin B.
From this preliminary screening of compound library, 4 compounds were effective in
potentiating the antimicrobial activity of PmB against the wild type K56-2 (Figure 40). These
compounds alone did not possess any toxic effects on the cells at the tested concentration (1
µg/ml); this does not preclude that they may possess direct antibiotic activity at higher
concentrations. These compounds were thielavin B, micacocidin B, and other 2 new compounds;
the chemical structure of one of them is yet to be determined.
Thielavin B (Figure 41A) is a Prostaglandin synthesis inhibitor produced by the fungus
Thielavia terricola (6); it inhibits glucose-6-phosphatase (G6Pase) (7), telomerase and viral
reverse transcriptase (8), and interferes with cell wall transglycosylation in Enterococcus faecalis
(9). Micacocidin B (Figure 41B) is a Copper-containing compound produced by Pseudomonas
species previously shown to exhibit potent activity against various Mycoplasma species (10).
Notably, 3 other compounds with similar structure but not in complex with metal were included
in the compound library; however, these did not have any synergistic effects with PmB against
B. cenocepacia. Interestingly, derivatives of Micacocidin have recently been synthesized with
activity against Mycoplasma pneumoniae (11). The third compound was a novel cyclic peptide
coded CL0231 (Figure 41C). Interestingly, a similar compound (CL0236, Figure 41D) with
slight side chain modification did not have any synergistic effects with PmB. The fourth
synergistic compound was also novel and its chemical structure is yet to be determined.
Follow up experiments were not possible due to inability of extraction of higher
concentrations of these compounds from their marine sources. Ideally, confirming the results of
the primary screening assays followed by determination of the optimal dose ratio for the
combinations of these compounds with PmB would have been the next steps. However, these
results offer a proof of concept for the screening of synergists for the activity of PmB. In
addition, the positive hits may be worth pursing in more details in the future by fermentation
from their producer organisms or their expression from an expression system for further
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Figure 40. Screening of a library of ~450 compounds for synergists of the antimicrobial
activity of PmB against B. cenocepacia K56-2 at 20 h.

185

A

B
OH
O

HO

H

O
O

S

H
H
N

O
O

H

S
O

O

2+ O

N

Cu

N

O
OH

O
O

C

D

Figure 41.Chemical structures of compounds from the screened library of compounds.
A, Thielavin B. B, Micacocidin B. C, CL0231. D, CL0236.
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S

evaluation of their antimicrobial activity. These results encourages screening larger libraries of
compounds for synergists. On the other hand, future studies should aim at screening for
inhibitors targeting a specific pathway or signal known to be involved in antibiotic resistance
such as putrescine biosynthesis or bacteriocalins as previously discussed in the different chapters
of the thesis.
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Appendix C

Characterization of the more resistant subpopulation of
B. cenocepacia ∆rpoE/500

189

Heteroresistance complicates the problem of antibiotic resistance and hence may pose serious
problems in microbial infections. Hence, determination of the mechanism of heteroresistance is
required. Characterizing the more resistant subpopulation in terms of its phenotypes in response
to PmB is the first step towards understanding the mechanism of heteroresistance.
For practical reasons, I used for these experiments a subpopulation isolated at 500 µg/ml
in the ∆rpoE mutant, which displayed a stable higher level of resistance to PmB as indicated in
their individual PAP (details in Chapter 2), as it was difficult to isolate the more resistant
subpopulations of the parental strain K56-2 due to its extreme resistance to PmB. As discussed in
Chapter 2, no differences in the secreted extracellular proteases, or LPS profiles between the
∆rpoE/500 resistant subpopulation, its naïve population and the wild type K56-2 (details in
Chapter 2). On the other hand, experiments of microbial adherence to n-hexadecane (1) revealed
that the ∆rpoE/500 subpopulation was more hydrophilic than the naïve bacteria (Figure 42A),
suggesting cell surface changes in the more resistant subpopulation.
Exposure of the wild type K56-2 and ∆rpoE/500 to PmB led to reduction in their
swimming motility and ability to form biofilm [determined as previously described in (2) and (3)
respectively; Figure 42B and C respectively]. This agrees with previous findings showing that
genes encoding proteins required for building and operating flagella are downregulated in B.
cenocepacia following exposure to PmB (2), which would lead to reduction in motility. This
reduced motility might, in turn, be responsible of the reduced biofilm formation, since motility
and the flagellar apparatus are required in the initial steps of biofilm establishment (4). On the
other hand, only ∆rpoE/500 treated with PmB exhibited reduced metabolic activity at 24 h
relative to its naïve population and the wild type K56-2, whether treated with PmB or not, in a
resazurin metabolic assay (details in Chapter 2). Thus, the increased resistance displayed by the
more resistant subpopulation comes at a fitness cost.
While these phenotypic characterizations provide insights about the properties of the
more resistant subpopulation, detailed analysis of this subpopulation is required to understand
the mechanism of its increased resistance to PmB. Therefore, whole-genome sequencing of this
subpopulation in comparison with its naïve population is underway. The significance of this
study is that it would advance the understanding of the mechanism of heteroresistance providing
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Figure 42.Characterization of the more resistant subpopulation ∆rpoE/500.
A. Cell-surface hydrophobicity; B. Motility assay; and C. Biofilm assay.
CV: Crystal violet.
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targets for therapeutic intervention to disrupt such phenomenon, hence reducing the window for
therapeutic failures.
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Appendix D

Characterization of other mechanisms of Putrescinemediated protection from the antimicrobial activity of
Polymyxin B by 2-dimensional gel electrophoresis
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In Chapters 2 and 3, I have shown that putrescine protects from the antimicrobial activity of
PmB through two distinct mechanisms; protection of the bacterial surface from the initial
binding of PmB and reduction of PmB-induced oxidative stress. Indeed, these mechanisms of
protection against PmB do not preclude other mechanisms by which putrescine modulate the
response towards antibiotics and hence acting as a chemical signal communicating antibiotic
resistance. To further investigate the role of putrescine in the protection against the effects of
PmB, I initiated an unbiased proteomic approach. I compared the total cell lysate of cells treated
with PmB (500 µg/ml), putrescine (50 mM) or both, relative to control untreated cells using 2dimensional gel electrophoresis. Preliminary experiments were performed using 7 cm
immobiline dry strips of pH range 3-10; following the first dimension of isoelectric focusing
(Ettan IPGphor II, Amersham), the strips were run on 12% SDS-PAGE and stained with Sypro
Ruby stain. The gels were visualized and scanned using ProXPRESS 2D Proteomics Imaging
System and analyzed using Progensis SameSpots Software. Six strips were used per condition.
This revealed a total of 27 differentially expressed protein spots among the different tested
conditions (Figure 43). However, the amount of protein in these spots was not sufficient to be
visualized by the Page Blue secondary stain and the subsequent Mass Spectrometric
identification; also the resolution of the proteins at certain areas of the gel needed to be
improved. Therefore, the next step is to use 13 cm strips, in which the total amount of proteins
loaded can be increased (200 µg of proteins/strip instead of 75 µg) and the separation will be
improved in both dimensions, to compare total cell lysates of PmB treated wild type and
ornithine decarboxylase BCAL2641 mutants.
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Figure 43. Two-dimensional gel electrophoresis investigation of the mechanism of putrescine to
protect against PmB.
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A representative gel is shown for total cell lysates obtained from the different conditions: A,
Control untreated cells; B, Putrescine-treated cells; C, PmB-treated cells; and D, both PmB and
Putrescine-treated cells. Panel E shows a representative gel with locations of differentially
expressed protein spots under the different conditions.
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Appendix E

Expression profiles of gene clusters (BCAL3309 and
BCAL3313) adjacent to B. cenocepacia bacteriocalins
clusters in response to antibiotics
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Parallel to the evaluation of the expression of the transcriptional units of B. cenocepacia
bacteriocalins (Chapter 4), similar promoter-luxCDABE reporter constructs were prepared in
K56-2 B. cenocepacia (details of construction of mutants are in Chapter 4) for downstream
(BCAL3309; in OME59) and upstream (BCAL3313; in OME62) genes. The expression profiles
of these genes were determined using luciferase expression assays under the same conditions
described in Chapter 4.
BCAL3309 is a putative Major Facilitator Superfamily protein. Its expression was
stimulated by rifampicin, norfloxacin and paraquat; whereas it was inhibited by gentamicin and
PmB after 3 h of incubation at the concentrations used in this assay (Figure 44A). Ceftazidime
did not alter the expression of BCAL3309.
BCAL3313 is a hypothetical protein predicted to be paraquat-inducible protein A. Its
expression was stimulated by rifampicin, norfloxacin, paraquat and ceftazidime as well; whereas
it was inhibited by gentamicin under the tested conditions (Figure 44B). However, PmB did not
alter the expression of BCAL3313.
These results suggest the involvement of these proteins in the response to various
antibiotics and potentially oxidative stress being responsive to paraquat. This warrants further
characterization of their role in antibiotic resistance and stress response initially by deletion
mutagenesis.
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A

B

Figure 44. Luciferase expression assay of BCAL3309 in OME59 (A) and BCAL3313 in OME62
(B) in response to antibiotics at 3 h.
Results are shown as percentage of relative light units RLU/OD600 relative to the control
(untreated K56-2 background). n=6 from 2 different clones. * p<0.05, ** p<0.01 and ***
p<0.001.
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COPYRIGHT RELEASES FOR CHAPTER 1
The following request was sent to Future Medicine Ltd.:
30 May 2014

Re: Permission to Use Copyrighted Material in a Doctoral Thesis

Dear Madame/Sir:
I am a University of Western Ontario graduate student completing my Doctoral thesis entitled
“Chemical Communication of Antibiotic Resistance by Highly Resistant Bacteria. ”.
I would like permission to allow inclusion of portions of the following material in my thesis:
El-Halfawy OM, and Valvano MA (2013). Communication is key: do bacteria use a
universal „language‟ to spread resistance? Future Microbiology, November 2013, Vol. 8,
No. 11, Pages 1357-1359.
El-Halfawy OM, and Valvano MA (2011). Heteroresistance of opportunistic bacteria to
antimicrobial peptides: a new challenge to antimicrobial therapy of cystic fibrosis
infections. Therapy, November 2011, Vol. 8, No. 6, Pages 591-595 , DOI 10.2217/thy.11.69
Proper credit will be given to the original publications.
My thesis will be available in full-text on the internet for reference, study and / or copy. Except
in situations where a thesis is under embargo or restriction, the electronic version will be
accessible through the Western Libraries web pages, the Library‟s web catalogue, and also
through web search engines.I will also be granting Library and Archives Canada and
ProQuest/UMI a non-exclusive license to reproduce, loan, distribute, or sell single copies of my
thesis by any means and in any form or format. These rights will in no way restrict republication
of the material in any other form by you or by others authorized by you.
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Please confirm in writing or by email that these arrangements meet with your approval.
Thank you for your assistance with this matter, please do not hesitate to contact me if you require
additional information.
Sincerely
Omar M. El-Halfawy
I received the following reply from Pamela Cooper from Future Medicine Ltd.:
Dear Omar M. El-Halfawy,

Thank you for your request.
Please find attached a copy of the permission grants for your records.
Sample Citations:
Reproduced from Future Microbiology. (2013) 8(11), 1357-1359 with permission of Future
Medicine Ltd
Adapted from Future Microbiology. (2013) 8(11), 1357-1359 with permission of Future
Medicine Ltd
Reproduced from Therapy. (2011) 8(6), 591-595 with permission of Future Medicine Ltd
Adapted from Therapy. (2011) 8(6), 591-595 with permission of Future Medicine Ltd

Kind regards,
Pamela Cooper
Publishing Administrator
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The permission grants are kept for the record.
A request was submitted through the online form of Copyright Clearance Center's
RightsLink. The following confirmation was received:
Thank You For Your Order!
Dear Mr. Omar El Halfawy,
Thank you for placing your order through Copyright Clearance Center's RightsLink service.
Informa Healthcare has partnered with RightsLink to license its content. This notice is a
confirmation that your order was successful.
Your order details and publisher terms and conditions are available by clicking the link below:
http://s100.copyright.com/CustomerAdmin/PLF.jsp?ref=d124bf0e-92b5-4100-9913-30a82021981d

Order Details
Licensee: Omar El-Halfawy
License Date: Jun 3, 2014
License Number: 3401400596747
Publication: Expert Opinion on Drug Discovery
Title: Non-genetic mechanisms communicating antibiotic resistance: rethinking strategies for
antimicrobial drug design
Type Of Use: Dissertation/Thesis
Total: 0.00 USD
To access your account, please visit https://myaccount.copyright.com.
Please note: Online payments are charged immediately after order confirmation; invoices are
issued daily and are payable immediately upon receipt.
To ensure that we are continuously improving our services, please take a moment to complete
our customer satisfaction survey.
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COPYRIGHT OF CHAPTER 2
The following is quoted from PLOS One website at
(http://www.plosone.org/static/license;jsessionid=143CACBB004B7D2C222B1CA785EAA375) accessed
on 9 June 2014:
“No Permission Required
PLOS applies the Creative Commons Attribution (CC BY) license to all works we publish (read
the human-readable summary or the full license legal code). Under the CC BY license, authors
retain ownership of the copyright for their article, but authors allow anyone to download, reuse,
reprint, modify, distribute, and/or copy articles in PLOS journals, so long as the original authors
and source are cited. No permission is required from the authors or the publishers.”
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COPYRIGHT OF CHAPTER 3
The following is quoted from American Society for Microbiology website, the publisher of
Antimicrobial Agents and Chemotherapy Journal at
(http://journals.asm.org/site/misc/ASM_Author_Statement.xhtml) accessed on 9 June 2014:
“LAST UPDATED: November 5, 2009

ASM Journals Statement of Authors‟ Rights
Authors may republish/adapt portions of their articles
ASM also grants the authors the right to republish discrete portions of his/her article in any other
publication (including print, CD-ROM, and other electronic formats) of which he or she is author
or editor, provided that proper credit is given to the original ASM publication.”
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